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HIRA was originally identified in the group of Peter Scambler as a candidate gene for 
DiGeorge syndrome and was later identified to deposit the histone variant H3.3. Constitutively 
null Hira embryos all die between embryonic day (E) 6.5 and 10.5, with some mutants 
presenting with heart defects. A conditional allele was therefore employed to examine the role 
of HIRA during heart development. Conditional ablation in the cardiogenic mesoderm 
(Mesp1Cre) led to surface oedema, ventricular septum defects (VSD) and embryonic lethality. 
More specific Cre drivers have shown that HIRA is essential in cardiomyocytes (Nkx2.5Cre) but 
is not in endothelial cells (Tie2Cre). 
RNAseq analysis and in situ hybridization were used to detect an upregulation of the 
troponins Tnni2 and Tnnt3 and a decreased expression of Epha3, a gene necessary for fusion of 
the interventricular septum with the endocardial cushions. In addition, immunostaining of 
Troponin C (TnC) emphasised a disorganisation of the contracting meshwork of myofibril. 
ChIPseq experiment revealed that HIRA binds to GAGA rich DNA sequence in the embryonic 
heart and is enriched at the common enhancer of Tnni2/Tnnt3 (TLT). Furthermore, in vitro and 
in vivo co-immunoprecipitations revealed that HIRA interacts with WHSC1 a protein thought to 
play a major role in Wolf-Hirschhorn syndrome, as well as BRG1, a chromatin remodelling 
complex required for cardiogenesis. WHSC1 also interacts with NKX2.5, a major cardiac 
transcription factor that binds the same regulatory TLT site as HIRA. Altogether, this work gives 
evidence for a specific requirement of HIRA in mesodermal cardiac progenitors during heart 
development. HIRA influences contractility, troponins expression and the endothelial to 
mesenchymal transition in the cardiac cushions.  
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 Chapter 1 INTRODUCTION 
 
1.1)  Heart development and cell lineages contributing to the heart 
Being the first organ to be formed in the embryo, the heart plays a pivotal role during 
embryogenesis and is necessary for survival past midgestation. Cardiogenesis involves tightly-
regulated morphological changes orchestrated by many different lineages each contributing to 
a specific cardiac structure. An overview is given here on the temporal development and tissue 
contributions of some cardiac progenitors. 1.1.1) Cardiogenic mesoderm  
In the murine model, the heart first arises from mesodermal cells in the primitive 
streak at embryonic day (E)6 (Buckingham et al., 2005). As gastrulation proceeds, mesodermal 
multipotent cardiac progenitors (MCPs) migrate to the splanchnic mesoderm forming the 
cardiac crescent which is constituted of both first heart field and second heart field (FHF and 
SHF) cells (Buckingham et al., 2005) (Figure 1-1).  
 
Figure 1-1 Two lineages contribute to the formation of the heart  
At E7.5 the cardiac crest forms, composed of the FHF (red) and lying medial to it, the SHF 
(green). The SHF is divided into the anterior (aSHF) and posterior regions (pSHF). Between E8 
and E9, the cardiac crescent fuses at the midline to form the primitive heart tube.  The cardiac 
neural crest cells (cNCC) migrate from the neural tube to colonise the pharyngeal arch arches 
and eventually the OFT. At E10.5 the heart is composed of primitive chambers which will 
undergo septation until E14.5-E15.5. RV/LV: Right/Left ventricle. RA/LA: Right/Left atrium. 
OFT: Outflow tract. IVS: Interventricular septum. Ao: aorta. AA: arch arteries. Pt: Pulmonary 
trunk. Adapted from (Zaffran et al., 2014) and (Buckingham et al., 2005) 
 
 
The primitive heart tube then forms at E8 as the population of cells referred to as the FHF 
merges in the midline (Vincent and Buckingham, 2010). Those cardiogenic mesodermal cells of 
FHF serve as a scaffold for a second wave of myocardial cells, referred to as the SHF (Dyer and 
Kirby, 2009). This population of undifferentiated MCPs comes from the pharyngeal mesoderm 
and lie medial to the FHF (Buckingham et al., 2005). The FHF will then contribute exclusively to 
the left ventricle whilst the SHF cells will form the outflow tract, and a mix of  both heart fields 
will participate in the  formation of the right ventricle (RV) and both atria (Figure 1-1).  
 1.1.2) Heart looping and formation of the chambers 
The heart tube at E8 is formed by endocardial cells coming from both sides of the 
embryo and the neural crest cells. As these endocardial cells form a lumen, they are enveloped 
by myocardial cells (Moorman et al., 2003). The inflow tract sits posteriorly to the heart tube, 
whilst the outflow tract (OFT) is located anteriorly. As the SHF cells extend the heart tube by 
making a significant contribution to the cranial pole, the connection between the primitive left 
ventricle and the mediastinum (central component of the thorax) is disrupted and the now 
free tube starts looping in the rightward direction at E8.5-E9, which is a necessary event for 
the formation of the primitive chambers (Moorman et al., 2003). 
  At E10.5 the heart displays the following anatomical features: the ventricle, the 
atrioventricular canal (AVC), the atrium and the OFT with an inner endocardial lining and an 
outer myocardial layer. The heart can be described as partially partitioned by the primitive 
atrial septum, inter-ventricular septum (IVS) and atrioventricular cushions (AV cushions). 
Between E10.5 and E15.5, those prototypic four chambers will be become fully separated. The 
IVS starts to grow from the apex of the heart to separate the ventricular chamber into left and 
right ventricles, eventually connecting with the OFT to separate ventricular outlets (Anderson 
et al., 2014). Between the endocardial lining and an outer myocardial layer, the endocardial 
cushions arise through the accumulation of cardiac jelly (i.e. extracellular matrix). These local 
tissue swellings are rapidly invaded by mesenchymal cells resulting from the epithelial to 
mesenchymal transition (EMT) (Lin et al., 2012). In the heart this process is often referred to as 
endothelial to mesenchymal (EndMT) since the cells involved are endothelial (Kovacic et al., 
2012). However, the distinction between EMT and EndMT remains unclear in the current 
literature, since both terms encompass endothelial cells. EndMT is crucial to the growth and 
correct establishment of the semilunar valves, the atrioventricular septum, the mitral and 
tricuspid valves and the membranous part of the IVS, which is derived from the 
atrioventricular cushions (Person et al., 2005) (Figure 1-2). Many soluble growth factors such 
as TGF-β, EGF-related growth factors, and VEGF have been shown to govern endocardial 
cushion transformation shaping (Person et al., 2005, Barnett and Desgrosellier, 2003). 
However EPH receptor family and its ephrin ligands, which are of particular interest in this 
thesis (see p75), have also attracted the attention. Originally found to be axonal guidance cues 
(Moorman and Christoffels, 2003), this family of receptors and ligands regulate an important 
aspect of the heart morphogenesis. Lethal valve and cushion malformations have been 
identified in mouse embryonic mutants for Ephrin-A1 (Frieden et al., 2010), Ephrin-B2 (Cowan 
et al., 2004) ligands and EphA3 receptor (Stephen et al., 2007).  
 
Figure 1-2 Mesenchymal cells contribute to the formation of the AVC and the IVS 
Endothelial to mesenchymal (EndMT) leading to local tissue swellings gives rise to endocardial 
cushions. Here, transverse section of the heart in chicken embryos at stage 28 show the 
participation of the mesenchymal tissue derived from the atrioventricular cushions (AVC) on 
the interventricular septum (IVS) (arrows). RV/LV: Right/Left ventricle. RA/LA: Right/Left 
atrium. Adapted from (Strauss et al., 1987). 
 1.1.3) Septation of the OFT into pulmonary trunk and aorta 
After heart looping, the common OFT needs to be septated in order to form the aorta 
(Ao) and the pulmonary trunk (PT). The walls of the OFT are made of myocardium whilst the 
lumen is lined with cardiac jelly, containing mesenchymal cells originating from the 
endocardium (proximal) the neural crest (distal). These cardiac neural crest cells (cNCC) 
delaminate from the dorsal neural tube and migrate through the pharyngeal arches to colonise 
the OFT. As the pharyngeal region is being remodelled, the aorto-pulmonary septum starts the 
distal septation of the OFT (Webb et al., 2003). This septum is comprised of proliferating 
mesenchymal cells which arise from an EMT on both sides of the vessel. Once the endothelium 
fuses, the septal bridge is formed and SHF-derived smooth muscle cells as well as myocardium 
further separates the OFT into two distinct vessels (Plein et al., 2015). Eventually, the “zipper 
like” fusion of the cushions attach to the IVS, thus fusing the base of the aorta to the left 
ventricle and the PT to the right ventricle (van den Hoff et al., 1999). 1.1.4) Lineages contributing to the heart 
As mentioned above, MCPs arise from the differentiation of a common progenitor. 
Through labelling of cardiac precursors in different regions of the mouse heart during 
development (Meilhac et al., 2004), it is possible to identify molecular markers for cardiac 
progenitors. There are many known core genes which are part of the regulatory network for 
early cardiac development determining First and Second Heart Fields (Herrmann et al., 2012). 
Below is the description of those genes which have been better characterised and which have 
been used to drive Cre expression and thereby the ablation of Hira in various conditional 
contexts.  
    1.1.4.1) Mesp1 
In 1999, Saga et al were the first to demonstrate that Mesp1 is the earliest cardiac 
progenitor and is “activated at first in the extraembryonic mesoderm and then in the common 
precursor cells of myocardium, endocardium, and the vascular system” (Saga et al., 1999). It 
belongs to a basic helix-loop-helix (bHLH) transcription factor family and is first detected at 
E6.5 (Figure 1-3) in a certain part of the mesoderm which has ingressed through the primitive 
streak. Defined as a cardiogenic mesodermal marker, Mesp1 is a potent tool to use for 
conditional knockout. All cells that constitute the heart come from Mesp1-expressing cells, 
except for a small population of cardiac neural crest cells (see p7). However, the skull vault and 
its connective tissues in the craniofacial mesenchyme also have some Mesp1 positive cells 
(Yoshida et al., 2008). Recently, Mesp1 lineage was found come from two temporally distinct 
pools of cells restricted to either the FHF or SHF (Lescroart et al., 2014). In contrast to the 
model in which Mesp1 is expressed in the earliest multipotent cardiovascular progenitors 
common to the FHF and SHF, single cell recombination event in Rosa–Confetti mice 
demonstrated that Mesp1 actually marks distinct classes of cardiovascular progenitors which 
are restricted to specific lineages during gastrulation (Error! Reference source not found.).  
 
Figure 1-3 Mesp1 is an early regulator of cardiovascular progenitors 
Studies have demonstrated that Mesp1 represents the earliest marker of cardiovascular 
progenitors. Mesp1 expression is shown here by in situ hybridization from E6.5 to E8.5. The 
activity of the Mesp1Cre recombinase at E9.5 is done by crossing a knock-in Mesp1Cre mouse 
to a transgenic mouse line carrying the reporter gene construct CAG-CAT-Z which directs 
expression a lacZ gene upon Cre-mediated excision of the loxP-flanked chloramphenicol 
acetyltransferase (CAT) gene located between the CAG promoter and the lacZ gene. This 
lineage trace shows the strongest expression of Mesp1 in the heart (H), some in Otic Vesicle 
(Otv), in the optic vesicle (OV), in the mandibular arch (M) and in the anterior limb (AL). A/P: 




Figure 1-4 Mesp1 expressing cells consist of distinct pools of FHF or SHF progenitors 
Clonal analysis of prospective cardiovascular progenitors revealed that Mesp1 progenitors 
consist of two temporally distinct pools. The model presented here show cardiovascular 
progenitors which are committed to a particular lineage, depending of their temporal 
expression of Mesp1 between E6.25 and E7.5. FHF is shown in red and SHF in green. The two 
populations have an overlapping expression at E6.75. PS: primitive streak EPDC: epicardial 
derived cells CM: cardiomyocytes EC: endothelial cell SM: smooth muscle cell. Adapted from 




    1.1.4.2) Nkx2.5 
Nkx2.5 is highly expressed in the early heart progenitor cells in both the FHF and SHF 
during murine embryogenesis from E7.5 (Biben and Harvey, 1997). It is the homologue of 
Tinman (drosophila) which is a master cardiac regulator (Bodmer, 1993). In contrast to Mesp1 
which is switched off around E10.5, it continues to be expressed at a high level in the heart 
through adulthood (Kasahara et al., 1998).  Nkx2.5 progenitors are expressed in cardiac 
endothelium and smooth muscle, in addition to virtually all cardiomyocytes of all four 
chambers of the heart (Figure 1-5) (Ma et al., 2008). NKX2.5 cooperates, amongst other, with 




Nkx2.5 is a transcription factor expressed 24 hours after Mesp1 in heart progenitor cells in 
both the FHF and SHF. Nkx2.5 expression is shown here using a knock-in Nkx2.5Cre construct. 
When crossed to ROSA26 (R26R), activity of the Nkx2.5Cre recombinase allele is detected here 
by β-gal at E9.5 (A) and at E11.5 (B-C). Lateral view (B) and transverse section (C).  Both stages 
reveal an expression restricted to cardiac tissues. Right/Left ventricle (RV/LV), Endocardial 
cushions (EC), Left atrium (LA). Adapted from (Moses et al., 2001). 
 
   1.1.4.3) Mef2c 
Mef2c is partly controlled by Nkx2.5 and therefore expressed slightly later at around 
E7.75 (Lin et al., 1997). Mef2c null embryos fail to develop cardiac structures which derive 
from the anterior heart field (AHF) (Lin et al., 1997). The SHF regions can be split into the 
anterior and posterior, each transcriptionally distinct (Zaffran et al., 2004) (Figure 1-6). The 
AHF includes the splanchnic and pharyngeal mesodermal regions that encompass the arterial 
pole of the primary heart tube. Using a Mef2cCre transgenic allele (used in this PhD project) 
crossed to a Cre-dependent LacZ reporter mice, the expression of Mef2c was traced to the 
right ventricle and ventricular septum, and the endothelial and myocardial cells of the OFT. 
However, no staining was observed in cells from the atria, the epicardium nor the coronary 
vessels (Verzi et al., 2005) (Figure 1-7). 
 
 
The SHF has two transcriptionally distinct regions. The schematic represents the heart tube at 
E8.0. Nkx2.5 is expressed in both the posterior (green) and anterior (yellow) parts of the SHF, 
whilst Mef2c is restricted to the anterior region. Adapted from (Vincent and Buckingham, 
2010). 
 
Figure 1-5 Cardiomyocytes express Nkx2.5 from E7.5 during heart development 
Figure 1-6 The SHF is made of an anterior and posterior part 
 
Figure 1-7 Mef2c is expressed in the SHF 
Mef2c is cardiac transcription factor which is a key regulator of the SHF. The expression of the 
Mef2cCre transgene allele is displayed here in the cardiac lineage as seen in the lateral view at 
E9.5 (A). Cre activity can be detected with as early as E7.75 in the cardiac crescent by the same 
method to the one described above with Nkx2.5Cre (6). Expression is detected here in the right 
ventricle (RV), outflow tract (OFT), in the pharyngeal mesoderm (PM) and in the branchial 
arches at E9.5 (A). Expression in absent from common arterial chamber and most of the left 
ventricle (heart at E9.5 (B) and at E12.5 (C). Adapted from (Verzi et al., 2005). 
 
    1.1.4.4) Wnt1 
Wnt1’s vital role in the development of the central nervous system (CNS) was 
apparent when mutant embryos showed a complete loss of the entire mid/hindbrain region 
(McMahon and Bradley, 1990). A lineage study using transgenic Wnt1Cre mice crossed with 
R26R conditional reporter allele revealed that NCC are highly migratory (Jiang et al., 2000). 
NCCs which derive from the dorsal aspect of the neural tube are expressed in dorsal root 
ganglia, peripheral nervous system, melanocytes, adrenal medulla and craniofacial 
mesenchyme (Jiang et al., 2000). Early experiments which used a combination vital dye 
labelling and exo utero embryological injections revealed that the NCCs populate the 
pharyngeal arches (Serbedzija et al., 1992) (Figure 1-8). Wnt1 was found to be expressed in 
the mesenchymal component of the pharyngeal arches at E9.5 (Jiang et al., 2000). At E12, 
during the asymmetric reorganisation of the great vessels, NCCs actively participate in the 
remodelling and septation of the OFT. It should be noted that NCCs are also involved in the 
formation of atrioventricular valves (Nakamura et al., 2006), their supporting sinuses, the 
coronary arteries and cardiac neural ganglia, as well as the parasympathetic and the 
sympathetic innervation of the venous pole of the heart (Hildreth et al., 2008). 
 
Figure 1-8 Wnt1 is expressed in neural crest cells which contribute to the formation of 
the heart 
A subpopulation of NCCs migrate along the pharyngeal arches and are necessary for the 
remodelling and septation of the OFT. The expression of Wnt1Cre is shown here, using a R26R-
lacZ transgene, and can be detected in the NCCs from E7.5. At E9.5, the expression is visible in 
fore- and midbrain and in the mesenchymal component of the pharyngeal arches (red arrow) 
(A). Migratory neural crest cells colonise the brachiocephalic artery (BCA), the carotid artery 
(CA) and parts of the ascending/descending aorta (A/DAo) (B) at E14.5. Adapted (Jacques-
Fricke et al.)(A) and (Nakamura et al., 2006)(B). 
 
   1.1.4.5) Tie2 
Tie2 was originally shown to  target reporter gene expression (LacZ) in virtually all 
vascular endothelial cells during embryogenesis and in postnatal life (Schlaeger et al., 1997). 
Both Tie2-lacZ transgenic mice (Schlaeger et al., 1997) and Tie2-Cre transgenic crossed with 
CAG-CAT-Z (Kisanuki et al., 2001) (in which LacZ expression is activated by Cre-mediated 
recombination) show a strong β-galactosidase activity in every ECs of blood vessels by E11.5 
(Figure 1-9). Using the Tie2Cre allele, an early expression was noticed at E7.5 in some 
mesodermal cells and extraembryonic tissue. By E8.5, a fraction of the ECs in the aorta and the 
endocardium were labelled. From E9.5 though, the expression of Tie2 was ubiquitous in the 
developing endocardium and ECs present in cardiac tissue, including mesenchymal cells 
resulting from the endothelial to mesenchymal transition in the endocardial cushions (Kisanuki 
et al., 2001). Although Tie2 is not expressed in the haematopoietic lineage, some circulating 
endothelial progenitor cells have been detected, which originate from the bone marrow 





Figure 1-9 Tie2Cre labels endothelial cells throughout the organism 
The endothelial specific promoter/enhancer Tie2 was used to create a Tie2Cre transgenic mice 
which has a Cre recombinase activity in the endothelial lineage. Here, the transgene Tie2Cre 
activity is visualised via a CAG-CAT-Z reporter. All blood vessels reveal a Cre activity, as seen in 
the lateral view at E11.5 (A). The endocardium shows expression of Tie2cre in this transverse 
section (B). Both images are from an E11.5 embryo and adapted from Kisanuki (Kisanuki et al., 
2001) 
 1.1.5) Heart contractility governed by troponins 
After cardiac looping at E10.5, the heart becomes increasingly essential for the rest of 
the embryo to receive enough blood to proceed with development. Cardiac and skeletal 
muscle progenitors are both derived from mesoderm and differentiate into striated muscle 
fibres, which have a comparable structure. Muscle fibres contain tubular myofibrils, composed 
of numerous sarcomeres. The two boundaries of a sarcomere are called Z discs, to which actin 
molecules are bound. Parallel to the actin thin filaments lies the myosin heads of the thick 
filaments (Figure 1-10). The myosin heads bind to and exert force onto the actin molecule 
thus forcing the two filaments to slide along one another and shorten the sarcomere and 
initiate global muscle contraction. The actin thin filament consists of 3 troponin subunits: TnC, 
TnI, and TnT, to which Ca2+ can bind. Calcium ions generate the interaction force between actin 
and myosin, whilst local ATP hydrolysis promotes the high energy configuration of the myosin 
head and drives muscle contraction (Lehman et al., 1994). The thin filament is helically 
arranged with tropomyosin, a long flexible molecule, which together with troponins, are 
attached to actin (Figure 1-10). When Ca2+ bind specifically to TnC, TnC-TnI interaction is 
strengthen whilst the interaction between TnI and actin weakens. This enables Tropomyosin to 
“rock and roll” dynamically to modify the strength with which myosin head binds to actin 
(Gordon et al., 2001). The organisation of the contracting meshwork of myofibril and the 
regulation of cross-bridge actin-myosin interactions is highly dynamic and vital during heart 
development, and reduced cardiac output can arrest development or lead to pericardial 




maximum Ca2+-activated isometric force normalized to the cross-sectional area (FCSA). Between 
E10.5 and E19.5, contractility increases by 5-fold (Siedner et al., 2003). 
 
Figure 1-10 Sarcomeres drive muscle contraction 
Muscle fibres contain many tubular myofibrils, arranged parallel to each other and composed 
of numerous sarcomeres. The schematic representation of a sarcomere is shown here, with 
the two opposite conformations of the myosin head: released (left) and anchored (right) to the 
actin filament. An actin filament consists of 3 troponin subunits (TnC, TnI, and TnT) which 
govern the release of Ca2+ and the local hydrolysis of ATP.  
 
 
1.2) Chromatin structure and regulation of transcription 
 1.2.1) Chromatin structure 
 The DNA of the entire genome is compacted in most cells, as it needs to be packaged 
tightly in the nucleus whilst remaining accessible to the molecular machinery. Chromatin 
serves various purposes: compacting DNA into the nucleus, protecting it from damage caused 
by reactive oxygen species (Mansoor and Ali, 2007) or ultra violet light (Durante et al., 2013), 
controlling gene expression (Felsenfeld et al., 1996), DNA replication (Alabert and Groth, 2012) 
and DNA repair (Price and D’Andrea). Two main global states define chromatin; 
heterochromatin where the chromatin is highly condensed, and as a consequence where gene 
expression is usually silent, and euchromatin where the chromatin is more open, and as a 
consequence where genes are more accessible by the transcription machinery. The scaffold of 
chromatin is essentially made of nucleosomes, which are responsible for the chromatin 
conformation and contain eight histone proteins with 145-147 nucleotides wrapped around 
them (Figure 1-11). There are five types of histones: H1, H2A, H2B, H3 and H4 (Annunziato, 
2008). Apart from the linker H1 all histones assemble in pairs which together form an octamer 
(Figure 1-12). The H1 linker histone supports unwrapped DNA which varies in length between 
10 to 50 bp. It has been shown that 75 to 90% of genomic DNA is wrapped around 
nucleosomes (Segal et al., 2006). This structure is highly stable as a result of the negatively 
charged deoxyribose-phosphate DNA backbone and the positively charged histones (Blank and 
Becker, 1996). DNA sequences, which have a variable capacity to bend (Widom, 2001),  can 
affect the position of nucleosomes (Segal et al., 2006) and to a certain extent impact 
transcription. Studies of the DNA deformability sequence pattern have all converged to the 
sequence motif “CGRAAATTTYCG”, where R= A or G (purines) and   Y = C or T (pyrimidines) 
(Trifonov, 2011), which would favour the wrapping around a histone octamer. However such a 
sequence is highly degenerate and much controversy surrounds the field of nucleosome 
positioning (Kaplan et al., 2010). Linear DNA wrapped around nucleosomes is compacted 30 to 
40 times, by bending it at an atomic level, but also on a larger gene scale by forming higher-
order helices (Van Holde et al., 1974). These higher order tertiary structures are the result of 
complex interactions between chains of nucleosomes and are dynamically adjusted in part by 
histone modification patterns. Via the modification of histones, nucleosomes recruit other 
proteins and this can drastically affect transcription. The patterns of histone post-translational 
modifications which correlates with chromosomal state and indirectly, transcriptional levels is 
sometimes referred to as the “histone code” hypothesis (Jenuwein and Allis, 2001). The term 
“code” refers to the numerous possible combinations that, for example, a single H3 can have. 
There are 10 lysines which can adopt 4 methylations: mono-, di-, and tri- or unmethylated. 








Figure 1-11 DNA wraps around nucleosomes which are constituted of a histone 
octamer  
The diagram represents the eukaryotic chromosomal structure and compaction, in which 147 
nucleotides of linear DNA are wrapped around a histone octamer and between 10 to 50 
nucleotides are bound to the H1 linker histone. Adapted from Namrata Chhabra (2015). 
 
In eukaryotes, highly compacted DNA cannot host the basal transcriptional machinery and 
needs to be modified (Struhl, 1999) by three main mechanisms: either through methylation of 
CpG dinucleotides, or via ATP-dependent chromatin remodelling, or by histone modifications 
(Agalioti et al., 2000). The latter include methylation, acetylation, phosphorylation, 
ubiquitination and sumoylation (Bannister and Kouzarides, 2011), some examples of which will 





Figure 1-12 Crystal structure of a nucleosome reveals the interaction between histones 
The X-ray crystal structure of the nucleosome core presented here shows the 146-bp DNA 
phosphodiester backbones (brown and turquoise) in a superhelix conformation with the eight 
histone protein forming the nucleosome (blue: H3; green: H4; yellow: H2A; red: H2B). The 2.8 
angstrom resolution of the crystal gave an overview of histone-histone interactions. For 
example, the two H3 bind through their C-terminal domain which forms a 4-helix bundle. From 
(Luger et al., 1997). 
 1.2.2) DNA methylation  
Whilst the regulation of gene expression during development is primarily encoded in 
the DNA sequence itself, epigenetic information which lies in the methylation status of the 
fifth position in the cytosine 6-atom ring (Smith and Meissner, 2013), also has a general impact 
on the transcriptome.  First discovered in the early 1980s (Haigh et al., 1982), evidence was 
given for the upregulation of unmethylated genes in the chicken β-globin locus. The 
methylation is mainly governed by three highly conserved enzymes: DNA methyltransferase 1 
(DNMT1), DNMT3A and DNMT3B (Okano et al., 1999). Methylation can take place during the 
semi-conservative replication of DNA, copying the methylation from a parental DNA strand to 
its new partner after replication but also de novo. To maintain the expression of a gene, the 
DNMTs keep CpGs at promoters unmethylated and are vital for the expression of 
housekeeping genes. DNA methylation tends to be more stable than histone methylation in 
somatic cells, although the diversity of the latter has recently attracted a lot of attention. 1.2.3) Histone modification 
 The roles of histone acetylation and methylation in “nuclear function” were first 
described by Vincent Allfrey (Allfrey et al., 1964) in the 1960s, who discovered that acetylated 
histone increased RNA synthesis compared to arginine rich histones. Experiments which used 
electron microscopy and analytical ultracentrifugation (sedimentation velocity) showed that 
acetylated oligonucleosomes remained in an extended conformation (Garcia-Ramirez et al., 
1995) compared to controls, thus further supporting the idea that chromatin condensation is 
reduced by histone acetylation. Histone dimers H2A-H2B and tetramers H3-H4, the latter 
ultimately driving the assembly of the nucleosome (Talbert and Henikoff, 2010), are all made 
of a globular domain and a NH2 terminus, called the “tail”. This tail can be modified post-
translationally. In addition to altering chromatin structure, histone acetylation can regulate 
transcription by recruiting chromatin remodelling enzymes (Agalioti et al., 2000) (see p20). 
Histone tail modifications are regulated by many proteins such as histone acetyltransferase 
(HAT) and histone deacetylases (HDAC)(Figure 1-13). They govern acetylation of the ε-amino 
group via catalysis of an acetyl group from acetyl-CoA onto a lysine residue at multiple sites, 
thus weakening the binding strength between DNA and histones. 
 
Figure 1-13 Lysine is reversibly acetylated  
Histones have a globular domain and a NH2 terminus, which can be acetylated by a histone 
acetyltransferase (HAT) or deacetylated by a histone deacetylase (HDAC). The representation 
here shows both nonacetylated (left) and acetylated lysine residues (right). Adapted from 
(Yang and Seto, 2007) 
There are three main groups of HATs: GNAT ((Gcn5)-related N-acetyltransferases), 
MYST and CBP/p300 (adenoviral E1A-associated protein of 300 kDa) (Bordoli et al., 2001). 
Using high temporal fluorescence microscopy, evidence demonstrated that histone H3 lysine-
27 acetylation (H3K27Ac) influenced transcription within minutes of its incorporation in 
nucleosomes, in two distinct steps: first the acetylation facilitated the binding of 
transcriptional activators to the chromatin and second, RNA PolII complex rapidly switched 
from initiation to elongation state (Stasevich et al., 2014). The effect of the accumulation of 
various methylation and acetylation modifications of histone lysine residues is discussed 
below. 
The inheritance of histone modification during cell division remains unclear. In a semi 
conservative model of replication, the transmission of DNA methylation has been well 
characterised: DNMT1 specifically targets hemi-methylated sites to replicate methylation 
patterns (Jin et al., 2011). One theory named “piggy-back model” suggests that the cell uses 
DNA methylation pathways to replicate histone modifications (Martin and Zhang, 2007). In 
mouse fibroblast cells, the methyl-CpG-binding protein MeCP2 can deposit H3K9 
monomethylation (Fuks et al., 2003). Evidence for “reading” and “writing” modifications from 
the old H3/H4 to the new one, thereby transferring the modifications to the de novo 
synthesized strand, is provided by WDR5 and HP1 proteins (Wysocka et al., 2005) in X.laevis, 
which recruit methyltransferases. A similar mechanism in yeast suggested that the old histones 
from the bulk chromatin segregated randomly to both daughter strands during DNA 
replication, with Swi6, a H3K9 “reader”, triggering methyltransferase activity on adjacent 
nucleosomes (Hall et al., 2002). However, addition players involved in epigenetic inheritance 
have also been identified. A cofactor of DNA polymerases, PCNA (Proliferating cell nuclear 
antigen), which binds to both the leading and lagging strands during DNA replication 
(Moldovan et al.) was found to recruit HDACs (Milutinovic et al., 2002), chromatin remodellers 
(Poot et al., 2004), methyltransferase (Huen et al., 2008) and histone chaperone CAF1 (Quivy 
et al., 2008). These chromatin-binding proteins or chromatin modifiers have been involved in 
copying DNA methylation and specific histone modifications from mother to daughter cells 
(Probst et al., 2009). 1.2.4) Epigenetic modification regulating transcription  
 There are many examples in which the environment impacts epigenetic marks. Neural 
plasticity, for example, is durably changed by cocaine via HDACs. This was seen by the 
acetylation of H3K9/14 and H4K5/8/12/16, markers of transcriptional activation, in the 
promoter region of cocaine responsive genes (Rogge and Wood, 2013). Interestingly in hearts 
where hypertrophy has been induced, the promoters of a set of NFκB target genes were found 
to be overacetylated thus suggesting a mechanism for potential cardioprotection by inhibition 
of HDAC activity (Ooi et al., 2015, Kang et al., 2015). Some lysine acetylation can also reside in 
the histone core itself, rather than in the “tail”, such as H3K56 (Bannister and Kouzarides, 
2011). Enrichment of H3K56Ac at the Vegfr1 promoter was found to be vital for the 
upregulation of this gene in endothelial cells (Dutta et al., 2010), and since this residue is 
located towards the major groove of the entry-exit site of the DNA super helix, it is more likely 
to affect the DNA/histone interaction (Masumoto et al., 2005). There are many different 
HDACs and they have a low substrate specificity, thus allowing one enzyme to deacetylate 
multiple residues. HDACs can be classified into four families: HDAC1, -2, -3 and -8 (class I); 
HDAC4, -5, -6, -7, -9 and -10 (class II) and HDAC11 (class IV) which all require Zn2+ for 
deacetylase activity and the sirtuin family (class III) which require NAD+ as a cofactor (Yang and 
Seto, 2007). HDACs are often part of a large multiprotein complexes as exemplified by HDAC1 
and HDAC2 which are part of the NuRD, Sin3a and Co-REST complex. However, it has been 
shown that HDAC1 can act independently to control embryonic stem (ES) cell differentiation 
(Dovey et al., 2010). An increase of H3K56Ac in ES cells lacking HDAC1 led to an overexpression 
of cardiomyocyte-, muscle-, and neuronal-specific markers (Dovey et al., 2010). HATs have 
often been implicated in cardiac muscle development. The HAT P300 for instance is expressed 
from E7.5 in the mouse, and P300-null embryos die between E9.5 and E11.5 as a result of thin 
myocardium and diminished trabeculation (Yao et al., 1998). 
Histone tails can be methylated on arginines or lysines. SUV39H1 was the first protein 
to be identified as a histone methyltransferase (Rea et al., 2000) (HMTase), after it was found 
to be responsible for position effect variegation in drosophila (Tschiersch et al., 1994).  
SUV39H1, acting through H3K9 methylation, recruits HP1 to juxtapose euchromatin with 
heterochromatin (Elgin and Reuter, 2013, Stewart et al., 2005). Many other HMTases have 
been identified and all present with a highly conserved SET domain. Depending on their 
intrinsic properties, they can modify specific lysine residues to a certain degree. For instance, 
the phenylalanine in DIM5 allows tri-methylation of a lysine (Zhang et al., 2003), whilst the 
tyrosine in SET7/9 in the equivalent catalytic domain only deposits mono-methyls (Xiao et al., 
2003). Specific methylation patterns have been found to have strong connections to gene 
expression (Sims and Reinberg, 2006, Wamstad et al., 2012). H3K4me1 is usually found on 
active/poised enhancers, H3K4me3 on active/poised promoters and H3K36me3 on actively 
transcribed regions (Hon et al., 2009). H3K27ac has a similar enrichment pattern to H3K4me1 
(Table 1-1) but can also predict active versus poised enhancers (Creyghton et al., 2010). 
H3K27me3, on the other hand, is associated with inactive promoters (Wamstad et al., 2012).  
Differentiation of mesodermal progenitors to cardiomyocyte requires EZH2, the major histone 
methyltransferase of the Polycomb repressor complex 2 (PRC2), which deposits H3K27me3 to 
repress foetal genes like Nppa, Nppb and Myh7 (Delgado-Olguin et al., 2012). Thus, post-
translational modification of histones play a key role in gene regulation, however the 
incorporation of core histone variants can also govern gene expression. 
 
Table 1-1 H3K4me1 and H3K27Ac enhancer marks strongly overlap in the developing 
heart (mouse genome) 
E11.5 H3K4me1 peaks  146 000 
E11.5 H3K27Ac peaks 77 000 
Overlapping regions (E11.5) 58 000 
E13.5 H3K4me1 peaks 260 000 
E13.5 H3K27ac peaks 116 000 
Overlapping regions (E13.5) 110 900 
 
Genome wide regions enriched for the histone marks for enhancers in the embryonic heart 
were downloaded from ENCODE project (Encyclopedia of DNA Elements, encode database 
ENCSR663VWL) (Shen et al., 2012) 
 
1.2.5) Histone variants  
Nucleosomal histones were previously thought to be highly stable and static once 
incorporated within the chromatin of non-dividing cells. However, separately encoded forms 
of canonical histones, or variant histones, can also be deposited as the replication fork carries 
out DNA synthesis (replication dependent) or as it is often the case, independent of replication 
(Maze et al., 2014). Canonical histones are defined by their expression which peaks during the 
S phase of replication, unlike variant histones (Szenker et al., 2011). Histone variants are 
deposited via a replication independent manner (Henikoff and Ahmad, 2005), as opposed to 
canonical histones, which are translated only during the replication phase (Hardy and Robert, 
2010). Some histone variants are nonallelic variants of the canonical form and present distinct 
biophysical characteristics which can alter nucleosome stability (Kamakaka and Biggins, 2005). 
Furthermore, unlike canonical histones, variant histone gene contain introns and are 
polyadenylated, which allows them to be post-transcriptionally modified (Old and Woodland, 
1984). Among the core histones, H2A has the most variants: H2A.Z, MacroH2A, H2A-Bbd, 
H2AvD, and H2A.X. They differ both in size of their C-terminal tails and their sequence (Figure 
1-14). H2B known variants are TSH2B, H2BFWT, H2BE. H3 has H3.1, H3.2, H3.3, H3.4 (also 
known as H3.1t and H3t) and H3.5 (H3.3C). H4 does not seem to have any variant. Genome 
wide studies have demonstrated that various genome regions sometime present a higher 
proportion of certain histone variant (Yukawa et al., 2014).  Two well studied variants are 
discussed below: H2A.Z and H3.3.  
 
 
Figure 1-14 H2A, H2B and H3 have variants in human  
Graphical representations of H2A (yellow), H2B (red), H3 (blue) variants are displayed here. H4 
(green) is the most conserved histone which acts as an anchoring site for the other histones 
and does not have variants. Key amino changes and position number are displayed. Black line 
represent unstructured histone tails. 
 
H2A.Z is constitutively expressed but is predominantly located in intergenic regions of 
the genome (Rangasamy et al., 2003, Kamakaka and Biggins, 2005). Experiments in 
promyelocytic cell line HL60 have shown that H2A.Z serves a dual purpose: it associates with 
promoters to demarcate active genes and maintain transcriptionally poised status, and its 
incorporation in coding region represses transcription by increasing nucleosomal stability 
(Farris et al., 2005). Similarly in the plant Arabidopsis thaliania, H2A.Z’s occupancy changes 
with temperature in order to either physically block the progression of RNA Pol II (since DNA 
will be wrapped more tightly around nucleosomes) or occlude cis-elements from activating 
transcription factors (Kumar and Wigge, 2010). In human T lymphocytes, a genome wide study 
showed that H2A.Z is deposited at the promoter region, upstream and downstream of the 
transcription start site (TSS). This deposition was positively correlated with the level of gene 
expression (Barski et al., 2007) (Figure 1-15). 
 
Figure 1-15 H2A.Z is enriched around the TSS in human cells 
Binding levels of the H2A variant H2A.Z are shown here. An enrichment was observed in the 
promoter region, upstream and downstream of the transcription start site (TSS). In addition, 
the deposition of H2A.Z was found to correlate with level of gene expression in human CD4+ T 
cells. Y-axis: normalised counts. X-axis: base pairs upstream (-) and downstream (+) of the TSS. 
Each groups represent 1000 genes ranked according to their levels of expression. Adapted 
from (Barski et al., 2007) 
 
H3.3 can be deposited during and outside of replication in drosophila (Ahmad and 
Henikoff, 2002). This variant histone has the particularity of having two separate coding genes: 
H3.3a and H3.3b which, in mouse, human and Drosophila, have a different DNA sequence 
(distinct untranslated region), and sometimes pattern of expression (Bramlage et al., 1997), 
but both translating to the same chain of amino acid (Bramlage et al., 1997, Szenker et al., 
2011). H3.3 differs by only four amino acids from the canonical form of H3 in the fly (A->S31, S-
>A87, V->I89 and M->G90), and five in human and mouse (an additional V->C96), on its α2 
helix, and yet it has a major impact on chromatin conformation. In Drosophila melanogaster, a 
single mutation of H3.1 or “canonical H3” towards H3.3 is sufficient for replication 
independent deposition (Ahmad and Henikoff, 2002). The functional properties of H3.3 are 
diverse: for example the phosphorylation of serine on position 31 (S31P) of H3.3 at the 
metaphase potentially protects the spread of heterochromatin onto euchromatin, thus 
keeping H3.3 chromatin in an open conformation (Hake et al., 2005). In HeLa cells, H3.3 
disturbs higher order chromatin folding, protects from H2A.Z-mediated compaction and 
promotes gene expression (Chen et al., 2013). Many looked at H3.3 in the context of 
epigenetic memory (Ng and Gurdon, 2008). In X.laevis embryos, nuclear transfer experiments 
demonstrated the capacity of H3.3 enrichment to maintain genes in an active state, for up to 
24 cell division (Ng and Gurdon, 2008). In development, H3.3 has been associated with 
transcriptional activity. For example in X.laevis, H3.3 incorporation is associated with gene 
activation at enriched sites (Ng and Gurdon, 2008). H3.3 enrichment has also been observed in 
silent chromatin loci at telomeres and centromeres in ES cells and mouse embryonic 
fibroblasts (Goldberg et al., 2010, Wong et al., 2009, Santenard et al., 2010). The TTAGGG 
sequence repeated in telomeres was found to be significantly enriched in H3.3 (Goldberg et al., 
2010), which carried the H3K9me3 mark thus revealing a function of H3.3 in maintaining 
constitutive heterochromatin (Udugama et al., 2015). In ES cells, H3.3 enrichment was found in 
gene rich regions of the genome and overlapped with markers of transcription such as 
phosphorylated RNA polymerase II (RNAPII), H3K4me3, H3K36me3, H3K4me1 (Goldberg et al., 
2010) as well as transcription factor binding sites. H3.3 was found to be enriched around the 
TSS of both active and repressed genes which have a high CpG content in ES cells, but not on 
the TSS itself, probably due to the CpG residues locally depleting nucleosomes (Fenouil et al., 
2012, Goldberg et al., 2010). In addition, H3.3 deposition at the gene body was only observed 
on active genes and not on repressed genes (Goldberg et al., 2010).  
 Similarly in HeLa cells, H3.3 is selectively enriched at TSSs of active genes (Jin et al., 
2009). Bivalent genes bear both the activating H3K4me3 and repressing H3K27me3 histone 
modifications and are thought to be poised for activation during differentiation (Mikkelsen et 
al., 2007). In ESCs, a strong enrichment of H3.3 was observed at the TSS of bivalent genes, 
which was abolished by mutations towards H3.2 or H3.1 (Banaszynski et al., 2013). 
In conclusion, H3.3 deposition has a pleiotropic role across different regions of the 
genome and at different times during development. Interestingly, studies on the combination 
of histone variants (eg: H2A.Z and H3.3) on nucleosome core particles in HeLa cells revealed 
that H3.3 enrichment at the TSS often co-locates with H2A.Z, which suggests H3.3 could play a 
role on DNA accessibility and gene regulation. The distribution of these unstable double 
variants (H3.3/H2A.Z) is different from nucleosomes with H2A.Z and H3.3 alone, and are 
thought to play a central part in the activation of promoters and the formation of 
“nucleosome-free regions” (Jin et al., 2009). 1.2.6) Examples of chromatin remodelling proteins in the heart 
ATP dependent chromatin-remodelling enzyme seem to have evolved to 
accommodate the growing complexity of chromatin as eukaryotic unicellar life evolved into 
complex organisms. Using techniques such as chromatin immunoprecipitation serial analysis of 
gene expression (ChIP-SAGE) and ChIP-seq (Schones and Zhao, 2008), four classes of ATP 
dependent chromatin-remodelling enzyme have been identified: SWI/SNF, ISWI, CHD and 
INO80 complexes, which are encoded by a total of 30 subunits. These enzymes are crucial for 
the assembly and the dissolution of chromatin structures and they all share one function: to 
increase nucleosome mobility. However, new functions are still being discovered such as 
maintaining higher order structure of chromosome, regulating telomeres structure and 
maintenance (Yu et al., 2007), segregating chromosomes or serving as DNA replication 
checkpoints. In the SWI/SNF complex, there are many subunits, including BRG1 and BRM. 
Officially named “SWI/SNF-related, matrix-associated, actin-dependent regulator of 
chromatin” (SMARC), this complex is more often referred to as Brg1/Brm-Associated Factors 
(BAF). BRG1 (Brahma-related gene 1) has been associated with transcription factor of the 
pluripotency network in ES cells, such as Oct4, Sox2 and Nanog (Ho et al., 2009) and when 
mutated, can cause tumours (Jones et al., 2012, Love et al., 2012).  BRG1 attracted much 
attention for its role in heart development and maintenance. In zebrafish, DPF3 is part of the 
BAF complex and is required for cardiac looping and contractility (Lange et al., 2008). Brg1 
myocardium conditional mutants are embryonic lethal as a result of thin compact myocardium 
and complete lack of interventricular septum (IVS) (Hang et al., 2010). BRG1 directly bind to 
and regulates α-MHC and β-MHC to preserve the α/β –MHC ratio in the foetal heart 
myocardium (Hang et al., 2010). In vitro experiments showed that the α-MHC repression by 
BRG1 was dependant on HDACs (Hang et al., 2010). Similarly, BAF60c, which recruits BRG1 to 
heart-specific enhancers (Tbx5, Nkx2.5 and Gata4) is required for cardiogenesis (Lickert et al., 
2004). Furthermore, Tbx5, Tbx20 and Nkx2.5 all share an essential allelic balance with Brg1, 
supporting the dosage sensitive model of the BAF complex during heart development 
(Takeuchi et al., 2011). A trans differentiation experiment using mesodermal cells 
differentiating to cardiomyocyte gave evidence for the critical role of Baf60c in the cardiac 
lineage (Takeuchi and Bruneau, 2009). Ablation of Brg1 by Tie2Cre in the endocardium led to 
hypotrabeculation (Stankunas et al., 2008) . BRG1 normally binds the promoter area to 
negatively regulated ADAMTS1 protein, a secreted matrix metalloproteinase, which shape the 
extracellular matrix (cardiac jelly) to form the trabeculae.   
The chromatin remodelling BRG1 has various roles during cardiogenesis, which 
implicates multiple pathways. 1.2.7) WHSC1: an example of a Histone methyltransferase playing a role during heart development  
The HMTase Wolf–Hirschhorn syndrome candidate 1 (WHSC1, also known as NSD2 or 
MMSET) specifically trimethylates H3K36. Intriguingly, Whsc1-/- embryos, which have a global 
reduction of H3K36me3 across the genome, show upregulation of genes implicated in heart 
development (Nimura et al., 2009) (Pdgfra, Igfbp5, Bmp2, and Isl1) but a downregulation of 
bone development-related genes (Lee et al., 2014) (Opn, Col1a1). The discrepancy between 
the two phenotypes can be explained by multiple factors. First WHSC1 deposits H3K36me3 
which acts as a “repressor of overactivation of transcription in active genes” (Lee et al., 2014) 
but this methyltransferase also associates with co-factors that may influence gene expression 
themselves, such as transcription factors. In the developing murine heart for instance, the 
WHSC1-NKX2.5 complex mainly acts through H3K36me3 deposition which negatively regulates 
transcription, whilst in the osteoprogenitors, the WHSC1-p300-RUNX2 complex drives the 
deposition of H4Ac (Lee et al., 2014) (marker of activation) which has a superior impact on 
gene expression than H3K36me3 deposition. Methylation of histone tail can also be modified 
dynamically during the differentiation process. For instance, certain domain structures in the 
PRC2 complex such as the Tudor domain and PHD finger domain have the capacity to bind or 
read histone tail modifications. It was shown that in mouse ES cell differentiation, PHF19 and 
No66 (a demethylase) bind to H3K36me3 on hitherto activated genes, recruit the PRC2 
complex, and drive a switch from H3K36me3 to H3K27me3, which ultimately leads to 
transcriptional repression (Brien et al., 2012). 
 
1.3) Known role of HIRA 
HIRA (HIR histone cell cycle regulation defective homolog A or Histone chaperone 
histone regulator A) is a large protein of 1017 amino acid residues first discovered in the yeast 
Saccharomyces cerevisiae (Sherwood et al., 1993). In the yeast, there are two proteins Hir1p 
and Hir2p which interact. Their names derive from the fact that they are transcriptional 
corepressors of six of the eight histone genes (HTA1-HTB1, HHT1-HHF1, and HHT2-HHF2) 
(Spector et al., 1997, Osley, 1991). When the DiGeorge critical region (see below) was cloned 
from human DNA, the 1017 amino acids sequence, which contained the 766 amino acids 
previously known as TUPLE1, was identified as HIRA, the human homologue of Yeast Hir1p and 
Hir2p (Lamour et al., 1995). Northern blots identified HIRA transcripts in all foetal organs, 
including the heart (Lamour et al., 1995).  Research on cell cycle regulators through cyclin-
dependent kinases (cdks) in a human osteosarcoma cell line revealed that HIRA is a cyclin cdk2 
substrate phosphorylated during S phase. Its overexpression led to an arrest in S-phase (Hall et 
al., 2001). Its role has since been identified in Xenopus laevis (Ray-Gallet et al., 2002) and 
Drosophila melanogaster (Loppin et al., 2005) as a histone chaperone which deposits core 
histones and has been studied to gain some insight into the mechanism of epigenetic 
regulation.  1.3.1) Disputed candidate for DiGeorge syndrome 
Our group was originally researching HIRA since it was a candidate genes for DiGeorge 
syndrome (Halford et al., 1993, Farrell et al., 1999, Scambler, 2000, Lamour et al., 1995) (DGS). 
First characterised by Angelo DiGeorge in 1965 (Cooper et al., 1965), this condition is often 
caused by a well characterised deletion of chromosome 22q11 (de la Chapelle et al., 1981), 
with 1 in 4000 live births affected (Scambler, 2000). Many birth defects have been associated 
with this deletion, which leads to various abnormalities such as facial dysmorphism, 
hypoplastic thymus gland and learning difficulty. The main cause of mortality in those patients, 
however, are congenital heart defects. They vary between persistent outflow tract 
abnormalities (truncus arteriosus, interrupted aortic arch type B), ventricular septal defect 
(VSD) and tetralogy of Fallot (ToF).  A high resolution analysis of this region helped 
chromosome 22 to be the first fully sequenced human chromosome (Kirsch et al., 2000), which 
maps to chromosome 16 in the mouse (Lund et al., 1999). Mapping the deletion revealed that 
most patient had a 3 Mb deletion, covering 35 genes (Scambler, 2000), including TBX1 and 
HIRA (Figure 1-16). 
 
Schematic representation of the genes of the 22q11 deletion located in the human genome 
(top) and their homologue in the mouse genome (bottom) on chromosome 16. HIRA (framed 
in red) in the centre in human and on the edge of an engineered deletion in the mouse. Taken 
from Scambler (2000) (Scambler, 2000).  
 
In an Israeli cohort of DGS patients, the 22q11.2 deletion was detected in 109 of 140 
subjects (77.8%) by fluorescent in situ hybridization (FISH) using a HIRA probe (Michaelovsky et 
al., 2012). In another cohort of 350 patients with traits typical of DGS/VCFS (Velo-cardio-Facial 
syndrome, another name for DGS (Shprintzen, 2008)), a typical 22q11 deletion was reported in 
78% of cases using the available FISH probes (Rauch et al., 2005). The 20% unaccounted for 
might be due to a poorly defined etiology, or misdiagnosed patients showing common 
symptoms which together phenocopy DGS. By using a PCR based technique called multiplex 
ligation-dependent probe amplification (MLPA), sensitivity was increased and allowed for the 
detection of deletions either proximal or distal to the FISH probes (Stachon et al., 2007), 
although between 10 and 20% of patients remained negative for HIRA FISH and/or MLPA 
testing. These patients might display microdeletions, variant breakpoints or atypical deletions 
which challenges the use of HIRA as the best candidate loci for DGS. A mouse model which has 
a heterozygous deletion (Df(16)) encompassing around 1 Mb of the homologous region on 
chromosome 16 displays cardiovascular abnormalities characteristic of DGS (Lindsay et al., 
1999). This phenotype was rescued when a P1-bacteriophage artificial chromosome containing 
Tbx1 was expressed in transgenic embryos. Furthermore, haploinsufficiency (the result of a 
decreased gene dosage) of Tbx1 reproduces many features of DiGeorge in mouse embryos 
(Lindsay et al., 2001, Paylor et al., 2006, Calmont et al., 2009). Hira heterozygous mutants, on 
the other hand, do not show any abnormality and are viable (Roberts et al., 2002). Therefore, 
TBX1 seems to be the most critical candidate (Restivo et al., 2006, Calmont et al., 2009) for 
Figure 1-16 Hira is located within the 22q11 deletion region in human and mouse 
DGS. In addition, human TBX1 missense mutations have been associated with the major 
features of DGS (Zweier et al., 2007). 
 1.3.2) HIRA is part of multiprotein complex 
Soon after its discovery, evidence was given for the capacity of HIRA to bind histones 
(Lorain et al., 1998). In the developing nervous system, HIRA was found to interact with the 
transcription factor PAX3 (Magnaghi et al., 1998). In HeLa cells transfected with H3.3 tagged 
HIRA, immuno-affinity purification experiments identified that HIRA was part of a multiprotein 
complex which includes UBN1, CABIN1 (Rai et al., 2011) and ASF1a (Tagami et al., 2004).  
Ubinuclein (UBN1) was first known for being a ubiquitously expressed nuclear protein 
which binds various transcription factors (Aho et al., 2000) such as C-jun. UBN1 binds to HIRA 
through its WD40 domain and is required for HIRA mediated formation of senescent 
associated heterochromatin foci (SAHF) (Banumathy et al., 2009). SAHFs are domains of 
facultative heterochromatin which have the ability to silence genes necessary for proliferation 
during senescence (Aird and Zhang, 2013) 
 Recently, a novel UBN1 domain (Hpc2-related) was identified, which gives the HIRA 
complex its H3.3 binding specificity (Daniel Ricketts et al., 2015). 
CABIN1, also known as CAIN, is the mammalian homologue of Hir3 in yeast. It is a 
known repressor of the transcription factor MEF2 which is done via the recruitment of both 
histone deacetylases and a histone methyltransferase (Jang et al., 2007). In the U2OS bone 
osteosarcoma cell line, CABIN1 directly interacts with HIRA and UBN1 (Rai et al., 2011). Further 
evidence for a functional role of CABIN1 came from a knockdown (KD) experiment followed by 
transcriptome analysis: in both HIRA KD and CABIN1 KD, the resulting set of dysregulated 
genes in HeLa cells was almost identical (Rai et al., 2011). 
ASF1 (Anti-silencing function 1) was originally recognised as a gene that de-represses 
silenced loci when it was overexpressed in the yeast (Le et al., 1997) and its function as a 
mediator of chromatin assembly after DNA replication was then established in the fly (Tyler et 
al., 1999). ASF1 is known to directly interact with histones through its hydrophobic beta sheet 
motif (English et al.). Its role during DNA replication is vital since in the absence of ASF1, DNA 
unwinding necessary to establish the replication fork is greatly reduced, probably due to an 
altered displacement of nucleosomes (Groth et al., 2007). The maintenance protein complex 
(MCM) interacts with ASF1a and the histone chaperone FACT (facilitates chromatin 
transcription) via histones H3 and H4 (Groth et al., 2007). Interestingly, FACT interacts with 
HIRA and together participate in H3.3 replacement (Nakayama et al., 2007). In this large 
quaternary HIRA/UBN1/CABIN1/ASF1a complex sometimes referred to as HUCA, HIRA is 
thought to act as a scaffold (Rai et al., 2011). 1.3.3) Known roles in vitro  
In a model of embryonic stem cell differentiation, Hira null cells were found to have an 
accelerated rate of differentiation (Meshorer et al., 2006). Embryonic bodies developed as 
soon as 24h in the mutant cells as opposed to 72h in WT control cells. It was suggested that 
this rapid differentiation correlates with a reduced incorporation of H3.3 thereby promoting 
the change of euchromatin into heterochromatin thus contributing to the loss of stemness. 
These data reveal the importance of HIRA in the early differentiation steps of ES cells to 
control the major rearrangements of the chromatin. However, HIRA has a moderate effect on 
gene expression in undifferentiated ESC (Goldberg et al., 2010). Similarly in HeLa cells, HIRA or 
CABIN1 knockdown only “modestly” affected gene expression (Rai et al., 2011). HIRA controls 
H3.3 enrichment at active and repressed high-CpG-density promoters (HCP) genes in 
undifferentiated cells. More precisely, HIRA deposits H3.3 at, and around the gene’s TSS 
(Goldberg et al., 2010). In HeLa cells, HIRA collaborates with histone binding protein ASF1a to 
deposit H3.3 at active promoters and at active/weak poised enhancers (Pchelintsev et al., 
2013b). Four clusters involving HIRA have been defined, each with a different coregulator 
composition and associated with a different nucleosome deposition pattern. For example, in 
the cluster in which HIRA is associated with active enhancers, there was an enrichment of 
H3K4me1, H3K4me3 and p300 whereas in the cluster marking promoters of actively 
transcribed genes, there were CpG islands and a similar methylation/acetylation pattern 
except for the absence of H3K4me1 (Pchelintsev et al., 2013a).  
Using a C2C12 myoblast cell line, it was shown that HIRA is required for differentiation 
into multinucleated myotubes (Yang et al., 2011). The deposition of H3.3 was detected at the 
core enhancer region (CER), the distal regulatory region (DRR) and the proximal regulatory 
region (PRR) of MyoD which is expressed during myogenic differentiation (Yang et al., 2011). 
Similarly, transdifferentiation experiments using C2C12 revealed a transient requirement for 
HIRA/ASF1a during osteogenesis (Song et al., 2012). 
 In vitro research on angiogenesis using yolk sac endothelial cells (YSECs) revealed an 
important role for HIRA in regulating the response of endothelial cells to angiogenic signals. 
When stimulated with fibroblast growth factor FGF2 and epidermal growth factor EGF, the 
upregulation of Vegfr1 seems to be mainly associated with histone H3 becoming acetylated at 
Lysine 56 (H3AcK56) at the Vegfr1 loci. This process happens via an exchange of nonacetylated 
histone H3 with H3AcK56, rather than direct acetylation of the Lysine 56 at the chromatin. 
Knockdown of HIRA prevented both upregulation of Vegfr1 and drastically reduced levels of 
H3AcK56 (Dutta et al., 2010). 
1.3.4) Known roles in vivo 
In Drosophila, Hira has been linked to male infertility. In the fly, the sperm nucleus is 
lacking all 4 core histones, replaced by the chromosomal proteins protamines. Upon 
fertilization, the nucleosome particles are assembled from maternal histones which are 
deposited in the male pronucleus. In sesame mutated eggs which have a homozygous 
mutation in Hira (Llevadot et al., 1998), this process fails and the haploid (maternal only) 
embryos die before hatching (Loppin et al., 2000). HIRA is therefore required to form DNA 
replication competent male pronuclei. Further investigation revealed the existence of multiple 
chromatin assembly machineries since in Hira mutant embryos, H3.3 deposition remains intact 
in all somatic and germline nuclei, except for late spermatid and sperm nuclei (Bonnefoy et al., 
2007). 
 HIRA-dependent H3.3 deposition is required for the late stage of gastrulation in the 
Xenopus Laevis embryo. Hira morphants and H3.3 morphants showed very similar phenotypes 
(Szenker et al., 2012). Both mutants had almost identical levels of H3.3 in total chromatin and 
a comparable sensitivity to micrococcal nuclease assay, a tool used to assess the conformation 
and condensation of chromatin.  
In the chick, Hira’s role was investigated in the neural crest cells (see p7). Total 
ablation of this cell population in the developing chick embryo leads to phenotypes similar to 
the ones observed in DGS patients (Kirby and Waldo, 1995). cHira antisense treatment (used 
for gene attenuation before the development of siRNA) in the premigratory neural crest cells 
also resulted in cardiovascular features of DGS (Farrell et al., 1999), such as persistent truncus 
arteriosus. This condition happens when the common truncus arteriosus fails to septate thus 
not giving rise to the pulmonary trunk and aorta. Neural crest cells normally contribute to the 
aorticopulmonary septum separating the arterial trunk and prevent the formation of other 
anatomical defect such as VSDs.  
In the mouse, maternal HIRA is present and required for mouse development past the 
zygote stage (Lin et al., 2014). Hira starts to be expressed in the blastula stage from E4.5 
(Ariane Chapgier personal communication). Described by our group in 2002, the Hira null mice 
are early embryonic lethal. No embryos survived past E11 with all mutants displaying growth 
retardation and some displaying severely disorganised tissues as early as E6.5. Early cardiac 
markers myosin heavy chain 2a and 2v (MCL2a/2v) were either severely downregulated or 
absent at around E10. Therefore, HIRA is thought to be required in the mesendoderm from the 
beginning of gastrulation (Roberts et al., 2002). 
These results demonstrate the importance of HIRA during cellular differentiation in 
various species and tissues.  
1.3.5) HIRA in DNA repair and cellular senescence  
Genome stability is critical to preserve cell functions. Histone variants and histone 
signature patterns are crucial in establishing that robustness (Talbert and Henikoff, 2010). In 
yeast, hormesis, also known as “cross-tolerance”, is the phenomenon by which cells exposed 
to mild stress activate certain core environmental stress response (CESR) genes. There is 
evidence for HIRA in increasing the accessibility of RNA pol II to the required genes during heat 
stress and oxidative stress response by nucleosome eviction (Chujo et al., 2012b). This was 
shown to be dependant of Slm9, one of the fission yeast homologue of HIRA, which was 
enriched at the promoters of ctt1, gpx1, and hsp9 (CESRs) in a stress-dependent manner 
(Chujo et al., 2012b).  
Senescence is a vital response acquired by the cell after the activation of oncogenes. 
This proliferation arrest is necessary to control and confine nascent tumours (Collado and 
Serrano, 2010). The mechanisms by which pre-malignant tumours enter senescence are 
complex. However, a remarkable phenomenon is the appearance of SAHFs (Cruickshanks et al., 
2013). This local remodelling of chromatin structure requires the incorporation of 
Heterochromatin protein 1 (HP1) and the histone H2A variant macroH2A. In human 
fibroblasts, HIRA and ASF1a (members of the HUCA complex) regulate the formation of SAHFs 
(Zhang et al., 2005), thus driving cell cycle exit. In addition of SAHFs, general chromatin 
changes are likely to contribute to senescence. For instance, DNA methylomes revealed that 
methylation changes in senescence resemble those in cancer (Cruickshanks et al., 2013), 
further supporting the notion of a fine balance separating premalignant senescent cells from 
malignant tumours. The epigenetic landscape of senescent cells is therefore more dynamic 
than previously thought. HIRA has been shown to be one of the critical regulators of chromatin 
required for efficient suppression of oncogene induced neoplasia (Rai et al., 2014). H4K16Ac is 
highly enriched in the promoters of genes active during senescence. HIRA governs the 
Incorporation and maintenance of H4K16ac and H3.3 into chromatin to suppress 
tumorigenesis and induce senescence (Rai et al., 2014).  
During cellular life, chromatin alteration due to cell stress can result in DNA damage, 
which can impact both the genome and the epigenome. Research on DNA damage-induced 
chromatin plasticity in response to UV radiation has shown that histone chaperones are 
important for restoring the structure and the function of chromatin. In the “access–repair–
restore” model (Figure 1-17), damaged chromatin is loosened to facilitate the access of repair 
machineries, before being reorganized once DNA repair has been completed (Adam et al., 
2014). HIRA has been identified as a promoter of transcription “restart” after severe genotoxic 
stress in both tumour cells and primary fibroblasts, through the deposition of newly 
synthesized H3.3 at genomic sites where UV irradiation was directed using a micropore filter 
(Adam et al., 2013). In addition, the acetyltransferase HAT1 which incorporates H4K5/K12Ac-
H3.3 at sites of double-strand breaks and associates with other homologous repair proteins 
such as RAD50/51 was found to interact with HIRA. This histone turnover activity at the site of 
DNA lesions was found to be HIRA dependant (Yang et al., 2013).  
 
Figure 1-17 HIRA is recruited at DNA damage sites to participate in chromatin 
bookmarking  
DNA damage such as UV radiation can be partly repaired by histone chaperones, which can 
restore the structure and the function of chromatin. Here, this schematic representation 
shows the recruitment of HIRA at sites of DNA damage. HIRA deposits new H3.3 histones to 
promote chromatin reorganisation such as CAF1 mediated canonical histone H3.1 deposition. 
Adapted from (Adam et al., 2013) 
 1.3.6) H3.3 mutations and its consequences 
H3.3 mutations can affect development.  For example in zebrafish H3.3 mutants, only 
tissue cranial neural crest (CNC) cell population was affected. A mutation in H3f3a, one of five 
zebrafish variant H3.3 genes, demonstrated that one of the roles of H3.3 is to prevent the 
formation of aberrant H3 homodimers. H3.3 mutants died by 7 days post fertilization (dpf) 
from CNC-derived cartilage, bone and teeth malformations preventing the fish from eating 
(Cox et al., 2012). Using timelapse immunofluorescence on live embryos, a lack of mutated 
H3.3 was only observed in the chromatin during metaphase/anaphase, rather than at all times 
during the cell cycle. This shows that H3.3 is present but is not integrated to the nucleosome. 
Further investigation of the nucleosome showed that mutated H3.3 “overbinds” WT H3.3, thus 
preventing normal formation of WT H3.3-H4 heterodimers (Cox et al., 2012). The replication 
independent property of H3.3 deposition proved to be crucial to CNC development since the 
same mutation in replication dependant H3.2 did not lead to any defects. The authors propose 
a model in which the unique developmental pattern of ectomesenchyme makes this CNC 
lineage particularly sensitive to H3.3 incorporation compared to lineages with simpler 
differentiation pathways (Cox et al., 2012). 
In the mouse, ex vivo research has shown that H3.3 is required early during 
development. Morpholinos injection targeted against both H3.3A and H3.3B in zygotes at the 
two cell stage led to arrest at the morula stage (Lin et al., 2013). In contrast to Drosophila 
where H3.3 mutants are viable but sterile (Sakai et al., 2009), H3.3 seems to be crucial during 
mouse development (Lin et al., 2013).  The arrest at the morula stage was not cause by 
dysregulation of genes related to lineage commitment (Oct4, Nanog or Sox2) but was due to 
over-condensation and mis-segregation of chromosomes due to a specific decrease of 
H3.3K36me2 and H4K16ac. During early development, the chromatin needs to stay condensed 
to achieve faithful chromosome segregation and developmental competence. H3.3 and H1 
have an antagonistic epistatic relationship, which explains the over incorporation of linker H1 
to the chromatin in H3.3 mutants (Lin et al., 2014) and the resulting chromosome over-
condensation. 
In human, heterozygous mutations in H3.3 were found to be responsible for the lethal 
brain tumour Glioblastoma Multiforme(GBM) (Schwartzentruber et al., 2012). In almost a third 
of the affected children, a single nucleotide variant (SNV) was found in H3F3A, one of the two 
genes coding for H3.3. The switch from glycine to arginine or valine on the 34th amino acid of 
H3.3 (G34R/V) or a change from lysine 27 to methionine (K27M) is sufficient to cause GBM. 
44% of these paediatric GBM patients also had mutations in either ATRX (a-
thalassaemia/mental retardation syndrome X-linked) and/or DAXX (death-domain associated 
protein), which are H3.3 histone chaperones active in the telomeres (Figure 1-18). However, 
recent research on ATRX-dependent deposition of H3.3 has unveiled that this chaperone is not 
entirely restricted to pericentric heterochromatin and telomeres but also occurs at 
heterochromatic sites throughout the genome, especially at sites carrying H3K9me3, a 
modification associated with silenced imprinted alleles (Voon et al., 2015). The rest of the 
tumours were largely explained by mutations in the tumour suppressor TP53. Mutations in 
H3.3 genes are highly prevalent in GBM, only one patient suffering from myelodysplastic 
syndrome (MDS) out of 77 had a mutated H3F3A gene in bone marrow cells (Attieh et al., 
2013).  
 
Figure 1-18 DAXX deposits H3.3 at the telomeres and centromeres 
DAXX is a H3.3 histone chaperone that targets subtelomeric and pericentromeric regions of 
the chromosome, whilst HIRA deposits H3.3 in transiently nucleosome-free gene rich regions. 
From (Kallappagoudar et al., 2015). 
In a cohort of patients suffering from chondroblastoma and giant cell tumour of bone, 
a unique “signature” was identified in the genes coding for H3.3. The same mutation, a 
p.Lys36Met, was identified in H3F3B in all patient with chondroblastoma, whilst the vast 
majority (49 out 53) of patients with giant cell tumour of bone had a p.Gly34Trp alteration in 
H3F3A. 
1.4) HIRA conditional allele 1.4.1) Hira null embryos are lethal early in development 
As discussed above, Hira was not the strongest candidate amongst the 35 genes 
deleted in the typical DGS. However HIRA is a well characterised histone chaperone depositing 
the variant histone H3.3 within chromatin which has been implicated in a multitude of 
biological processes from fertilization, through nuclear reprogramming, maintenance of 
stemness, cell cycle regulator and cellular senescence.  
Hira null embryos display a range of developmental defects during and subsequent to 
gastrulation (Roberts et al., 2002) and a small proportion of these mutants which survived to 
E10.5 showed abnormal heart looping and substantial pericardial oedema.  1.4.2) Hira conditional allele 
In order to bypass the early lethality of Hira null embryos, a Hira conditional allele 
(Hirafl/fl) was designed by the Sanger institute (Figure 3-1,p48). This allele contains a Beta-
galactosidase cassette surrounded by FRT (flippase recognition target) sites which can be 
targeted by the flippase recombinase. It is analogous to Cre-lox recombination. Once flippase 
is applied, the Beta-galactosidase cassette is lost and the allele becomes functional. Further 
recombination by CRE recombinase, which targets LoxP sites, ablates exon 4 which creates a 
non-functional copy of Hira.   
1.4.3) Rationale 
Hira has never been examined in the heart before. The global aim of this thesis was to 
dissect the potential role of Hira during heart development. To this aim, the following genetic 
tools were used: a floxed Hira allele, a Hira null allele and various Cre recombinase expressed 
in cardiovascular precursor cells. 
The following questions were addressed:  
• Is HIRA expressed in the heart? 
• What phenotype results from the ablation of Hira in cardiogenic mesoderm 
(Mesp1Cre)? 
• What phenotype results from the ablation of Hira in other lineages contributing to the 
formation of the heart? 
• Does ablation of Hira in adult cardiomyocyte affect normal heart function? 
• Does HIRA interact with transcription factors or chromatin remodeling protein? 
• What are the downstream transcriptional effects resulting from the ablation of Hira?  
• Is there evidence for specific HIRA binding sites across the genome that might directly 
affect transcription?  
Chapter 2 Materials and methods 
 
2.1) Animal breeding  2.1.1) Mouse lines and breeding 
Animal maintenance, husbandry and procedures were carried out in accordance with 
British Home Office regulations. All lines were maintained on a CD1-ICR background. Pups 
resulting from various breeding pairs were ear-clipped between 11 and 13 days old identify 






Tie2Cre (MGI: 2450311) 
Tcf/Lef GFP reporter (MGI: 4881498T) 
Myh6MerCreMer (MGI:3050453) 
 
Whilst all Cre are constitutively active, the Myh6MerCreMer, also referred to as 
alphaMHC-Cre-Mer-Cre needs tamoxifen injection to be activated. Tamoxifen was prepared in 
sesame oil (Sigma-Aldrich) and was administered by intraperitoneal injections (0.05 mg/g body 
weight), every day for three consecutive days. 2.1.2) Embryo collection 
Sexually mature mice (6 weeks old female and 8 weeks old male) were paired and 
overnight mating was verified by vaginal plug in the morning, which translated to half a day of 
gestation (E0.5). Pregnant females were sacrificed at the relevant stage (E10.5 - E18.5) by 
cervical dislocation. Collected embryos were briefly stored in cold phosphate buffered saline 
(PBS) before being dissected. E18.5 embryos were stored overnight in PBS at 4C or killed 
directly by decapitation before dissection. 2.1.3) DNA extraction and polymerase chain reaction for genotyping 
       DNA was extracted using the yolk sac for embryos younger than E11.5, tail tips for 
embryos older than E11.5 and ear clips for postnatal and adult mice. The tissues were digested 
in adequate volume of Tail Lysis Buffer (below) containing 400ug/ml proteinase K (Sigma) 
overnight at 56°C. The same volume of 100% isopropanol was then used to precipitate the 
DNA, which was washed using 70% ethanol, before air drying and resuspension in 100 to 200 
µl of distilled H2O. 
 Tail Lysis buffer 
Stock content Final Concentration 
1M Tris pH8.8 100mM 
0.5M EDTA       5mM 
10% SDS            0.20% 
5M NaCl            200mM 
 
Genotyping for mutant, heterozygous and wild-type animals carrying the Sanger allele 
was done with a BIOTAQTM DNA Polymerase kit using the following primers (table below).The 
PCR product was run on a 2% agarose gel to differentiate between the two amplimers (wild 
type, and the construct containing loxP sites). Furthermore, the presence of Cre activity was 
confirmed in embryos by detection of a third “rec” product following recombination (see p50). 




HIRA-KO-R GGGACTGGCTGCTATTGGGC  
FRT-F (red arrow) CCTCTCAGTGTCACTGGG 
FRT-R (red arrow) CCCAGCCCTGATTCAGAT 
 
PCR reaction mix 
Components for 1 reaction Total volume 25µl 
Buffer 10X 2.5µl 
MgCl2 0.75µl 
dNTPs (25mM) 0.2µl  
Forward and Reverse Primers (10µM) 1µl 
Taq Pol 0.2µl 
Genomic DNA 1µl 
  H20        17.35µl 
PCR cycling conditions 
94° 3 min 
94° 30s 
60° (all PCR except Cre) Cre:64° 30s 
72° 1min 
Repeat steps 24 40 times  
72°  10min 
 
2.2) Imaging methods to phenotype mutants and assess HIRA 
expression  2.2.1) Dissecting microscope for macro histology 
Embryos were dissected and captured using a dissecting microscope (Zeiss AxioCam 
HRc). An ultra-violet lamp was used to detect GFP expression if needed. 
2.2.2) Optical projection tomography 
First presented in a Science paper in 2002 (Sharpe et al., 2002), OPT offers the 
possibility to image various tissues using different wavelengths thus allowing the use of 
probe/antibody based immunofluorescence. Samples are cleared using 2 parts benzyl alcohol 
to 1 part benzyl benzoate (BABB). This step is crucial since the parallel light beams going 
through the specimen will not diffract or scatter extensively, thus increasing the final 
resolution.  The sample contained in agarose rotates and is imaged every 0.45°. The acquisition 
is done by projection onto a CCD sensor (Figure 2-1). 
 
Figure 2-1 Optical Projection Tomography allows 3D visualisation of whole embryos 
Optical projection tomography (OPT) allows the imaging of large biological samples. Here, this 
schematic shows a cleared sample lit by a source of light. The resulting image of the projection 
is captured by a CCD sensor. That process is repeated after the sample rotates by 0.45° to 
obtain a total of 800 images. Taken from (Sharpe et al., 2002). 
 
Once the scan is complete, a back-projection algorithm and a 3D reconstruction step 
are applied to obtain the final useable data. The resolution (9µm) exceeds more often used 
techniques such as MRI and is roughly equivalent to µCT although it does not reach cellular 
level.  More importantly in this context, OPT data gives the possibility of viewing the sample in 
any plane orientation, by “virtual reslicing” (Figure 2-2).  This feature has proven very useful 
for the detection of VSDs. 
  
An OPT scan can result in a slightly tilted sample as seen in this image J screenshot of a 3D 
reconstruction of an embryonic heart (in grey/black) at E15.5. It is necessary to virtually 
“reslice” the heart for the identification of certain cardiac defects, such as a VSD or valve 
malformations. Image J can correct the angle as seen by the stacks (yellow) which have a 15° 
tilt compared with a horizontal line.  
 
 
Embryos were fixed overnight in 4% PFA/PBS and mounted in low-melting agarose 
(Life Technologies). Up to E14.5, whole embryos were processed. At E15.5, the trunks were 
opened and cartilage from the rib cage was discarded to help with the subsequent scanning 
since cartilage does not clear completely. Samples were then trimmed to remove the excess of 
agarose and washed in 100% methanol followed by clearing in BABB. Scanning was undertaken 
using a Bioptonics OPT Scanner 3001M (MRC Technology, Edinburgh, UK). NRecon software 
(Skyscan NV) was used for image reconstruction from projections using a back-projection 
algorithm. FIJI (Image J) and Volocity were used for image analysis and 3D reconstruction. 2.2.3) Image J and Volocity for 3D visualisation 
 FIJI (Fiji Is Just ImageJ) (1.46r) was used to visualise the long axis sections 
reconstructed by OPT. "Sliding" along the antero-posterior axis allowed for the correct 
identification of vessels. The pulmonary trunk (PT) was traced by semi-automatically filling out 
the vessel for approximately 150 slices, starting from the OFT and finishing in the lungs.   
 The extracted 3D vessel was loaded in Volocity® 3D Image Analysis Software, along 
with the original OPT reconstructed scan. Volocity, unlike FIJI, has a set of transparency and 
black level fine tuning functions which, combined with 3D visualization of samples, allows the 
full restoration of specific subparts of the captured image. The channels were set as followed: 
Figure 2-2 Image J is used to perform virtual reslicing of OPT acquired image stacks 
red for PT and green for the heart. Way points were set up for 360 degree rotation and zoom 
(see supplementary video). 2.2.4) Ultrasound scan for heart function 
The heart function of adult (~6 months) Myh6MerCreMer;Hirafl/- and 
Myh6MerCreMer;Hirafl/+ controls were measured using a Visualsonics Vevo 2100 ultrasound 
system prior to Cre induction. Echocardiography M-mode recordings were used to measure 
chamber dimensions. Using left ventricular systolic and diastolic chamber dimensions, the 
ejection fraction was calculated by the software. During the following 3 days, the mice were 
injected every day with tamoxifen (Sigma-Aldrich) which was prepared in sesame oil (Sigma-
Aldrich) using 0.1 mg/g body weight by intraperitoneal injection. The mice were subjected to 
echocardiography analysis 2 and 8 weeks after the injection period. 2.2.5) Paraffin embedding and Haemotoxylin and Eosin staining  
Dissected embryos were fixed overnight in 4% paraformaldehyde (PFA) in PBS and 
then dehydrated by increasing concentration of ethanol (30% to 100%). They were then 
cleared using histoclear (National Diagnostics) for one hour, and embedded in paraffin 
overnight after several wax washes at 60°C. A microtome was used to section embryos to 10-
12μm thickness and sections were transferred onto SuperFrost®PLUS microscope slides (VWR) 
for overnight drying. Most sections presented in this thesis will be following the long axis of 
the heart, unless stated otherwise. For morphological examination, sections were warmed to 
60°C to dewax, then rehydrated through a decreasing concentration of ethanol (100% to 30%) 
and finally H20. Slides were stained using freshly-filtered Mayer’s Haematoxylin solution 
(Sigma-Aldrich) followed by aqueous Eosin solution (Sigma- Aldrich) and rinsed further in H2O. 
Slides were mounted with glass coverslips using DPX solution (Merck). 2.2.6) Alcian Blue staining for Cartilage visualisation  
Due to the extremely fine balance between KOH mediated tissue digestion and 
keeping the skeleton in one piece, the traditional approach for alcian blue cartilage described 
by McLeod (McLeod, 1980) was  abandoned, following many failures. The observed embryos 
were young (E12.5-E13.5) and presented mostly fragile cartilage. Therefore the following 
alternative protocol adapted from (Nagy et al., 2009) was used. 
Embryos were fixed in Bouin’s solution overnight at 4°. The next day they were washed 
in a solution of 70% ethanol plus 0.1% NH4OH for 24 hours until the embryos appear white 
with no remaining yellow colour. Then they were equilibrated in 5% acetic acid (two changes, 
each for at least one hour) before being stained with 0.05% alcian blue in 5% acetic acid for 2-4 
hours. 4 hours tended to yield a nicer stain. The embryos were sequentially washed twice with 
5% acetic acid for 1 hour each. Finally the embryos were washed in methanol (two times 1 
hour) and then cleared in BABB. 
 2.2.7) Beta Galactosidase to trace HIRA expression 
X-gal staining is a convenient way to detect β-galactosidase enzyme activity. In 
bacteria, β-Galactosidase catalyzes β-galactosides into monosaccharides. Here X-gal (5-bromo-
4-chloro-3-indolyl-beta- D-galactopyranoside) was used as a substrate which is cleaved into 
galactose and 5-bromo-4-chloro-3-hydroxyindole. The latter is dark blue which is easily 
detected under white light.  
E10.5 embryos were dissected in cold PBS and fixed in 4%PFA at room temperature for 
2 hours. Subsequently, they were washed 3 times for 20 min in detergent at RT: (0.1M Na2 
HPO4 pH 7.3, 0.1 M NaH2PO4 pH 7.3, 2 mM MgCl2, 0.1% sodium deoxycholate, 0.02% Nonidet 
P-40, 0.05% bovine serum albumin (BSA), in ddH2O.). X-gal (Thermo) is added (0.3mg/ml) last 
minute to the stain solution (2 mM NaCl, 5 mM K3Fe(CN)6 , 5 mM K4Fe(CN)6 , in detergent 
wash). E10.5 embryos were placed in stain solution for up to an hour, E13.5 for up to 4 hours 
and E15.5, around 12 hours. They were wrapped in foil to conceal from light and placed in a 37 
degrees incubator. For older embryos (E13.5 – E15.5), the penetration of the stain solution 
was incomplete so embryos were sectioned prior to staining. 2.2.8) In situ hybridisation 
Plasmids for synthesising antisense RNA probes were kindly given by Tim Mohun 
(Tnni2, Image clone 1448494 cut with EcoRI  and RNA synthesized with  T3 RNA polymerase) 
and by Jeffrey Bush (Epha3  cut with  XhoI and synthesized with T7 polymerase). Plasmids were 
linearised using the appropriate restriction enzymes for generating antisense probes, and 
extracted from a 1% agarose gel using the QIAquick Gel Extraction Kit (Qiagen). 1µg of 
linearised plasmid was used for in vitro transcription of probes using a DIG RNA labelling kit 
(Roche). Probes were precipitated by addition of 2µl 0.5M EDTA (pH 8), 5µl 4M LiCl and 150µl 
ethanol to the reaction and extracted by centrifugation.  
Paraffin sections were prepared as previously described in milliQ water treated with  
RNAse-A. Slides were rehydrated then incubated in 20µg/ml Proteinase K (Sigma-Aldrich) for 8 
minutes, washed in 2mg/ml glycine then PBS, and fixed in 4% PFA/PBS for 20 minutes. 
Following further PBS washes they were incubated for 1 hour at 70°C in a humidified chamber 
in hybridisation buffer (50% formamide, 5xSSC pH 4.5, 50µg/ml yeast RNA, 1% SDS, 50µg/ml 
heparin) followed by overnight incubation in hybridisation buffer containing between 1 and 
2µg/ml of antisense RNA probe. Slides were then rinsed twice in 2x SSC buffer pH4.5, followed 
by three washes at 65°C in Solution I (50% formamide, 5x SSC pH4.5, 1% SDS), two washes in 
Solution II (50% formamide, 2x SSC pH4.5) and finally two washes at room temperature in 
MABT (0.1M maleic acid, 0.15M NaCl, 0.01% Tween-20, 2mM Levamisole (Sigma-Aldrich), 
pH7.5). Slides were then incubated in blocking solution (2% Boehringer Blocking Reagent 
(Roche), 10% sheep serum in MABT) for 1 hour followed by overnight incubation at 4°C with an 
alkaline-phosphatase (AP) conjugated anti-DIG antibody (Roche) diluted 1:2000 in blocking 
buffer. Following further washes in MABT and AP buffer (100mM Tris, pH 9.5, 50mM MgCl2, 
100mM NaCl, 0.1% Tween-20, 2mM Levamisol), AP activity was detected using BM Purple 
(Roche) for at least 24 hours. Signal took up to 4 days to appear but was highly specific.   
2.3) Quantifying gene expression in the heart 2.3.1) RNA extraction 
2.3.1.1) Trizol 
Total RNA from embryonic hearts was first extracted with Trizol (Invitrogen 15596-
018) following the manufacturer’s instructions. Briefly, E12.5 hearts with the relevant 
phenotype which had been stored at -80°C were dissolved in 350μl Trizol reagent using a 
needle and syringe. Samples were incubated at room temperature (RT) for at least five 
minutes. 60μl chloroform was then added and tubes shaken vigorously and centrifuged at RT 
for 15 minutes. The upper aqueous layer was transferred to a fresh tube and 150μl 
isopropanol added to precipitate the RNA.  Samples were centrifuged for 10 minutes at 4°C 
and RNA pellets were washed in 70% EtOH, air dried and resuspended in 30μl RNase-free H2O. 
Nanodrop1000 was used to quantify and assess sample quality.  The A260/A280 ratio should 
be above 1.6, and although it was around 1.8, the nanodrop measurements displayed an 
isopropanol contamination (Figure 2-3). Subsequent washes with 70% ethanol helped purify 
the RNA, but the quality was never good enough for RNAseq.  
 
 
Figure 2-3 RNA extracted by trizol can result in chloroform or isopropanol 
contamination  
The absorbance (or optical density (OD)) measured by the nanodrop is used to check the purity 
of the nucleic acid extraction. A peak is normally expected at 260nm for nucleic acids. The OD 
ratio A260/A280 and the A260/A230 have to be greater than 2 to ensure an optimal quality of 
RNA/DNA. This shift seen here may be caused by residual chloroform or isopropanol, used 
during Trizol extraction.  
2.3.1.2) Qiagen column  
Total RNA was isolated using RNeasy Mini kits (Qiagen) according to manufacturer’s 
instructions, including the optional on column DNase digestion step, and eluted into 30μl 
RNase-free H2O. The extractions resulted in a more consistent yield (around 100ng/µl) and 




The nanodrop absorbance profile here shows A260/A230 ratio equal or greater than 2.  2.3.2) Reverse transcription 
The High-Capacity RNA-to-cDNA™ Kit (Thermo fisher 4387406) was used to obtain 
cDNA for the qRT-PCR experiments, according to the manufacturer’s instructions. Briefly, up to 
2 µg of RNA in 9µl was added to the 10 µl of 2x RT Buffer and 1µl of 20x RT Enzyme for a total 
of 20µl. The reaction mix was placed at 37°C for an hour and at 95°C for 5 min. 2.3.3) Designing primers using primer blast 
Primers for qRT-PCR were designed using primer-blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) with the following option: primers must 
span an exon-exon junction, thus ensuring amplification of cDNA only since contamination by 
genomic DNA remains possible. Furthermore, pair of primers were tested against a database 
of mRNA possible off-targets. Finally the PCR product size was set to be between 80 and 160 
bp (Figure 2-5). 
 







 Table 2-1 Primers used for qRT-PCR 
 
2.3.4) SYBR green Real-time PCR: absolute quantification 
Absolute quantification was performed using SYBR green to determine the amount of 
original transcripts in the total RNA.  This method uses the standard curve method, which 
establishes a quantity for an unknown sample based on a serial dilution of a known quantity. 
Standard curves were established by pooling all the samples together and diluting 
subsequently or in series 10 times, twice, to obtain 1, 0.1 and 0.01 quantities of cDNA 
templates. There are two main reasons for using this technique as opposed to the more 
traditional ΔΔCT method:  The efficiency of the primers is analysed using the standard curve 
and is taken into account when measuring unknown samples every time but mainly we do not 
need to spend time optimising the efficiency so it fits GADPH’s. Second, there is no need for 













































Figure 2-5 Example of primers spanning exon-exon junctions 
Touch™ Real-Time PCR Detection System was used. Following the reaction, samples were run 
on an agarose gel to verify the amplimer size.  2.3.5) RNAseq: analysis with Strand NGS 
RNA extraction was done in triplicate from Mesp1Cre;Hira-/fl and Mesp1Cre;Hira+/fl  
embryonic hearts at E11.5 and E12.5 using the QIAGEN RNeasy mini kit (74104). RNAseq was 
processed by the ICH genomics facility, which used an Illumina NextSeq 500, and paired ends 
reads were produced. Reads were aligned and normalised using BOWTIE and DEseq R package. 
Strand NGS 2.5 software was used which uses the DEseq algorithm, was used to incorporate 
additional downstream analysis such as Gene Ontology and to re-analyse the aligned files 
(.bam). By applying the Mann Whitney unpaired test, Benjamini Hochberg False discovery rate 
(FDR) and filtering the genes using adjusted p-value ≤ 0.05 and  absolute fold change ≥ 1.5, 95 
% of the results were identical to the DEseq package used by the UCL Genomics facility. The 
main advantage provided by strand NGS is the ability to perform a gene ontology (GO) analysis 
and generate heatmaps of various groups of genes.  
 
2.4) Investigating HIRA’s binding partners: Co-immunoprecipitation 
Immunoprecipitation (IP) is a commonly used method for antigen detection: it involves the 
capturing of an immune complex using antibodies bound to a heavier molecule (i.e., beads) 
which can be retrieved by centrifugal force or magnets. Co-Immunoprecipitation is an 
extension of IP: it allows the purification of the primary target (i.e., the antigen) as well as 
other macromolecules which are bound to the original target. After elution of this large 
complex from the beads, the samples are analysed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), followed by Western blot detection to verify the identity of 
the antigen. 
Around 20 embryonic hearts at E14.5 and 30 hearts at E12.5 from WT embryos were 
dissected in cold PBS and flash frozen in liquid nitrogen before being digested using a syringe 
with gradually smaller needles (19G, 23G, 25G) in RIPA buffer (50mM Tris pH 7.4, 150mM 
NaCl, 1% NP-40, 1mM EDTA, 50mM NaF, 0.5% Deoxycholic acid, sodium orthovanate 20nMm, 
anti-protease cocktail 1X, 1mM PMSF). In parallel, magnetic beads coated with sheep anti-
mouse IgG (AB 11201D) and the supernatant recovered from HIRA hybridomas (prepared by 
Dr Chapgier) were mixed and left rolling overnight at 4°. The mouse IgG (mouse IgG1 k 
monoclonal isotype control AB 18447, lot GR 53099-6) and the beads were mixed in a separate 
tube. The beads were washed with RIPA buffer the next day using magnets. After the final 
wash, the protein lysate was mixed mix with the beads overnight rolling at 4°. 100µl was saved 
and stored at -80° to load as the input. The next day the beads which have 
immunoprecipitated HIRA were washed in RIPA and resuspended in Laemli buffer (3X Laemli: 
120mM Tris pH6.8, 3% SDS, 5% Glycerol, 0.01% Bromophenol, 1.5% β-Mercaptoethanol) and 
boiled at 100° for 15min to separate the beads from the antibodies and proteins. After a 1min 
cooling on ice, the magnet was used to collect the beads. The lysate is then stored at -80° 
before being loaded on the polyacrylamide gel.   
Separating gel: 8% acrylamide: 18.5ml H20, 10.7ml acrylamide 30%, 10ml Tris 1.5M pH8.8, 
400µl SDS 10%, 400µl APS 10%, 24µl Temed. Stacking gel: 5% acrylamide, 6.8ml H20, 1.7ml 
acrylamide 30%, 1.25ml Tris 1M pH 6.8, 100µl SDS 10%, 100µl APS 10%, 10ul Temed. Run 
buffer (10x): 30.25g Tris, 144g Glycine, 100ml SDS 10%. Up to 1 L of H20. Transfer buffer (10X): 
30.25g Tris, 144g glycine, Up tp 1 L of H20. For 1X, use 20% methanol.  
Pre-cast gradient gels (Mini-PROTEAN TGX 4%-15%, Biorad 456-1083) were also used. 30µl 
were loaded per well. The gels were then transferred onto a PVDF membrane (Biorad 162-0177) 
using a semidry or wet technique. The membrane was blocked with 5% milk-TBST 1X for 1h at 
RT, washed 3 times with TBST then incubated with Hira antibody (supernatant from WC119 
hybridoma)  in 1% milk- TBST 1X overnight at 4°C. Next the membrane was washed 3 times with 
TBST, incubated with a secondary antibody (Amersham NA93310V) for 45 min at RT then 
washed 3 times with TBST and finally revealed with ECL (Amersham RPN2209, 28906837) with 
the appropriate secondary (Amersham NA93340V or NA93310V). 
Table 2-2 List of commercial antibodies 
GAPDH  Millipore MAB374 
BRG1 Millipore 07-478  
WHSC1 Atlas HPA015801 
HDAC1 Millipore 05-100 
HDAC2 Millipore 05-814 
CAIN  Abcam ab3349 
 
2.5) Chromatin immunoprecipitation (ChIP) 
As mentioned in chapter one, the biological significance of the location of the 
interactions between proteins and DNA can have an important impact on the understanding of 
gene expression regulation, differentiation and disease. Chromatin immunoprecipitation (ChIP) 
is the precipitation of a protein of interest from a chromatin preparation (usually fragments 
with a size of 500 to 1000bp) to determine the DNA sequences associated with it (Figure 2-6). 
The main issue with ChIP is that given the broad diversity of tissue and cell types, types of 
chromatin bound proteins or modifications being assayed, it is difficiult to define one single 




Figure 2-6 Main steps involved in ChIP and methods of analysis 
Schematic of the steps necessary to carry out chromatin immunoprecipitation (ChIP) assay 
with the associated methods commonly used for downstream analysis. Taken from (Collas, 
2010) 
 2.5.1) Dual Fixation 
The first step of ChIP relies on the cross-linking of proteins to DNA. The fixation 
reagent used most commonly is formaldehyde (HCHO). However, this molecule has relatively 
short spacer arm. There is an ongoing debate whether HIRA directly binds to DNA or rather, 
like a transcriptional coactivators, it is in close proximity to the DNA. The HIRA ChIP protocol 
developed by Dr Chapgier was used which involves a combination of HCHO and EGS, a large 
molecule with long spacer arms (Zeng et al., 2006). 
30 to 40 E12.5 hearts were pooled (equivalent to 10 million cells for ESC experiments), 
washed in PBS and cross-linked for 45 min with 1.5mM of EGS (Sigma, E3257), followed by 
15min of 1% formaldehyde (from a freshly made filtered stock at 18.5%) at 37°C. The reaction 
was quenched by the addition of 125mM of Glycine, left for 15min at RT. Hearts/cells were 
lysed in 50mM Hepes-KOH pH 7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% 
Triton, 1X anti-protease cocktail (Roche, 04693132001), 1mM PMSF for 10 min at 4°C (LB1). 
The hearts/cells were briefly spun down resuspended in 10mM Tris-HCL pH 8.0, 200mM NaCl, 
1mM EDTA, 0.5mM EGTA, 1X anti-protease cocktail, 1mM PMSF for 10 min at 4°C (LB2). Finally 
the hearts/cells were resuspended in10mM Tris-HCL pH 8.0, 100mM NaCl, 1mM EDTA, 0.5mM 
EGTA, 0.1% DOC, 0.5% N-Lauroylsarcosine, 1X anti-protease cocktail and 1mM PMSF rolling 
o/n at  4°C (LB3). 2.5.2) Sonication 
Fixed and lysed chromatin needs to be broken into small fragments before being 
immuno-precipitated. A fine balance is required in this step. Having too large fragments 
reduces the resolution of the protein of interest binding sites and having fragments too small 
might fail to provide the necessary template for PCR amplification. HIRA ChIP requires a total 
combined time of 1 hour of sonication at 5µA with Soniprep 150 MS, with at least the 
equivalent time resting on ice to prevent the chromatin solution from overheating.   2.5.3) Immunoprecipitation and purification of DNA 
In parallel to the sonication step, antibodies were coupled to magnetic beads 
(dynabeads InVitrogen, 112.03D, 112.01D) for at least 4 hours and washed 3 times in LB3. 10% 
of input was taken and protein–DNA complexes were selectively immunoprecipitated using 
WC15 antibody against HIRA, rolling overnight. Beads were then washed once with 20mM tris 
pH 8.0, 150mM NaCl, 0.1% SDS, 1% Triton, 2mM EDTA (WB1), once with 20mM Tris pH 8.0, 
500mM NaCl, 0.1% SDS, 1% Triton, 2mM EDTA (WB2), once with 10mM Tris pH 8.0, 150mM 
LiCl, 1% NP-40, 1% DOC, 1mM EDTA, then TE 10:1, 50mM NaCl (WB3), and finally in TE 10:1. 
Samples were treated overnight with 50mM Tris pH 8.0, 10mM EDTA and  1% SDS at 65°C 
(elution buffer),  to reverse cross-linking, then with RNAse (Qiagen, 19101) for an hour at 25°C 
and with PK for 2h at 56°C. DNA was purified with QIAGEN’s PCR purification kit (28104).  2.5.4) Designing genomic primers using IGV 
Integrative genome viewer (IGV), created by the Broad Institute, is a software in which 
enrichment of a given protein across the genome can be viewed easily (Figure 2-7). For 
example, ChIP-seq for a specific histone trace allows the user to browse genomic regions 
enriched (usually gene rich) or depleted (usually intergenic). Once the sequences are 
extracted, they can be loaded in a program such as primer blast to design primers (see p39). 
 
Figure 2-7 IGV screenshot displaying two tracks 
Integrative genome viewer displaying here two different types of genome wide data: a “wig” 
file (for wiggle) on top, and a “bam” file in the middle, which displays individual reads from a 
massive parallel sequencing platform. The lower trace is the mouse reference genome. DNA 
sequence can be retrieved, here shown in red over the TSS of Iffo1. 
 2.5.5) Q-ChIP 
In the last step of ChIP, purified DNA is quantified by quantitative PCR, using the 
purified input chromatin as a positive control. As a first quality control, the Ct values obtained 
from the input (genomic DNA) for any target loci should be almost identical, unless the region 
presents high copy number variants (CNVs). ChIP enrichment was calculated using the percent 
Input Method. Signals obtained from the ChIP were divided by signals obtained from the input. 
This input sample represents the amount of total chromatin used in the ChIP, here 10% was 
used. See the example below: 
z= 2^-(Ct_ChIP – Ct_Input) * 100 * (b/a) * (d/c) 
z= enrichment to Input (=100%) 
a=Volume of sample used for IP 
b=Volume of sample saved for Input 
c=Amount of DNA ChIP used for Q-PCR 
d=Amount of DNA Input used for Q-PCR 
 
Using 10% input and taking the same amount from ChIP and input for the PCR: 
z= 2^-(Ct_ChIP – Ct_Input) * 100 * (10/100)  
  
Table 2-3 Primers used for qChIP 
Lsp1F 180bp upstream of TSS TGCTACTCTTGGGGCTGACT 
Lsp1R 180bp upstream of TSS CAGGACCTCAAATCCAGCAG 
Lsp1F 160bp upstream of TSS TGGCTGGAATGCACCGATAA 
Lsp1R 160bp upstream of TSS ATGCATTTGGCAGGTGACAG 
Gata5F upstream of TSS AAGCCTGGCAGCTACAAGAA 
Gata5R upstream of TSS AAGGAACTAAGCCCCTGCTG 
Gata5F2 upstream of TSS GATAGGCCTGGTCTGGTTGG 
Gata5R2 upstream of TSS GGACACCAGCTAACAGGGAG 
Ctrl neg X6 -F CCCCTTTCTGAAGCACTCTG 
Ctrl neg X6 –R TAAGGCGTCATTTCCCAAAG 
Ctrl neg X8 -F AAGGGGCCTCTGCTTAAAAA 
Ctrl neg X8 -R AGAGCTCCATGGCAGGTAGA 
Tbx3 exon5 - F CTCAGTCCCAGTCCCTTGAC 
Tbx3 exon5 - R CACCCTGCTGAGGGTCAATA 
 2.5.6) ChIPseq and analysis  
Current state-of-the-art technologies allows for genome-wide sequencing of ChIPed 
DNA. ChIPseq provides fewer artefacts and greater coverage compare to ChIP-chip (Park, 
2009). This process first involves the amplification of the immunoprecipitated chromatin 
(input) to construct a library. Depending on the “expected” outcome of a ChIPseq, different 
peak callers can be applied. Experiments can be ranked in the following 3 categories: point 
source (highly localized signals, such as for transcription factors), broad source (signals that 
span large domains; for example a histone modification) and mixed source (signals that have 
elements of both, such as for RNA polymerase II) (Furey, 2012). The required sequencing depth 
was difficult to assess since the types of peak were uncertain. A histone chaperone is more 
likely to generate broad peaks (or not “discrete” peaks), therefore the maximum number of 
reads were selected: 120 million. This would allow the detection of lower levels of enrichment 
over the genomic background. Finally ChIPseq can be used for “footprinting”, which allows the 
identification of DNA binding motifs. Most motifs are already present in databases, such as 
JASPAR (Neph et al., 2012) (Figure 2-8). 
  
Diagram displaying the steps necessary to obtain a binding motif from ChIPseq data. The 
sequence retrieved from peaks (or binding sites) are aligned to the Jaspar database (a 
transcription factor binding profile database derived from published collections of 
experimentally tested DNA binding proteins). 
 
Libraries were prepped using the NEB DNA Ultra kit, with a selection of fragments size of 
~200bp. They were sequenced on the Illumina NextSeq 500, v2 chemistry. Alignment was done 
using bowtie2. Peak detection and consensus sequence discovery was done using Strand NGS 
software 2.5, which includes the algorithm of MACS1.4 (p≤10-4)(Model-based Analysis for ChIP-
Seq), after  removal of sequences with poor- quality bases and removal of duplicate 
sequences. List of genes within +/- 5Kb was generated using Strand NGS. Bedtools intersect 
tools was used (code was ran by Dr Chapgier and included with her permission) to define the 
overlaps between different BED files. (Code used: intersectBed -a NKX2-5Chipseqe11-
5MM10.bed -b Peaks_detected_by_MACS-4.bed > overlap2.bed). CEAS-Package-1.0.2 analysis 
of cis-regulatory elements was used for genome wide enrichment patterns of HIRA ChIPseq. IN 
addition, PAPST (Peak Assignment and Profile Search Tool) software was used to overlap 
regions of interest (Bible et al., 2015).  
 
Figure 2-8 Illustration of a ChIPseq workflow 
Chapter 3 HIRA is required in the cardiogenic mesoderm 
The development of the cardiovascular system is regulated by sequential, time 
controlled pathways. Transcription in the heart is partly regulated by the conformation of 
chromatin, which is likely to be dependent on histone variant deposition. HIRA has never been 
studied previously in the context of heart development. To adress its potential role during 
cardiovascular development, its expression was first traced using the β-galactosidase cassette 
of the transgenic mouse strain Hiratm1a (Figure 3-1). 
 
Figure 3-1 Hira pre-conditional allele was generated by the Wellcome Trust Sanger 
Institute 
Hiratm1a(EUCOMM)Wtsi, MGI:4431679 construct used for Hira reporter before Flippase was 
applied to revert it to a WT allele (“Flox allele”). Cre recombinase subsequently splices out 
exon 4 (“rec allele”). 
 
The pattern of expression of Hira during embryonic development are presented below as well 
as the various phenotypes observed when ablating Hira from the cardiogenic mesoderm. 
3.1) Expression of Hira at E10.5 and E13.5 and in the adult 
Described in the previous chapter, this method consists of identifying cells expressing 
the β-galactosidase-neomycin cassette, here located between exon 3 and exon 4 of Hira. By 
crossing HiraβGal/+ with Hira+/+ mice, HiraβGal/+ and Hira+/+ embryos were recovered with a ratio of 
1:1. The assay was conducted on whole embryos between E10.5 and E15.5. However, past 
E12.5, the penetration of the X-gal became problematic (data not shown), so cryosections 
were analysed after this stage. As shown by a long axis cross section of the heart at E13.5, all 
cardiac tissue were found to be Hira positive (Figure 3-2). At E8.5, Hira was expressed 




β-galactosiade knockin reporter showed that HIRA is ubiquitously expressed throughout the 
embryo at E10.5 (top panel). At E13.5 cardiac expression was verified by long axis section, 
prior to staining (bottom panel). 
Although not checked at the embryonic stage, HIRA protein expression was identified 
in the adult (Figure 3-3) by western blot analysis, from total protein extracts from dissected 
hearts. 
 
Figure 3-3 HIRA is expressed in the adult heart 
Western blot analysis from a heart biopsy of a 8 month old adult mouse revealed that HIRA is 
expressed in the heart postnatally. Western blot shown is representative of three biological 
replicates 
Figure 3-2  Hira is ubiquitously expressed in the heart at E13.5 
3.2) Conditional mutagenesis of Hira with Mesp1Cre 3.2.1) PCR 
The anterior limb of Mesp1Cre;Hirafl/- embryos was used for DNA extraction . 
Genotyping was done by detecting the presence of Cre and Hira null allele by PCR (data not 
shown). Cre activity was further confirmed by PCR amplification using primers outside the loxP 
sites (Figure 3-4).  
 
Figure 3-4 Recombination of Hira conditional allele is visualised by PCR  
Recombination of the floxed allele by Mesp1 driven CRE recombinase was assessed by PCR 
(red arrows represent forward and reverse primers) using DNA from the anterior limb which 
contains Mesp1 positive cells, detection of the various alleles is shown.  
 3.2.2) RNA-seq 
In addition to genomic DNA recombination, Cre activity was also confirmed in total 
RNA extracted from hearts by RNAseq. Reduced number of reads were observed at the exon 4 
of Hira (Figure 3-5). Transcriptome analysis will be covered in the next chapter.  
 
 
Figure 3-5 RNAseq gives evidence of recombination of the Hira conditional allele 
Recombination was also demonstrated at the mRNA level by the reduced number of reads in 
RNAseq (22 in control and 3 in mutant). 
3.3) HIRA is required in the Mesp1 lineage 
The Hira conditional allele was first tested by Dr Chapgier using ActinCre and TCre to 
validate the allele in vivo. Brachyury (T) is expressed early in development and marks 
progenitor cells arising from the primitive streak and tail bud, thus generating mesoderm and 
endoderm during gastrulation (Perantoni et al., 2005). Generation of TCre;Hira-/fl embryos 
resulted in a similar phenotype to Hira-/- embryos (Ariane Chapgier, personal communication). 
 3.3.1) Mesp1Cre;Hira-/fl is embryonic lethal.  
Mesp1Cre;Hira-/+ were crossed  to Hirafl/fl  mice to generate conditionally null embryos. 
Viability was assessed first. No mutants (Mesp1Cre;Hira-/fl) were recovered at P10, out of 4 







 Table 3-1 Embryonic phenotype resulting from the conditional ablation of Hira 
 Mesp1Cre;Hira-/fl Nkx2.5Cre;Hira-/fl Mef2cCre;Hira-/fl Tie2Cre;Hira-/fl Wnt1Cre;Hira-/fl 
STAGE E10.5 E12.5 E13.5 E15.5 E15.5 ADULT E15.5 E18.5 
VSD N/O N/O N/O 12/12 5/9 N/O 0/5 0/10 
ASD N/O N/O N/O 10/12 4/9 N/O 0/5 0/10 
Thin ventricular wall 0/4 0/9 0/12 3/12 0/9 N/O 0/5 0/10 
Constricted PT 0/4 0/9 0/12 1/12 3/9 N/O 0/5 0/10 
Oedema 0/4 0/9 3/12 12/12 0/9 N/O 0/5 0/10 
Haemorrhage  0/4 2/9 6/12 12/12 0/9 N/O 0/5 0/10 
Exencephaly 0/4 1/9 0/12 0/12 0/9 N/O 0/5 0/10 
VIABLE by P10 NO (0/12) YES (1/9) YES (4/4) YES (6/6) NO (0/40) 
Number of embryos observed for the indicated phenotype at the indicated stage related to the 
total number of embryos collected. N/O indicates none observed. The number of collected and 
thus viable embryos are also indicated at 10 days post-birth (P10) related to the number of 
expected embryos. 
 
 3.3.2) Mesp1Cre;Hira-/fl display fully penetrant oedema at E15.5 
The morphology of embryos was examined at E15.5, for which a Mendelian ratio of 
mutants was recovered (Table 3-1). This implied that most embryos were dying between 
E15.5 and birth (around E20). At E15.5, all Mesp1Cre;Hira-/fl embryos presented with a severe 
oedema, sometimes accompanied by haemorrhage (Figure 3-6). 
  
The Hira conditional allele was used in conjunction with the cardiac specific cre driver 
Mesp1Cre. Here the lateral view of littermate embryos with the indicated genotype show that 
at E15.5, all mutants displayed a severe oedema (O) and haemorrhage (H) as indicated. Scale 
bar represents 2mm 3.3.3) E15.5 Mesp1Cre;Hira-/fl embryos display a fully penetrant Ventricular Septum Defect (VSD) and partially penetrant Atrial Septal Defect (ASD)  
By Optical Projection Tomography (OPT), whole embryonic trunks were scanned at E15.5. The 
ribs were removed to enhance the quality of the image capture. A fully penetrant VSD was 
observed in the mutant hearts (n=12). The interventricular septum has completely separated 
the two ventricles in WT embryos at E15.5, as expected (Figure 3-7). 83% of mutants also had 
Figure 3-6  Mesp1Cre;Hira-/fl embryos display oedema and haemorrage 
at E15.5 
an ASD whilst none was observed in their WT littermates (n=10).
 
Figure 3-7 Mesp1Cre;Hira-/fl embryos display a VSD at E15.5 
Optical Projection Tomography was used to scan whole embryonic trunks of Mesp1Cre;Hira-/fl  
and Mesp1Cre;Hira+/fl  at E15.5. Long axis view of the heart revealed that a VSD (V) was 
systematically present at this stage in the mutants. An ASD (A) was observed in 9 out of 12 
embryos. Thin ventricular wall (TVW) was observed in 3 out of 12 embryos. Right/left ventricle: 
RV/LV. Right/left atrium: RA/LA. Scale bars represents 0.5mm 
 
 
3.3.4) Disruption of fusion between endocardial cushion and membranous portion  of the ventricular septum at E12.5 
The earliest defect observed in Mesp1Cre conditional Hira mutants were at E12.5. In a 
small proportion (11%) of mutants, exencephaly and haemorrhage were observed (Figure 
3-8). Interestingly, H&E staining on long axis sections revealed that some E12.5 Mesp1Cre;Hira-
/fl embryos displayed abnormally shaped endocardial cushions (Figure 3-9). The rightward 
tubercles of the atrioventricular cushions form the membranous septum (Anderson et al., 
2015). A deficiency of the muscular part of the ventricular septum was observed, since the 
point of contact between the septum and the atrioventricular cushions (or endocardial 
cushions (EC)) was mispositioned in the mutants compared to the control (Figure 3-9). 
 
Figure 3-8 Mesp1Cre;Hira-/fl embryos have a partially penetrant phenotype at E12.5 
Malformations in Mesp1Cre conditional Hira mutants were first detected at E12.5. Here a 
lateral view of littermate embryos is presented with the indicated genotype. A small 
proportion of Mesp1Cre;Hira-/fl embryos presented with exencephaly (E) and haemorrhage (H). 
Scale bars represent 2mm.  
  
Figure 3-9 Mesp1Cre conditional Hira mutants have a disrupted fusion between the 
endocardial cushion and the ventricular septum at E12.5 
At E12.5, some Mesp1Cre;Hira-/fl embryos displayed abnormally shaped endocardial cushions. 
The H&E staining on long axis sections presented here revealed a disruption of the endocardial 
cushion (EC) fusion (two controls and two littermate mutants shown). The muscular septum is 
deficient (*, top) and the relatively flat rather than crescentic cushion shape in the mutant are 
indicated (arrows). Scale bars represent 0.5mm 
 
 
3.4) Nkx2.5 driven ablation of Hira  
As mentioned above, cardiogenic mesodermal ablation of Hira leads to embryonic 
lethality, likely due to cardiac malformations.  The Nkx2.5Cre allele allows the ablation of Hira 
in cardiomyocytes, amongst other cell types, of the FHF and SHF, from E7.5 (see p5). This 
subset of cells is mostly directly derived from Mesp1 expressing progenitors (see discussion 
p64). Therefore, to further dissect the role of Hira in the cardiac lineage, Nkx2.5Cre;Hira+/-  
were crossed to Hirafl/fl mice.  3.4.1) Nkx2.5Cre;Hira-/fl embryos present with a partially penetrant VSD at E15.5 
  The morphology of the heart of Nkx2.5Cre;Hirafl/- embryos was observed at E15.5. 54% 
of mutants presented with a VSD (n=5). Unlike the Mesp1 conditional mutants, none of the 
mutants here displayed oedema.  
 
 
Ablation of Hira in cardiomyocytes was done using a Nkx2.5Cre allele. Here, the lateral view of 
Nkx2.5Cre;Hira-/fl mutants revealed a normal external appearance (top panel). OPT long axis 
section revealed a VSD (V) and an overriding of the aortic root of the muscular septum 
(bottom panel). The aorta (Ao) and the pulmonary trunk (PT) are indicated. Scale bars 
represent 2mm in whole embryo and 0.5mm in long axis sections. 
 
Figure 3-10 Nkx2.5Cre conditional Hira mutants display a VSD at E15.5 
3.4.2) Nkx2.5Cre;Hira-/fl embryos display a constriction of the pulmonary trunk 
33% of Nkx2.5Cre;Hira-/fl embryos had a hypoplastic pulmonary trunk (PT) (or 
constricted PT) at E15.5 by using OPT followed by 3D reconstruction of the vessel (Figure 
3-11).  
 
Ablation of Hira by Nkx2.5Cre led to a constricted pulmonary trunk (cPT) at E15.5. Here, the 3D 
reconstruction of Nkx2.5Cre;Hira-/fl embryonic hearts shows the cPT in red. Scale bars 
represent 0.5mm. 
 
3.5) Hira is not required in the SHF for heart formation and post-natal 
survival 
Using a Mef2cCre driver, the effect of Hira ablation was characterised in the SHF (see 
p6). Generation of Mef2cCre;Hira-/fl  animals led to a recovery of the expected mendelian ratio 
of mutants at the weaning stage (P21) (Table 3-1). The animals were observed until the age of 
6 months when they were culled and their hearts was analysed by OPT. As the adult hearts 
were much thicker than embryonic ones, the clearing process had to be extended and the 
clearing agent renewed multiple times. In addition, the OPT scanning settings had to be 
Figure 3-11 Nkx2.5Cre conditional Hira mutants have a constricted pulmonary trunk  
tweaked to acquire the images with a longer wavelength which gave higher imaging depth for 




Ablation of Hira in the SHF was done using the Mef2cCre driver. No embryonic lethality was 
observed. Here, the OPT scan shows a short axis section of the heart of a 6 months old 
Mef2cCre;Hira-/fl (right/left ventricle: RV/LV). This OPT scan is representative of all the hearts 
observed (n=4). Scale bars represent 2mm. 
 
3.6) Wnt1Cre;Hira-/fl embryos suggest a non-cardiac role for HIRA in 
the neural crest cell population  
Since a requirement for Hira has been described in neural crest cell in chick (Farrell et 
al., 1999), the role of Hira was tested in this lineage using Wnt1Cre.  3.6.1) Perinatal lethality of Wnt1Cre;Hira-/fl 
The litters resulting from crossing Wnt1Cre;Hira-/+ to Hirafl/fl mice were first surveyed at 
P10. No mutants were observed (Error! Reference source not found.).      3.6.2) No heart or great vessel abnormalities at E18.5 
Surprisingly, a Mendelian ratio of Wnt1Cre;Hira-/fl embryos was recovered at E18.5. 
The mutants had a normal external appearance and no OFT or great vessel malformations 
(Figure 3-13). The mutant hearts were dissected and analysed by OPT.  No OFT, valves or 
septation malformations were identified (Figure 3-13). 
Figure 3-12 Mef2cCre conditional Hira mutants present no cardiac defects  
  
Driving ablation of Hira in the neural crest cell population led to postnatal death but no 
cardiovascular malformations were detected at the embryonic stage. Here, the great vessel 
structure (top panel) and OPT long axis section (bottom panel) are presented in E18.5 
Wnt1Cre;Hira-/fl hearts and their control. No heart defects were observed in these mutants. 
This OPT scan is representative of all the hearts observed (n=10). rsc: right subclavian artery, 
rcc: right common carotid, lsc: left subclavian, lcc: left common carotid, aa: aortic arch. RV/LV: 
Right/left ventricle. RA/LA: Right/left atrium. Scale bars represent 0.5mm in long axis sections. 
Work carried out in collaboration with Yoann Rose and Ariane Chapgier  
 
Figure 3-13 Wnt1Cre conditional Hira mutants do not present with any 
cardiac phenotype  
3.7) Tie2Cre;Hira-/fl  embryos are viable but adults show a growth defect 
A requirement for Hira has been previously described in endothelial cells. An in vitro 
system revealed a HIRA-dependant upregulation of Vegfr1 in response to angiogenic signals 
(Dutta et al., 2010) (see p25). Tie2Cre;Hirafl/-  mutants only suffered from a partially penetrant 
proportionate growth reduction at the weaning stage (data not shown). At 6 weeks of age, the 
mutant animals remained smaller but behaved normally. At E15.5, embryonic trunks were 
analysed by OPT and no vessel nor endocardial tissue malformations were observed (Figure 
3-14). Hearts collected from growth retarded adults were smaller compared to their WT 
littermates (Figure 3-14) but only in proportion to their reduced body size and did not have 
any structural malformation. 
 
Figure 3-14 Tie2Cre conditional Hira mutants are viable  
Driving ablation of Hira in the endothelial lineage did not lead to embryonic lethality or 
malformations. Here, Tie2Cre;Hira-/fl long axis sections are shown at E15.5 and in the adult (8 
weeks) by OPT. Mutant embryos did not show any defects and their adult heart only showed 
proportional size reduction to the body size. This OPT scan is representative of all the hearts 
observed (n=5). The Aorta (Ao), the PT, the right and left atrium (RA/LA) and the right and left 
ventricle (RV/LV) are indicated. Scale bars represent 0.5mm in top panel and 2mm lower panel 
 
3.8) Myh6MerCreMer;Hira-/fl: A pilot study investigating the role of 
HIRA in adult cardiomyocytes 
Given the fact that HIRA is a replication independent histone chaperone, it was 
postulated that HIRA might be playing a role in post-mitotic cardiomyocytes. To test this 
hypothesis, a Cre driver was used (Myh6MerCreMer) which induces recombination in cardiac 
muscle cells upon injection of tamoxifen (Sohal et al., 2001). It is important to note that this 
inducible Cre driver is also known to provoke DNA damage once activated by tamoxifen, 
probably due to DNA breaks at non-loxP sites (Bersell et al., 2013). HIRA has been shown to be 
implicated in the DNA damage response (Adam et al., 2013) (see p27). The Visualsonics Vevo 
2100 ultrasound machine which measures heart function was used to measure the potential 
impact by the ablation of Hira on cardiomyocytes. The total ejection fraction was measured by 
quantifying the heart volume in triplicates at diastolic and systolic stages, prior to tamoxifen 
injection and 2 weeks and 8 weeks after (Figure 3-15). 
 
 
Figure 3-15 Experimental design to assess the effect on heart function of the ablation 
of Hira in post-mitotic cardiomyocytes: a pilot study 
Ablation of Hira in post-mitotic cardiomyocytes was carried out using a Myh6MerCreMer 
allele. The potential effect on heart function was done using an ultrasound machine. Here, 
stills from ultrasound image are shown with frames where the heart is in full diastole and 
systole with the indicated imaging planes (top panel). Below is a schematic representing the 





 The results (data not shown) showed a too great variability between each animal to 
draw any conclusion. The knockdown of HIRA was confirmed post-mortem by sampling 
ventricular wall tissue and detecting HIRA protein levels by western blot (Figure 3-16). 
 
Figure 3-16 Western blot analysis of HIRA knockdown in MyhMerCreMer conditional 
mutants 
Western blot of total protein extract from a heart biopsy postmortem are shown. HIRA level is 
diminished in the mutant compared to Cre control and WT. Western blot shown is 
representative of three hearts. 
 
3.9) Discussion  3.9.1) HIRA is required autonomously in the FHF 
The Mesp1Cre conditional Hira mutants all have cardiac defects and generalised 
oedema. The variability observed between mutants could be the result of the patchy level of 
efficiency of Mesp1Cre within a litter. Moreover, Hira phenotypes can be variable since Hira-
null embryos displayed a spectrum of phenotypes, from mildly affected to severe (Roberts et 
al., 2002). Some Mesp1Cre conditional Hira mutants collected at E12.5 were degenerating 
whilst some at E13.5 or E14.5 had a normal appearance.  
The data presented in this chapter shows that HIRA is required in the cardiogenic 
mesoderm for normal development after E10.5. As discussed earlier (see p4), Mesp1 is mainly 
expressed in the FHF and SHF, but is also partly expressed in muscles of the face, the 
embryonic liver and some foetal haematopoietic stem cells. Therefore, non-cardiac tissue 
could potentially contribute to the overall phenotype. Nkx2.5Cre conditional Hira mutants 
were used to test for that possibility. As mentioned earlier, Nkx2.5’s expression is principally 
restricted to cardiomyocytes of the FHF and SHF (see p5) although the SHF expression has 
been shown to be variable and highly dependent on genetic background (Moses et al., 2001, 
Ramsbottom et al., 2014). Nkx2.5Cre;Hirafl/-  mice were mostly embryonic lethal and displayed 
a similar phenotype to the Mesp1Cre;Hirafl/- animals, even if no mutant embryos presented 
with oedema. On the other hand, when Hira was ablated from a region of the SHF referred to 
as the anterior heart field, no effect on development or postnatal growth was detected. This 
lack of phenotype in Mef2cCre;Hirafl/- animals suggests that HIRA is not required in the anterior 
SHF for heart development to proceed normally. Taken together, this implies that HIRA is 
required in the FHF rather than in the SHF although absence of HIRA from the SHF could 
potentially act to exacerbate the phenotype of FHF mutants. Despite the known cooperation 
between the transcription factors Nkx2.5 and Mef2c during cardiogenesis (Vincentz et al., 
2008), the phenotypes resulting from the conditional Nkx2.5Cre and Mef2cCre Hira mutants 
differ significantly.  The mild phenotype observed in Nkx2.5Cre Hira mutants and the absence 
of phenotype in Mef2cCre Hira mutants, compared to the severe phenotype observed in 
Mef2cCre;Nkx2.5f/f (embryonic lethality at E9.5) (Cambier et al., 2014) might indicate that 
some transcription factors (NKX2.5) can have a stronger and more rapid impact on gene 
expression during development, compared a histone chaperone such as HIRA. 3.9.2) Pulmonary stenosis specific to Nkx2.5Cre;Hira-/fl  embryos 
A constriction of the pulmonary trunk (PT) was seldom found in Mesp1 conditional 
mutants (1/12) but was more prevalent in Nkx2.5Cre;Hira-/fl  embryos (3/9). Sometimes 
referred to as pulmonary Infundibular stenosis, this feature is one of the characteristics 
features of tetralogy of Fallot (ToF), a congenital heart defect. In ToF, the narrowing of the PT 
increases the pressure inside the right ventricle after birth which leads to ventricular 
hypertrophy. ToF patients also present with a VSD and an overriding aorta, which were also 
detected in some Nkx2.5Cre;Hira-/fl embryos at E15.5 (5/9). The single surviving Nkx2.5Cre 
conditional Hira, although much smaller compare to its littermate control (see p57), did not 
show any cardiac malformations by OPT (data not shown).  
Contrary to what was previously thought, pharyngeal arch arteries (PAAs) have been 
recently found to have an Nkx2.5-linage contribution. Endothelial cells from PAAs 3, 4 and 6, 
which give rise to postnatal carotid arteries, right subclavian artery and aorta, and pulmonary 
arteries, respectively, express Nkx2.5 at E10.5 and E11.5 (Paffett-Lugassy et al., 2013). In 
contrast to Mesp1’s expression which is strictly mesodermal, the expression of Nkx2.5 in 
pharyngeal endodermal cells underlying the SHF (Zhang et al., 2014b) could partially explain 
our phenotype.  
Finally, it is worth nothing that some patients with ToF have a mutated copy of NKX2.5 
(McElhinney et al., 2003). The Nkx2.5Cre used here is a knock-in allele and thus there is the 
potential for interaction between hemizygous levels of NKX2.5 and absence of HIRA. While no 
phenotypes were observed in Nkx2.5Cre;Hira+/fl embryos (n=6) such a genetic interaction 
remains a possibility. However, to our knowledge, no mutations of HIRA have been described 
in exome sequencing analyses of patients with congenital heart defect, although one study of 
a Chinese cohort associated a variant in the 3’ UTR region of HIRA to the diagnosis of ToF 
(Wang et al., 2014). 
 
Taken together, these results suggest that Hira might be involved in certain cases of 
ToF and could play a role in the CPF and in the PAAs. It is important to note that although the 
higher-level organization regulatory networks are conserved between mice and humans 
(Stergachis et al., 2014), an ENCODE project review stated how 50% of murine TF binding sites 
in regulatory elements are absent in humans, and 25% have migrated to different genomic 
locations (Carninci, 2014). Mutations can therefore be species specific and one has to be 
cautious in translating results across species.  
 3.9.3) Requirement of Hira in endothelial cells: in vitro vs in vivo results 
The low penetrant growth reduction phenotype observed in Tie2Cre conditional 
mutants did not seem to be due to cardiac malformations, according to the reconstruction of 
the adult hearts by OPT. However, since vascularisation is important for a proper bone 
formation (Portal-Nunez et al., 2012), it is possible that HIRA could be required for 
angiogenesis during skeletal development which would explain the growth retardation of 
Tie2Cre;Hirafl/- adults (n=3). Since no embryonic or postnatal lethality was observed and only a 
reduction of size was observed in some adult mutants, it suggests that the role of HIRA in 
postnatal angiogenesis is not as critical as the endothelial network formation on matrigel had 
originally predicted (Dutta et al., 2010). Taken together, these somehow contradicting data on 
the role of HIRA in endothelial cells highlight the differences between in vitro and in vivo 
systems. The later encompasses a significant amount of both angiogenic and angiostatic 
factors (Distler et al., 2003) (VEGFs, FGFs, angiopoietins, PDGF, angiogenin), which could 
compensate for the lack of Hira during angiogenesis. A requirement for HIRA in the endothelial 
cell population might be more evident in a repair or regeneration situation. For example, 
hypoxia-induced angiogenesis (Krock et al., 2011) could be used (during development or after 
birth) to see if Tie2Cre;Hirafl/- mice display a similar endothelial cell proliferation, sprouting, 
migration and adhesion compared to controls. In addition, a tumour-transplantation 
experiment, which is often used to survey angiogenesis in cancer (Eklund et al., 2013), could be 
carried out in this context to test the angiogenic capacity of Tie2Cre;Hirafl/- mice. Subsequently, 
the expression of Vegfr1 could be quantified to measure the impact of the ablation of HIRA in 
proliferating ECs, as predicted by (Dutta et al., 2010). 3.9.4) Possible causes of lethality of the Wnt1Cre;Hira-/fl newborns  
The absence of cardiac and great vessel phenotypes in the Wnt1Cre;Hira-/fl  embryos 
up to E18.5 argues against a requirement of HIRA in cNCCs during cardiovascular development. 
This was contradictory to the results found in chick, in which a knockdown of Hira in 
premigratory neural crest cells resulted in failure of outflow tract septation (Farrell et al., 1999) 
(see p26). The perinatal death that was observed in Wnt1Cre;Hira-/fl mutants could rather be 
the result of a neurological problem or a cleft palate defect interfering with swallowing 
(Trainor, 2010) since Wnt1Cre is expressed in craniofacial NCCs. It is worth noting that a review 
has recently pointed out the discrepancies often found in loss-of-function phenotypes 
between non-mammalian and mouse models (Barriga et al., 2015). For example the migration 
of neural crest cell is dependent on non-canonical WNT signalling in Xenopus, zebrafish and 
chick, but that is not the case in the mouse. Future experiments could involve examining 
neurological structures in Wnt1Cre;Hira-/fl mutants for possible malformations. The innervation 
of the heart could also be affected (Hildreth et al., 2008), which could be tested by 
immunostaining with neurofilament-66 (Payne et al., 2015). The neuronal axons of the 
sympathetic/parasympathetic system, if affected, could causes arrhythmias. 
 3.9.5)  HIRA is not required in normal conditions in post mitotic cardiomyocytes 
 The pilot experiment to investigate the potential role of HIRA in post mitotic 
cardiomyocytes suggests that HIRA is not required for normal heart function. After 3 
consecutive days of tamoxifen injection, the animals were monitored for 8 weeks. The 
behaviour and cardiac output both mutants, Cre controls and WT animals remained unaltered. 
However, there are many aspects of this pilot experiment which have not been investigated. 
For example, it remains a possibility that a diminished expression of Hira could impact on the 
DNA repair mechanism, which would have been solicited after the deleterious Cre expression 
(see p61). A quantification of total DNA lesions could have addressed this question. DNA 
damage rarely impacts rapidly on cell function and rather has long term effect, such as 
premature ageing (de Boer et al., 2002).  A long term ageing study of conditional Hira mutants 
could potentially shed some light on the role of HIRA in cardiac ageing. Furthermore, HIRA has 
already been shown to play an important part during the formation of SAHFs (see p27) which 
could further impact the rate of cells entering senescence. Future work involving 
immunofluorescence on heart sections to observe cell morphology or markers of senescence 
such as senescence associated beta-galactosidase (SA-βgal) activity or p16INK4a tumor 
suppressor protein (Debacq-Chainiaux et al., 2009). 
 Another means of testing the requirement of HIRA in the adult heart would be after 
cardiac stress.  Dobutamine, which stimulates the β1-adrenoceptors of the heart (Calligaris et 
al., 2013) and increases contractility and cardiac output could be used to see whether the 
hearts respond as well once Hira has been ablated. Gene activation after myocardial infarct 
(MI) has been well characterised (Haubner et al., 2012). It would be interesting to perform a 
RNAseq after MI or cryoinjury to analyse the role of HIRA in regulating key genes involved in 
cardiac recovery.  
In summary, this chapter has shown that HIRA is not required for homeostasis in adult 
cardiomyocytes. However, the external phenotype, embryonic lethality and cardiac 
malformations caused by the ablation of Hira in cardiogenic mesoderm during development 
indicate a crucial role of HIRA in myocardial precursors. The following chapter will examine the 




Chapter 4 Genome wide analysis of genes dysregulated in the 
absence of Hira 
4.1) RNAseq analysis of Mesp1Cre;Hira-/fl hearts at E11.5 and E12.5  
Ablation of Hira in the cardiogenic mesoderm (Mesp1Cre) led to the most drastic and 
penetrant phenotypes with a 100% penetrant oedema and VSD at E15.5. In order to 
investigate the transcriptional changes responsible for these defects, a RNAseq was performed 
on total RNA from embryonic hearts at E11.5, as the heart have just completed looping and 
prior to the appearance of the malformation of the atrioventricular cushions at E12.5. Since 
the majority of defects were only observed much later and that the cushion defects at E12.5 
were only partially penetrant, the E12.5 stage was selected as well.  4.1.1) List of genes significantly changed at E11.5 vs E12.5 
Mesp1Cre;Hirafl/- transcripts were compared to Mesp1Cre;Hirafl/+  by RNAseq. This 
genome-wide analysis was performed using total RNA extracted from embryonic hearts. 360 
coding transcripts were changed in the mutant hearts (MannWhitney unpaired test, Benjamini 
Hochberg FDR, p ≤ 0.05, FC ≥ 1.5) at E12.5, and 159 at E11.5 (Figure 4-1). 
 
 
Venn diagram indicating the number of genes whose expression is up or 
downregulated in Mesp1Cre;Hira-/fl compared to Mesp1Cre;Hira+/fl  hearts at E11.5 and 
E12.5. RNA extraction and sequencing was done in triplicate from Mesp1Cre;Hira-/fl 
and Mesp1Cre;Hira+/fl  embryonic hearts at E11.5 and E12.5.  
 
 
The E12.5 batch was mainly used for downstream analysis since there were 2.5 times 
more transcripts significantly affected at that stage, compared to E11.5 (Figure 4-1). This 
rational presents the risk of observing additionally dysregulated genes which would mainly 
reflect secondary events rather than genuine HIRA controlled genes, however the level of up 
or downregulation of genes observed at E11.5 was often too low to detect HIRA targets 
(Table 4-1). 
Figure 4-1 A higher number of genes are dysregulated at E12.5 compared to 
E11.5 in Mesp1Cre conditional Hira mutants 
Table 4-1 Gene dysregulation in Mesp1Cre;Hira-/fl hearts is more important at E12.5 
compared to E11.5  
 
 
The list of genes presented here is a subset of genes relevant for cardiac development, which 
have been extracted from the RNAseq list of genes dysregulated in both stages. The genes 
underlined are studied in greater depth in this thesis and have been partly selected for their 
early (E11.5) dysregulation.  
 
 
At E12.5, the RNAseq analysis demonstrated the absence of trend towards up or 
downregulation in the list of significantly dysregulated genes (48.8% down vs 51.2% up) 
(Figure 4-2). Genes of interest were identified based on their known roles during heart 




RNAseq comparing Mesp1Cre;Hira-/fl heart transcripts with Mesp1Cre;Hira+/fl  hearts at E12.5 
resulted in gene down- and up-regulation. Here the heatmap format is used to visualise the 
differential gene expression in the heart of mutants (Mesp1Cre;Hira-/fl) vs controls 
(Mesp1Cre;Hira+/fl) in triplicates at E12.5 
Figure 4-2 The ablation of Hira results in both up and downregulation of a set of genes  
 
 4.1.2) Gene ontology analysis: myofibril/sarcomere  
Since long lists of genes can be challenging to examine, a gene ontology (GO) analysis 
on the list of differentially expressed genes (p ≤ 0.05, FC ≥ 1.5) was carried out in an effort to 
group genes into defined functional groups which might be part of important processes 
relevant for cardiac development. There are now many databases contributing to the GO 
consortium. They include, amongst others, the Mouse Genome Informatics (MGI), UniProt-
Gene Ontology Annotation and the University College London-based annotation group. From 
the list of 46 GO terms obtained, 7 overlapping ones were of particular interest (Table 4-2) 
since they covered genes encoding proteins directly involved with muscle contractility.  
 
Table 4-2 List of GO terms 
GO number GO term p-value Number of genes 
GO:0005488 binding 1.03E-05 152 
GO:0032501|GO:0050874 multicellular organismal process 4.55E-06 81 
GO:0044707 single-multicellular organism process 7.83E-07 79 
GO:0044444 cytoplasmic part 2.83E-05 76 
GO:0032502 developmental process 1.80E-08 67 
GO:0044767 single-organism developmental process 1.58E-08 67 
GO:0048856 anatomical structure development 6.47E-10 65 
GO:0007275 multicellular organismal development 5.38E-08 61 
GO:0048731 system development 7.64E-10 59 
GO:0065008 regulation of biological quality 2.94E-08 42 
GO:0048513 organ development 4.03E-06 41 
GO:0005576 extracellular region 4.76E-08 41 
GO:0048869 cellular developmental process 7.05E-05 40 
GO:0030154 cell differentiation 2.12E-05 40 
GO:0002376 immune system process 5.16E-07 28 
GO:0044421 extracellular region part 3.08E-06 26 
GO:0042592 homeostatic process 7.58E-06 22 
GO:0005615 extracellular space 1.40E-04 19 
GO:0097458 neuron part 1.38E-04 19 
GO:0002520 immune system development 1.98E-06 16 
GO:0048534 hematopoietic or lymphoid organ development 9.92E-07 16 
GO:0030097 hemopoiesis 6.45E-06 14 
GO:0031012 extracellular matrix 8.83E-05 13 
GO:0048872 homeostasis of number of cells 8.48E-08 11 
GO:0030099 myeloid cell differentiation 9.08E-08 11 
GO:0030424 axon 7.66E-05 11 
GO:0015669 gas transport 3.90E-14 9 
GO:0002262 myeloid cell homeostasis 4.27E-08 9 
GO:0034101 erythrocyte homeostasis 6.97E-09 9 
GO:0030016 myofibril 1.16E-05 9 
GO:0030218 erythrocyte differentiation 3.43E-09 9 
GO:0043292 contractile fiber 1.98E-05 9 
GO:0005833 hemoglobin complex 1.33E-15 8 
GO:0044449 contractile fiber part 5.22E-05 8 
GO:0044445 cytosolic part 9.81E-05 8 
GO:0015671 oxygen transport 8.62E-14 8 
GO:0030017 sarcomere 2.72E-05 8 
GO:0005344|GO:0015033 oxygen transporter activity 3.72E-14 8 
GO:0019825 oxygen binding 8.65E-12 8 
GO:0020037 heme binding 1.67E-04 8 
GO:0048821 erythrocyte development 3.69E-05 4 
GO:0061515 myeloid cell development 7.34E-05 4 
GO:0005865 striated muscle thin filament 1.24E-05 4 
GO:0036379 myofilament 2.00E-05 4 
GO:0005861 troponin complex 3.59E-05 3 
 
GO analysis of the genes significantly dysregulated in Mesp1Cre;Hira-/fl embryonic hearts that have an 
over-representation of one or more GO terms that pass the cut-off p-value  of 10-4. Terms relating to 




A list of 8 genes was obtained from the GO terms “myofibril” and “striated muscle thin 
filament” (Figure 4-3) which are important in establishing and regulating cardiac contractility. 
A trend for upregulation was detected, except for Tnni1 and Slc4a1 which were downregulated 




The heatmap presented here revealed the colour coded fold change of genes grouped under 
the terms “contractile fiber” and “sarcomere”. A trend in upregulation was observed, aside 
from Tnnt1 and Slc4a1 which were downregulated. 
 
4.2) Validation of selected genes by qRT-PCR shows a great reliability 
of RNAseq 
Quantitative real time PCR (qRT-PCR) was carried out to validate candidate genes 
selected by RNAseq. Genes were selected for their known roles during heart development. 
Little or no variation of fold change between RNAseq and qRT-PCR data were observed (Figure 
4-4). 
  
Figure 4-3 The GO analysis grouped certain dysregulated genes 
under the term “contractile fiber” or “sarcomere”  
 
Selected genes whose expression is up or downregulated in Mesp1Cre;Hira-/fl compared to 
Mesp1Cre;Hira+/fl  at E12.5 were validated by QRT-PCR. The x-axis represents the absolute fold 
change in gene expression in the mutants compared to their WT littermates (n=3) is shown 
here for both techniques. T-test: p<0.05 *, p<0.01 **, p<0.001 ***. Data are shown as levels of 
mRNA normalized to Gapdh and are representative of three independent experiments. Errors 
bars represent the standard deviation of technical triplicates. This experiment represents a 
technological and biological replicate which highlights the reliability of RNAseq technology and 
validates the genes of interest.  
Figure 4-4 Ablation of Hira leads to dysregulation of a subset of genes: validation of 
RNASeq data by qRT-PCR  
 4.3) Expression of most upregulated gene: Tnni2 and disruption 
of troponin meshwork 
Tnni2 is a fast twitch skeletal muscle gene which was the most upregulated gene in the 
mutant hearts by both RNA-seq (5.9 fold) and qRT-PCR (7 fold) (Figure 4-4). ISH confirmed 
Tnni2 overexpression in the mutants (Figure 4-5), suggesting heart contractility could be 
affected by alteration of sarcomeric components (see discussion p77) 
 
Figure 4-5 Tnni2 is strongly overexpressed in the heart of Mesp1Cre;Hira-/fl embryos 
Tnni2 is a fast skeletal type troponin. Here, transverse sections of E12.5 embryonic hearts 
showed an abnormal strong expression of Tnni2 mostly in the ventricular wall (arrows) of the 
heart in Hira-conditional mutant hearts compared to the normal expression in the WT. Images 
are representative of two embryos for each genotype and incubation time were identical Scale 
bar: 100μm 
 
Staining with Troponin C on transverse sections to examine sarcomeric organisation 
was done in collaboration with Sarah Phelps. It demonstrated a lack of typical parallel 
organisation of the filament structures in the mutants (Figure 4-6). 
  
  
Troponins are known to regulate muscle contractility. Here, transverse sections of E12.5 
embryonic hearts immunostained with DAPI (nucleus) and Troponin C (sarcomeric structure) 
show a disorganisation of the contracting meshwork of myofibrils in the absence of HIRA, in 
the free ventricular wall of the mutants. Scale bar: 10μm Experiments carried out in 
collaboration with Dr Sarah Phelps and included with her permission. 
 
Figure 4-6 Ablation of Hira leads to disorganised sarcomeric structure in the heart 
 4.4) Epha3 is expressed in the atrioventricular cushions and is 
strongly reduced in Hira-conditional mutant hearts 
The expression of Epha3, encoding a receptor tyrosine kinase that is required for 
EndMT (see p2) in the atrioventricular cushions, was downregulated 2.7 fold in the heart of the 
mutants compared to their control littermates (Figure 4-4). In agreement, in situ hybridization 
(ISH) revealed that Epha3 expression was greatly diminished in the cushions and the 
membranous part of the ventricular septum in the mutants compared to their control 
littermates (Figure 4-7). 
 
 
Figure 4-7  Ablation of Hira results in the downregulation of Epha3 in the cardiac 
cushions  
In situ hybridization of Epha3 on transverse sections of E12.5 embryos with the indicated 
genotypes show a low expression of Epha3 in both the membranous portion of the 
interventricular septum (IVS) and the atrioventricular cushions (AVC) (lower panel) in the 
mutants. The littermate control have a high expression in those regions (arrows). RV/LV: 
Right/Left ventricle. RA/LA: Right/Left atrium. Images are representative of two embryos for 




  4.5.1) GO analysis: contractility likely to be affected in Mesp1Cre;Hira-/fl hearts at E12.5  
The ablation of Hira in the cardiogenic lineage resulted in the upregulation of Tnni2 (7 
fold) and Tnnt3 (3.2 fold), genes located close together in both the mouse and human 
genomes (see next chapter). The encoded proteins are classified as fast skeletal muscle 
troponins (Ochala, 2008). The troponin complex binds calcium ions, and through its association 
with actin and tropomyosin is involved in the regulation of striated muscle contraction. It 
consists of three different subunits, troponin C (TnC), troponin I (TnI) and troponin T (TnT). 
While various troponins are expressed in the developing heart at E12.5 (Franco et al., 1998), 
the skeletal troponins have a low expression in cardiac muscle, and upregulation of Tnnt3 has 
been associated with reduced cardiac contractility (Huang et al., 2008). In a Notch1 gain of 
function mutant, structural defects of the myocardium were attributed to elevated expression 
of Tnni2 (Watanabe et al., 2006). The GO analysis revealed several other sarcomeric genes 
(also under the GO term myofibril) which were dysregulated. Tnni2, Tnnt3, Casq1, Acta1, Krt8, 
Krt19 (Stone et al., 2007) were upregulated and the anion exchanger Slc4a1 and Tnnt1 were 
downregulated 3 fold and 2 fold, respectively (Figure 4-3). Tnnt1 is crucial for cardiac function 
during embryogenesis up to E16.5 (Manuylov and Tevosian, 2009) and Slc4a1-/-  neonates suffer 
from cardiac hypertrophy soon after birth (Alvarez et al., 2007). Immunofluorescence 
microscopy analysis of the troponin complex demonstrated a disorganised structure of the 
striated muscles of the myocardium (Figure 4-6). This disruption to the myofibril assembly likely 
contributes to a diminished efficiency of heart pumping (Risebro et al., 2009). The developing 
mouse heart starts beating at E8.5. Reduced cardiac output can lead to whole body oedema at 
E14.5 (Peng et al., 2008). Thus, the haemorrhage and oedema observed at E15.5 could be a 
consequence of diminished cardiac function secondary to poor maintenance of sarcomeric 
structure and myofibril disruption.  4.5.2) The role of Epha3 in the development of cardiac cushions and its potential role in the establishment of a VSD  
Epha3 had a diminished expression at E11.5 and E12.5 in Mesp1Cre;Hira-/fl hearts 
(Table 4-1). Epha3 is expressed in the heart from E10.5 in the atrioventricular cushion and in 
the mesenchymal cap of the developing septum primum (Stephen et al., 2007). Accordingly, 
the expression in E12.5 Mesp1Cre;Hira-/fl was examined in mutant hearts. Epha3 was 
downregulated in precisely those regions in the mutants versus the controls (Figure 4-7). 
Interestingly, Epha3-null embryos are perinatal lethals with ASD and cardiac failure, and have 
earlier atrioventricular cushion defects (Stephen et al., 2007). This is striking in view of the 
defects seen at E12.5 in Mesp1Cre;Hira-/fl mutant hearts (Figure 3-7). As the interventricular 
septal defect is at the site of the anticipated embryonic interventricular communication, it 
maybe that reduced growth of the muscular septum contributes to the abnormality. 
Furthermore, the ADAM10 membrane metalloprotease has been well characterised during 
heart development and is required for the EMT process of the atrioventricular cardiac 
cushions (Zhang et al., 2010). ADAM10 is known for interacting with Eph and Ephrin 
expressing cells. For instance, it can recognise and regulate the formation of Ephrin-A5/EphA3 
complexes (Janes et al., 2005). Epha3, through ADAM10, promotes cleavage of EphrinA5 on 
the surface of opposing cells (Atapattu et al., 2012, Janes et al., 2005).  It is likely that 
downregulation of Epha3 perturbs the Eph/Ephrin-mediated cell repulsion and segregation 
which could contribute to the septal defects in Hira mutants. 
 4.5.3) Other transcriptional changes possibly affecting heart development. 
Following the RNAseq at E11.5 and E12.5 of Mesp1Cre;Hira-/fl hearts,  transcripts were 
identified which were the most likely responsible for generating the phenotype described in 
chapter 3. However, 360 dysregulated genes represent a substantial list which cannot be fully 
discussed within a reasonable text length. The following discussion attempts to describe genes 
that would be high priorities for further work in the context of HIRA and its role in heart 
development. 
Lyve1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1) was found to be strongly 
downregulated (Figure 4-4, 5.1 fold by RNASeq and 8 fold by qRT-PCR at E12.5). Lyve1 is a 
marker of the lymphatic system first discovered in 1999 (Banerji et al., 1999) across many 
organisms (Okuda et al., 2012). The lymphatic system is crucial for fluid regulation. 
Interestingly, a lymphatic defect often result in substantial oedema (Gauvrit et al., 2014), 
which was identified in  Mesp1Cre;Hirafl/- from E13.5. Lymphatic endothelial cells are first 
detected at E12.5 using markers such as VEGFR-3 (Joukov et al., 1996) and PROX1 (Wigle and 
Oliver, 1999).  The earliest LYVE1 expressing cells occur at the venous pole of the heart (Figure 
4-8) around E12. At E12.5, cardiac lymphatic vessels begin to emerge, sprouting from extra-
cardiac regions proximal to the OFT (Klotz et al., 2015) and at E13.5, the surface of hearts is 
covered with LYVE1 expressing cells (Flaht et al., 2012). 
 
Figure 4-8 Schematic representing the lyve1 positive strands/tubules/vessels migration 
pattern 
Schematic representing progressive development of Lyve1 positive strands on the venous 




Although Lyve1 seemed like a strong candidate gene, it is important to note that fully 
form lymphatic vessels only begin to grow on the ventricular surface of the dorsal side of the 
heart from E14.5, and reach the apex by E18.5 (Klotz et al., 2015). In addition, Lyve1-/- mice are 
viable and present no lymphatic phenotype (Luong et al., 2009), which questions the exact role 
of this gene for the formation of the lymphatic system. On the other hand, Prox1-/- mice are 
embryonic lethal (Wigle and Oliver, 1999). Prox1 has also been shown to be important for 
lymphangiogenesis (Wigle and Oliver, 1999), with cells often expressing Prox1 and Lyve1 
simultaneously (Flaht et al., 2012). Prox1 was only slightly downregulated (1.4 fold) at E12.5 in 
Mesp1Cre;Hirafl/- hearts, suggesting that lymphatics growth was not greatly affected by Lyve1 
downregulation. Moreover, Tie2Cre;Hirafl/- conditional Hira mutant, in which Hira would also 
be ablated from in cardiac lymphatics, did not have an embryological phenotype and were only 
partially affected during their adult life (see p61). This result advocates only a minor role of 
HIRA in endothelial cells. Lyve1 downregulation is therefore unlikely to be the main cause of 
the oedema seen at E15.5 in Mesp1Cre;Hirafl/-embryos. 
 
Gata5 was not initially part of the dysregulated list of genes at E12.5 since its 
upregulation was 1.4 fold (Figure 4-4). However, qRT-PCR experiments on additional 
Mesp1Cre;Hira-/fl hearts pointed out a 1.6 fold overexpression, thus placing that gene in the 
group of significantly upregulated transcripts. Since GATA4, GATA5, and GATA6 share 85%  
homology of their DNA binding site (Singh et al., 2010),  Gata4−/− embryos die between E8.5 
and E10.5 due to a lack of linear heart tube and failure of ventral morphogenesis (Molkentin et 
al., 1997), and Gata4−/−Gata6−/− embryos completely lack a heart (Zhao et al., 2008), many 
groups have studied Gata5 during heart formation. In zebrafish, GATA5 directly regulates the 
cardiac transcription factor Nkx2.5 (Reiter et al., 1999), and is required for heart development. 
Although Gata5 is only expressed in the heart and the lung during embryonic development in 
the mouse (Morrisey et al., 1997), by itself Gata5 does not appear crucial for development 
since Gata5−/− mice are viable (Singh et al., 2010, Molkentin et al., 2000). However, Gata5, 
alongside Gata4, regulates the proliferation rate of cardiomyocytes in mice during 
embryogenesis (Singh et al., 2010). Although Gata4+/- embryos are viable and show no 
abnormalities, Gata4+/−,Gata5−/− compound mutant embryos at E12.5 presented with cardiac 
defects such as a hypoplastic ventricular compact myocardium and hypoplasia of the 
endocardial cushions leading to common atrioventricular canal (Singh et al., 2010). By E14.5, 
these mutants had systemic haemorrhage and body wall oedema, which the authors say is 
“suggestive of heart failure”. It is therefore a possibility for Gata5 dysregulation to be a 
contributing factor for the heart defects observed in Mesp1Cre conditional Hira mutants.  
Overall this chapter has described the most relevant differentially expressed genes in 
the heart of Mesp1Cre;Hirafl/- embryos at E11.5 and E12.5. The most upregulated gene, Tnni2, 
along with other dysregulated troponins such as Tnnt3 were validated by qRT-PCR.  Troponin 
staining revealed myofibrillar disarray in the heart wall, in the same subset of cardiac cells 
where an  overexpression of Tnni2 detected, which is likely to affect the contraction ability of 
cardiomyocytes. Of particular interest, Epha3 which has been associated with the EMT process 
and atrioventricular cushion formation, was found to be downregulated in the mesenchymal 
components of the cushions.  Taken together, these gene expression changes are likely to be 
responsible for the VSD and oedema observed at E14.5 and E15.5 in Mesp1Cre conditional Hira 
mutants.  
To potentially improve on our understanding of HIRA’s global gene regulation, the next 
chapter covers the regions of the genome which have an enrichment of HIRA.  
 
  
Chapter 5 HIRA ChIP followed by massively parallel DNA 
sequencing (ChIPseq) 
The genome-wide analysis of differential transcription in Mesp1 conditional mutants at 
E12.5 was covered in the previous chapter. To investigate the potential role of HIRA in 
transcriptional regulation through chromatin modification, genome-wide chromatin 
immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIPseq) was 
performed on WT hearts at E12.5. This approach might shed light on the dysregulation of 
certain genes resulting from the ablation of Hira in the cardiogenic lineage. Although HIRA has 
been shown to directly bind naked DNA (Prochasson et al., 2005, Ray-Gallet et al., 2011, Orsi et 
al., 2013), histone chaperones only bind chromatin transiently (Angelov et al., 2006, Adam et 
al., 2013). As mentioned in 43, it was therefore necessary to use EGS, a cross-linking agent with 
arms 8 times longer than traditional formaldehyde (FA) in addition to FA. (Figure 5-1). 
 
Figure 5-1 Cross-Linking Agents 
Table representing the molecular weight and respective spacer arm length in angstrom of 
crosslinking agents. Adapted from (Zeng et al., 2006) 
 
Due to the dual cross-linking (HCHO and EGS), sonication time had to be adapted. 25 rounds of 
sonication of 1 min were required to sufficiently shear chromatin and obtain fragments small 
enough to continue with the ChIP. QChIP requires sizes between 500 and 1000bp, whereas 
smaller fragments are preferred for ChIPseq (~300bp). This was verified by both standard 1% 
agarose electrophoresis (Figure 5-2) and by bioanalyser (Figure 5-3). 
 
 
Figure 5-2 Sonication levels of chromatin verified on an 1% agarose gel 
Electrophoresis 1% agarose gel displaying sheered chromatin after reverse crosslinking. 25 
rounds of replication were required in order to obtain the correct fragment size for ChIPseq. 
 
Figure 5-3 High Sensitivity DNA Assay on a Bioanalyser 
Analysis of fragment sizes with a bioanalyser. The “bump” here at ~500bp represents the 
correct fragment size for qChIP. 
 
5.1) ChIP-seq analysis using strand NGS and peak calling 5.1.1) Quality control 
 ChIP and input chromatin samples were analysed before massive parallel sequencing. 
The quantity, fragment size and quality of the purified input and ChIP DNA were assessed. The 
quantity of material was measured with a next generation fluorometer “Qubit® 3.0”.  The 
standard nanodrop 1000 would not have been sensitive enough to measure small ChIP DNA.  
The minimum required concentration for sequencing is 1ng. 0.118*30=3.54ng was obtained 
(Figure 5-4). 
 
Figure 5-4 ChIP DNA quantified by Qubit® 3.0 Fluorometer 
The Qubit fluorometer is designed to accurately quantify very small amount of DNA. The 
concentration of ChIP DNA and Input DNA are displayed here. 9 µl were used from the ChIP 
sample to obtain 1ng.  
 
The fragment size was checked by bioanalyser before and after library preparation. 
The library preparation involved a size selection step for fragments ~200bp +/- 100bp, with the 
adapters adding a further 120bp (Figure 5-5). It is challenging to decide the sequencing depth 
(total number of reads) required as it depends on how many sites have been enriched genome 
wide and the affinity of the antibody used. A maximum sequencing depth of 90million reads 
was performed. Please see discussion for further analysis. 
 
Figure 5-5 ChIP DNA and library bioanalyser trace 
Comparison of ChIP DNA and input after and before the library preparation (A), which includes 
a size selection between 150bp and 500bp (B). 
 5.1.2) Peak calling 
The genome alignment was done to the mouse genome mm10 using bowtie by the 
UCL genomics group (Mike Hubank group) and the generated .bam files were analysed using 
the strand NGS software. This software includes different algorithms to detect significant 
enrichment at given loci. The enriched region detection (ERD) was first used, followed by the 
better characterised Model-based Analysis of ChIP-Seq (MACS). Figure 5-6 illustrates the 
region upstream of Gata5 where both algorithms detected a region bound by HIRA. On the 
other hand, the putative HIRA enrichment at the Tbx3 locus was only identified by the ERD 
method (Figure 5-7). 
 
Figure 5-6 IGV HIRA has a putative binding site at the Gata5 locus (calculated with the 
MACS algorithm) 
Legend below  
 
Figure 5-7 HIRA has a putative binding site at the Tbx3 locus (calculated with the ERD 
algorithm) 
The ChIP track (top) and input track (middle) are represented here. Each grey/green block 
represents a 43bp read. The lower track represents the reference genome (mm10) and the 
“peaks” detected by MACS and ERD.  
 
The validation of those loci (Gata5 and Tbx3) by qChIP showed the ERD method to be 
unreliable, since the Tbx3 amplification was identical to the intergenic region of chromosome 6 
(X6) used as a negative control for specific binding (Figure 5-8). It is possible that the 
parameters for the ERD algorithm were not correctly defined, however MACS analysis 
rightfully predicted a ten-fold enrichment of HIRA at the Gata5 locus compared to the negative 
control (X6) (Figure 5-8). MACS is the most widespread method to identify read-enriched 
regions from ChIPseq data and had already been cited more than 300 times in 2012 (Feng et 
al., 2012).  
 
Figure 5-8 HIRA is enriched at the Gata5 locus but not at the Tbx3 locus 
QChIP shows an enrichment of HIRA upstream of Gata5. (validation of the peaks mentioned 
above). An intergenic region on chromosome 6 was used as a negative control. HIRA does not 
bind the Tbx3 locus. Data is normalized to the input (=100) and is representative of 2 
independent experiments. Errors bars represent the min/max from technical duplicates. 
Unpaired t-test: p<0.01 ** 
 
The genome analysis presented here was carried out following peaks obtained by MACS 
analysis. It contained the following four steps: 
- Remove redundant reads (if not done previously) 
- Adjust read position 
- Calculate peak enrichment 
- Estimate the empirical false discovery rate. 
 5.1.3) Gene list enriched for HIRA binding in their proximity 
The predicted HIRA binding sites obtained by MACS analysis were used to generate a 
list of genes which had a peak within their gene body and/or 5Kb upstream/downstream of 
the TSS/TES, respectively. A total of 6625 peaks generated a list of 2515 genes.  This method 
implied that 62% of peaks are distal intergenic and 38% are genic. To further characterise the 
HIRA ChIPseq enrichment genome-wide, the CEAS tool (Cis-regulatory Element Annotation 
System) was used which analyses ChIP signals over specific genomic features, such as 













Figure 5-9 CEAS display of HIRA enriched regions spread over the indicated categories 
Pie chart generated by CEAS presenting an overview of how ChIP regions are  distributed 
across the genome over important gene features such as promoters, regions 
upstream/downstream and exons and introns.  
 
With this analysis, only 54.7% of the 6625 peaks were classified as “distal intergenic”. 
The higher proportion of “genic” regions with this method (46% with CEAS compared to 38% 
with the method described above) was mainly due to certain genes having multiple HIRA peaks 
(e.g Epha3-Figure 5-10). 
 
 
This list of “HIRA enriched genes” was compared to the list of dysregulated genes obtained 
with the Mesp1Cre;Hirafl/- RNAseq dataset (Figure 5-11). A total of 47 genes, out of the 360 
genes dysregulated in Mesp1Cre;Hirafl/-  hearts  have regions in their gene body (Epha3) or 
within +/- 5Kb (Gata5) with a predicted HIRA binding site(Figure 5-11). A hypergeometric 
probability test shows that this was not statistically significant (Figure 5-12). 
Figure 5-10 IGV screenshot of HIRA binding at the Epha3 locus 
 
Figure 5-11 Venn diagram displaying the overlap between genes enriched with HIRA 
and genes significantly dysregulated in Mesp1 conditional Hira mutants 
Venn diagram displaying the overlap between genes whose expression is dysregulated in E12.5 
Mesp1Cre;Hira-/fl hearts and genes which are enriched for HIRA, as defined by the presence of 
a peak in the gene body and/or within 5Kb upstream of the TSS and downstream of TES 
 
 
Figure 5-12 Equation for the calculation of a hypergeometric probability 
Equation for calculation of the probability of having 47 genes (x) in common between two 
independent groups: 2515 (b, HIRA ChIPseq genes) and 360 (a, RNAseq data) in the mouse 
genome size which has approximately 22 000 genes (n). The result to this hypergeometric 
probability is:  P(X >= 47) = 0.184. 
(https://www.geneprof.org/GeneProf/tools/hypergeometric.jsp) 
 
However, most HIRA enrichment was situated outside genic regions, which suggested 
HIRA could have an impact on transcription by acting at distant enhancers, which are often 
situated over 5Kb away from a gene (Marsman and Horsfield, 2012) (see p96) 5.1.4) HIRA Binding motif 
Out of the 6625 peaks obtained from the HIRA ChIPSeq, the binding motif most 
commonly found using the strand NGS software, with a total of 29,899 matches, was the 
consensus sequence CTCTCTCT or the reverse complement GAGAGAGA (Figure 5-13) a motif 
which binds the GAGA factor in Drosophila melanogaster (van Steensel et al., 2003). This GA 
rich motif (GAGA motif) could be responsible, via other factors, for HIRA recruitment to the 
chromatin. These 29 899 matches mapped to 45% of peaks, since some peaks contained 
multiple GAGA motifs (Figure 5-15). Other motifs (see p46) from the Jaspar database were also 
detected in the 6625 peaks, which highly resemble the GAGA motif (Figure 5-14). 
 
 
Figure 5-13 Matrix-based nucleotide profile displaying the motif that HIRA binds the 
most in the HIRA ChIPseq  on E12.5 WT hearts 
The DNA binding motif most prevalent in the HIRA ChIPseq (29 899 matches), extracted from 
the JASPAR database. The Y-axis represents how conserved a particular nucleotide is, across 
the whole genome. Positions that are perfectly conserved contain 2 bits, whilst 1 bit 
represents the base pairs which occur 50% of the time. 
 
 
Figure 5-14 Matrix-based nucleotide profiles of HIRA ChIPseq 
The DNA binding motifs similar to the GAGA motif are displayed here. The number of instances 
where the motifs were present in the HIRA ChIPseq’s significant peaks are located above each 
panel.  
  
Figure 5-15 Example of multiple GAGA motifs between position 6115974 and 6116018 
on chromosome 1 
IGV screenshot with overlapping motifs displayed (top panel). Overlapping multiple motifs 
(horizontal blue bars) had to be clustered into one large region to determine the total number 
of peaks with a GAGA motif.  
 
As discussed in the fourth chapter, the most upregulated gene from the RNAseq 
dataset was Tnni2. A HIRA peak containing the GAGA motif was detected in proximity of that 
gene.  5.1.5) HIRA is enriched in the vicinity of the Tnni2/Tnnt3 loci 
A significant peak 17Kb downstream of Tnni2 and 38Kb upstream of Tnnt3 was 
detected (Figure 5-16). This peak will now be referred as the Tnni2/Lsp1/Tnnt3 (TLT) site. The 
next closed peak is located over 1Mb away. 
 
A. HIRA enrichment at the TLT site is situated between Tnni2 and Tnnt3 and is highly specific 
within that region. B. The HIRA enrichment overlaps with a NKX2.5 binding site in E11.5 hearts 
(Dupays et al., 2015) and in HL-1 cells (Bouveret et al., 2015), and enhancer signatures: histone 
modifications H3K4me1 and H3K27Ac in E13.5 hearts (Shen et al., 2012) and coactivator 
protein P300 binding in E11.5 hearts (Blow et al., 2010)  
 
The expression of both Tnni2 and Tnnt3 was strongly upregulated in our mutant model 
(see p73). However, no dysregulation of Lsp1 expression was observed. QChIP validation, in 
biological replicates, showed an average of 25 fold enrichment at the TLT site, compared to an 
intergenic region on chromosome 6 (Figure 5-17). 
Figure 5-16 IGV profile showing the HIRA enrichment at the TLT locus 
 
Figure 5-17 QChIP validation of the HIRA enrichment at the TLT locus  
QChIP validation of the HIRA enrichment at the TLT locus. Data is normalized to the input 
(=100) and is representative of 2 independent experiments. Errors bars represent the min/max 
from technical duplicates.  An intergenic region on chromosome 6 was used as a negative 
control. Unpaired t-test: p<0.001 *** 
 
In addition, this region was of a particular interest for the following reasons: recent research 
on the role of the transcription factor NKX2.5 during cardiac differentiation revealed that Tnni2 
and Tnnt3 are strongly upregulated at E11.5/E14.5 in the hearts of embryos with a 
hypomorphic mutation of Nkx2.5 and NKX2.5 ChIP experiment in WT E11.5 hearts also 
revealed a strong enrichment of NKX2.5 at the TLT site (Dupays et al., 2015). The authors argue 
that this site serves as a common enhancer for Tnni2 and Tnnt3, a contention supported by a 
luciferase assay. Genome wide analysis showed that in general overlap between HIRA and 
NKX2.5 enrichment is rare (2.98%) (Figure 5-18). In addition, an overlap of 9 genes was found 
between the set of upregulated genes in Hira conditional mutants and the Nkx2.5 
hypomorphic model, including Tnni2 and Tnnt3 (Figure 5-18). Moreover, H3K4me1 and 
H3K27Ac histone modifications in the heart at E11.5 and E13.5, which define putative 
enhancer elements, were also found to be overlapping at this region (Shen et al., 2012) 
(downloaded from www.encodeproject.org). H3K27me3, which is regarded as a repressive 
signal (Kim and Kim, 2012), is not present at the TLT site. P300, which defines enhancer regions 
in the developing heart also binds the TLT site (Blow et al., 2010) (Figure 5-16). Out of the 3000 
genome wide P300 bound regions, this study indicates that 4.3% (130) candidate regions were 
selected and validated using transgenic mouse assays. P300 bound regions therefore strongly 
represent enhancer regions in the developing heart. 80.7% of the regions enriched for both 
HIRA and NKX2.5 were found to be in sites coinciding with enhancer chromatin signatures 
(Figure 5-19). 
 
Figure 5-18 Venn diagrams displaying genome wide overlap of HIRA and NKX2.5 
A. Venn diagrams representing the overlap between loci associated with HIRA and NKX2.5. B. 
Overlap between the sets of upregulated genes in both mutant models. 
 
 
Figure 5-19 Venn diagram displaying HIRA and NKX2.5 enriched regions overlapped 
with enhancer marks 
 
5.2) HIRA interacts with BRG1 and WHSC1 in the developing heart 
HIRA is often part of multiprotein complexes and serves various functions dependent 
upon the developmental stage and/or tissue it is expressed in.  These roles are likely 
dependent upon the nature of HIRA’s interaction partners. Using knowledge of protein 
interactions outside the cardiovascular system, potential HIRA-partners were investigated in 
vivo. 5.2.1) HIRA interacts with BRG1 but does not interact with HDAC1 and HDAC2 in the heart 
 
BRG1 (Brahma-related gene 1) is the catalytic ATPase subunit of the SWI/SNF 
chromatin remodelling complexes BAF and PBAF (Ho and Crabtree, 2010, Vradii et al., 2006) 
which alter chromatin structure  to allow DNA accessibility is known to  be important for heart 
development (see p20). A genetic interaction between ASF1 (part of the HUCA complex) and 
the Brahma complex has been described previously in the fly (Moshkin et al., 2002). In yeast 
(Saccharomyces cerevisiae), three components of the SWI/SNF chromatin remodelling complex 
were found to physically Interact with Hir1p and Hir2p, the yeast homologues of HIRA (Dimova 
et al.). In HeLa cells, ChIPseq experiments investigating known transcription factors and 
transcription regulators revealed that the HUCA complex and the SWI/SNF ATP dependent 
chromatin remodeling complex (BRG1, INI1, BAF155 and BAF170) had a significant genome-
wide overlap, with BRG1 and HIRA sharing over a third of binding sites across the genome 
(Pchelintsev et al., 2013a). HIRA has been found to interact with Clr6 (orthologue to human 
HDAC1) in the yeast (Yamane et al., 2011), to promote global histone deacetylation. In 
fibroblasts cells (COS7), HDAC1 and HDAC2 were found to form a complex with HIRA which 
could regulate chromatin assembly/maintenance (Ahmad et al., 2003). The role of HDACs in 
ESC differentiation and in the heart has been well characterised (see p15). Co-
immunoprecipitation of material from WT embryos revealed that HIRA and BRG1 interact, at 
E12.5 and E14.5 in the heart but no interaction between HIRA and HDAC1/HDAC2 was 
detected (Figure 5-20). The HIRA antibody used for western blot (WC119) was not always 
reliably produced which made verifying the HIRA IP challenging. 
 
Figure 5-20 HIRA interacts with BRG1 and does not interact with HDAC1/2 in the 
embryonic heart 
Western blotting of immunoprecipitates (HIRA IP) or whole cell protein lysates (input) at E12.5 
and E14.5 using WT hearts. An interaction between HIRA and BRG1 was detected in both 
stages. No interaction between HIRA and HDAC1/2 was detected at E12.5 
 5.2.2) HIRA interacts with WHSC1 
Wolf-Hirschhorn syndrome candidate 1 (WHSC1) is a HMTase known to methylate 
histone H3 at lysine 36 (H3K36) (Popovic et al., 2014) (see p21). In interferon stimulated mouse 
embryonic fibroblasts, HIRA has been shown to interact with WHSC1 (Sarai et al., 2013). 
Interestingly, WHSC1 regulates the function of NKX2.5 in the embryonic heart (Nimura et al., 
2009). As described above, NKX2.5 binds the TLT site and directly represses Tnni2/Tnnt3 
(Dupays et al., 2015). Therefore, I was decided to test whether the HIRA-WHSC1 interaction 
took place in hearts. Co-immunoprecipitation revealed that HIRA and WHSC1 interacted in vivo 
at E12.5 and E14.5 in the heart (Figure 5-21). 
 
Figure 5-21 HIRA interacts with WHSC1 in the embryonic heart 
Western blotting of immunoprecipitates (HIRA IP) or whole cell protein lysates (input) with 
HIRA at E12.5 and E14.5 using WT hearts. An interaction between HIRA and WHSC1 was 
detected in both stages. CAIN (CABIN1) is a member of the HUCA complex and served as positive 
control for HIRA co-IP. 
 
5.3) Discussion 
The occupancy of HIRA across the genome at E12.5 in the developing heart revealed 
that approximately two-thirds of HIRA enriched regions are intergenic and that the most 
upregulated gene in the absence of HIRA, Tnni2, has a HIRA binding site 17Kb downstream. In 
addition, HIRA interacts with a chromatin remodelling protein (BRG1) and a HMTase (WHSC1) 
which suggests that HIRA has a specific set of co-regulators during heart development.  5.3.1) Enhancers and H3.3 deposition  
Since the overlap between HIRA enriched genes and genes dysregulated in Mesp1Cre 
conditional Hira mutants did not reach statistically significant levels (see p88), it is possible 
that HIRA acts on enhancers situated over 5Kb from the gene body. Enhancers are DNA 
elements that activate transcription by recruiting tissue-specific transcription factors (TF) and 
other co-factors required to assemble the pre initiation complex (Kornberg, 2007). Enhancer 
sequences often contain multiple recognition sequence to allow the binding of TFs (He et al., 
2012). However, in the fly, some enhancers can remain neutral when only bound by small level 
of TFs (Li et al., 2008). Enhancer-bound TFs can bind chromatin modellers which create 
nucleosome free regions or bend DNA to ultimately render a gene accessible for transcription 
initiation or elongation (Clapier and Cairns, 2009). A genome-wide characterization of 
enhancer-promoter interactions in CD4+ T cells revealed that 56% of enhancers were within 50 
kb and 44% were further than 50 kb from the gene body (Chepelev et al., 2012). In addition, 
this study showed that 25% of promoters associate with more than one enhancer. Some 
enhancers can be very distant from a gene as demonstrated by the 900kb upstream enhancer 
of POU3F4 (de Kok et al., 1996). Enhancers can even be located in exons of nearby genes, as 
demonstrated by H3K4me1, H3K27ac, and P300 (the same marks which were used for the 
HIRA ChIPseq analysis) which are present in 7% of coding exons in the limb of mouse embryos 
at E11.5 (Birnbaum et al., 2012). This suggests that chromatin has to loop for this enhancer-
promoter interaction to take place. Chromosome conformation capture (3C) involves 
crosslinking chromatin with formaldehyde in live cells, digesting DNA with restriction enzymes, 
and then religating DNA strands together before amplifying these new fragments by PCR. A 
successful amplification using a pair of distal primers (e.g. 40Kb) would indicate a chromatin 
loop in that region. This technique can provide evidence for interactions between spatially 
separated regions of chromosomes, and was first used in the context of β-globin genes. In the 
embryonic brain where erythroid cells are not produced, the globin cluster was found to be 
linear, as opposed to the liver which produces erythroid cells, where chromatin loops of 40 to 
60 kb were detected (Tolhuis et al., 2002). However, looping is not always associated with 
enhanced gene activity. For example, a higher order chromatin loop around the Brac1 gene 
was observed, which promotes promoter and terminator interactions, thereby repressing 
expression of that gene. Upon oestrogen stimulation of the human breast carcinoma MCF7 cell 
line, this loop unfolds, followed by increased Brac1 mRNA levels (Tan-Wong et al., 2008). 
Similarly, the upregulation of SAMD4A following TNF-α stimulation has been linked to the 
rupture of a “whole-gene” loop across its 221Kb gene body (Larkin et al., 2012). Within this 
gene, many “subloops” seemed to grow between transcribed regions during transcription. It 
was shown that the “whole-gene” loop, between the 3’ and 5’ end of SAMD4A is dependent 
on the transcriptional repressor CTCF (CCCTC-binding factor), which links those chromatin sites 
together. CTCF, the “master weaver”, is responsible for coordinating the structural 3D 
organisation of genes by forming intra- and inter-chromosome interactions (Phillips and 
Corces). A 3C experiment could indicate if the TLT site does come into proximity of the Tnni2 or 
Tnnt3 promoters and if so, whether this interaction is increased in the hearts of 
Mesp1Cre;Hirafl/- embryos at E12.5.  
 It is also interesting to note that in ESCs differentiated to cardiomyocytes (Wamstad et 
al., 2012), the TLT locus becomes enriched for the enhancer marks H3K4me1 and H3K27Ac at 
the differentiated cardiomyocytes stage, compared to undifferentiated ESCs (Figure 5-22), 
giving further evidence for the enhancer characteristics of the TLT. 
 
Figure 5-22 Histone enrichments at the TLT showing the characteristics of an enhancer 
in ESC derived cardiomyocytes compared to embryonic stem cells 
The enrichment of H3K4me1 and H3K27ac and the lack of repressive H3K27me3 modifications 
represent a distinct chromatin pattern observed in active enhancers (black box around the 
TLT).  The development of this pattern mirrors the upregulation of Tnni2 seen during the 
differentiation process and supports the association of the TLT enhancer with its expression. 
Histone ChIpseq in ESC derived cardiomyocytes and ESCs were obtained from Wamstad and 
colleagues (Wamstad et al., 2012) (Gnomex accession numbers 44R and 7R2). 
 As mentioned in p25, HIRA deposits H3.3 predominantly in genic regions of ESCs, and 
also at a subset of enhancer and intergenic regions (Goldberg et al., 2010). In parallel with my 
PhD project, Rasha Saleh has been working with a model of ESCs differentiating over the 
course of fifteen days towards cardiomyocytes.  H3.3 tagged WT and Hira 
-null ESCs have been used to observe HIRA and H3.3 occupancy by ChIP at various 
stages of differentiation. A significant enrichment of HIRA (3.5 fold) and H3.3 (7.7 fold) was 
detected at the TLT site at day 15 of differentiation (Figure 5-23). The H3.3 enrichment was 
quasi absent in Hira-null ESCs at day15, suggesting that the deposition of this histone variant is 
HIRA dependant.   
 
 
Figure 5-23 HIRA and H3.3 Chip during ESC differentiation 
QRT-PCR of Brachyury (T), Mesp1 and Nkx2.5 over the first 15 days of WT and Hira-null ESC 
differentiation. Data are presented as levels of mRNA normalized to Gapdh and are 
representative of five independent experiments. Errors bars are calculated from the standard 
deviation of technical triplicates (A). HIRA and H3.3 qChIP on differentiating ESC shows an 
enrichment of HIRA at the TLT site at day 15 (B&C). Unpaired t-test: p<0.05 *, p<0.01 **. 
Experiments carried out by Rasha Saleh and included with her permission. 
 
H3-H4 tetramers do not normally dissociate during replication dependent nucleosome 
assembly. However, experiments in HeLa cells revealed that splitting events were occurring in 
H3.3-H4 tetramers, but not in H3.1-H4 tetramers (Xu et al., 2010). In addition, electron 
microscopy analysis and sedimentation velocity experiments have shown that H3.3 
incorporation perturbs the intramolecular folding of nucleosomal architecture (Chen et al., 
2013).  Taken together, these results suggests that, at the TLT site, H3.3 enriched chromatin 
adopts a looser and more open structure. Since enhancers often require a combination of TFs 
to have a significant effect on gene transcription (Spitz and Furlong, 2012), the lack of H3.3 at 
the TLT site could potentially affect the accessibility of NKX2.5 (which has been shown to act as 
a repressor at this site (Dupays et al., 2015)), and the transcriptional coactivator P300 in 
Mesp1Cre;Hirafl/- embryos by impacting higher ordered chromatin folding. 
Further investigation of the 78 sites with a HIRA and NKX2.5 overlap revealed that 63 
have enhancer signatures. The list of genes within 50Kb of these 63 regions was compared to 
the genes significantly dysregulated in Mesp1Cre;Hirafl/-embryonic hearts at E12.5. In addition 
to the previously mentioned Tnni2 and Tnnt3, 3 genes were identified: Clcnkb, Abca4 and 
Slc9a3r1. Similarly to Tnni2 and Tnnt3, all three were upregulated 2.9, 1.72 and 1.53 fold, 
respectively. Although there are too few loci to draw conclusions, this pattern could imply that 
HIRA and NKX2.5 co-regulate targets during heart development. 
 5.3.2) HIRA is enriched at the Epha3 locus  
 Two significant sites of enrichment of HIRA were detected within intronic regions of 
Epha3 (Figure 5-10), suggesting that HIRA could be involved in transcription activation at this 
locus. There were no NKX2.5 binding sites by ChIPseq (Dupays et al., 2015) or by DamID (HL-1) 
(Bouveret et al., 2015) in the vicinity of that gene. Epha3 expression was  not altered in Nkx2.5 
hypomorphs (Dupays et al., 2015). Thus, HIRA might co-localise with different cofactors at this 
locus. Another possibility is the potential for HIRA enrichment at the gene body to deposit 
H3.3 and thus directly impact transcription rate, by loosening chromatin, rather than acting on 
enhancers. 72.5% of genes enriched for HIRA in their gene body only (as opposed to gene body 
and +/- 5Kb) were found to be downregulated in Mesp1 conditional mutants (Table 5-1). 
Table 5-1 Genes enriched for HIRA in their gene body cross-linked with genes 
dysregulated in Mesp1 conditional mutants 
 
 In order to test whether HIRA influences chromatin compaction a digestion of 
chromatin by micrococcal nuclease (MNase) (Yamasaki et al., 2007) could be performed. This 
enzymatic test digests unprotected DNA and can be used to measure the impact of histone 
chaperones on chromatin structure (Schneiderman et al., 2012). However, it does not 
distinguish between histone variants, but rather quantifies nucleosome distribution. In 
addition, a DNase hypersensitivity assay could test the level of chromatin compaction at a 
particular sites. This assay is often used as a readout of the accessibility a given region, which 
could partially reflect a local enrichment of H3.3. An interesting epigenomic profiling 
experiment is the recently developed  “assay for transposase-accessible chromatin using 
sequencing” (ATAC-seq) which, by directed in vitro transposition of sequencing adaptors into  
native chromatin can identify regions of open chromatin and nucleosome-bound/free regions 
at specific loci (Buenrostro et al., 2013).  Alternatively, the nucleosome turnover rate could be 
quantified. H3.3 deposition has often been measured in nucleosome turnover studies (Deal et 
al., 2010), since the RI H3.3 deposition necessitates unwrapping of the DNA around the histone 
core. Interestingly, in Drosophila melanogaster, this replacement occurs prominently in the 
gene body of transcribed regions of active genes (Mito et al., 2005).  
 5.3.3) HIRA, FACT and GAGA factor 
Many histone chaperones do not directly bind naked DNA (Ray-Gallet et al., 2011). 
However, experiments in HeLa cells by Almouzni et al have shown that 3 members of the 
HUCA complex (HIRA, UBN1 and CABIN1) can directly bind nucleotides (Ray-Gallet et al., 2011). 
The same research team stated that in HeLa cells, HIRA-dependent H3.3 enrichment did not 
have “apparent sequence specificity”. In other model systems such as the plant Arabidopsis, 
HIRA is thought to be recruited to, and repress, the knotted-like homeobox genes via the 
ASYMMETRIC LEAVES DNA binding proteins, which have loose homology to the MYB family of 
vertebrate transcription factors (Guo et al., 2008). Surprisingly, the overrepresentation of GA 
rich motif observed in the HIRA ChIPseq, which might be responsible for HIRA recruitment, was 
observed in 45% of HIRA binding sites. The core consensus within this site was GAGAGAGA and 
is equivalent to that first identified in Drosophila as the binding site for the GAGA factor, itself 
a transcriptional regulator (Adkins et al., 2006). In Drosophila, H3.3 deposition is directed by 
the GAGA factor and FACT (facilitates chromatin transcription) (Nakayama et al., 2007). DNAse 
hypersensitivity assays revealed that this complex can maintain gene expression by protecting 
certain loci from heterochromatin spreading (Nakayama et al., 2007). Interestingly, the GAGA 
factor-FACT complex also associates with HIRA and was found to bind DNA in a sequence 
specific manner (GAGAG cluster) (Nakayama et al., 2007). These proteins were found to be 
part of a very large complex, including the polybromoassociated Brm (PBAP) remodeling 
complex, which together direct H3.3 replacement to establish chromatin boundaries at HOX 
loci (Nakayama et al., 2012). These GAGAG sites also display an increase of H3K4 methylation 
and a reduction of H3K9 methylation (Nakayama et al., 2007), a combination typical of active 
chromatin which has been associated with the deposition of H3.3 in Drosophila (McKittrick et 
al., 2004). FACT has been studied in the context of disassembly and re-assembly of chromatin 
during transcriptional elongation (Belotserkovskaya et al., 2003) but has also been identified as 
a histone chaperone of H2A/H2B (Kemble et al., 2015). A model has been suggested in which 
FACT anchors and displaces a H2A-H2B pair, thus allowing PBAP to bind to and displace a H3-
H4 tetramer. This process creates accessible nucleosome free regions for the HUCA complex to 
deposit H3.3 (Figure 5-24). 
 
Figure 5-24 H3.3 replacement model involving FACT and the GAGA factor in Drosophila 
Schematic model showing how the GAGA factor can recruit FACT and PBAP to a chromatin 
boundary to create nucleosome free regions which allows the HUCA complex (HIRA-ASF1) to 
deposit H3.3. Adapted from (Nakayama et al., 2012). 
 
Most of the polycomb group (PcG) and trithorax group (trxG) proteins in Drosophila 
have vertebrate homologues. However, finding a homologue for the GAGA factor has been 
challenging. Bioinformatics and antibody cross-reactivity between the fly and humans have 
identified the POZ-Kruppel-like factor c-Krox/Th-POK, which is encoded by the Zbtb7b (also 
Zfp67) gene (Matharu et al., 2010). Th-POK has been linked to CD4/CD8 lymphocyte lineage 
commitment (He et al., 2005). A more recent strictly in silico study has revealed that the 
mouse homologue of the GAGA factor could be a slightly different gene: Zbtb3 (Th-POK) 
(Kumar, 2011), a protein that binds to chromatin boundary elements in a muscle cell line, 
although no in vivo studies have been undertaken (Srivastava et al., 2015). 5.3.4) Interaction between HIRA and WHSC1 suggests the formation of a tri-complex at the TLT site  
As mentioned in p90, HIRA and NKX2.5 at the TLT site, both in the HL-1 cardiomyocyte 
cell line by DamID (Bouveret et al., 2015) and in embryonic hearts at E11.5 by ChIPseq (Dupays 
et al., 2015). Moreover, in hearts of E11.5 and E14.5 embryos with a hypomorphic allele of 
Nkx2.5 there was upregulation of Tnni2 and Tnnt3 (Dupays et al., 2015) mirroring what was 
observed in Hira conditional mutants at E11.5 and E12.5. Interestingly, in the heart 
development, NKX2.5 interacts with the HMTase WHSC1 to repress the expression of specific 
genes involved in cardiac morphogenesis (Nimura et al., 2009). Furthermore, work carried out 
by Rasha Saleh suggests that the HIRA-WHSC1 interaction is specific to fully differentiated 
cardiomyocytes, since these protein were only found to interact in ESCs after fifteen days of 
differentiation towards cardiomyocytes (Figure 5-25).  
 
  
Figure 5-25 HIRA interacts with WHSC1 during ESC differentiation towards 
cardiomyocytes 
Western blotting of immunoprecipitates with HIRA (HIRA IP) or whole cell protein lysate 
(before immunoprecipitation) from WT and Hira-null ESCs on undifferentiated ESCs (D0) and 
ESCs differentiated towards cardiomyocytes (D15). HIRA was found to interact with WHSC1 at 
day 15 of differentiation. Experiments carried out by Rasha Saleh and included with her 
permission. 
 
Remarkably, this HIRA-WHSC1 interaction occurred at the same stage during which an 
enrichment of HIRA at the TLT site was observed (Figure 5-23). This suggests that the 
formation of a HIRA-WHSC1-NKX2.5 complex which is likely to directly impact transcription 
during cardiogenesis (see final chapter). 
  
Chapter 6 Overall conclusion and future work 
 
6.1) Final discussion and conclusion 
Hira encodes a histone chaperone whose major function is to deposit the variant 
histone H3.3 within chromatin, and which plays an essential role in regulating chromatin 
structure stability. HIRA-dependent H3.3 deposition has been linked to important biological 
processes, such as intellectual disability (Chen et al., 2015), fertilization (Bonnefoy et al., 2007) 
and response to stress (Chujo et al., 2012a). In my PhD project, the role of HIRA was 
investigated during the post gastrulation stage of vertebrate development. Conditional 
mutagenesis was employed to study heart development. The heart is the first organ to fully 
form during development and presents with complex morphological dynamic changes, which 
require a tight regulation of numerous genes. The early lethality of Hira null embryos was 
successfully bypassed which was necessary for investigating HIRA’s role in the different 
cardiogenic lineages.  
HIRA has been shown here to play an important role in heart development and by 
extension, in embryonic survival. Cardiogenic mesoderm ablation of Hira (Mesp1Cre) resulted 
in cardiac malformations and embryonic lethality. Other conditional Hira mutations within the 
cardiogenic lineages resulted in milder abnormalities or absence of cardiac defects. Nkx2.5Cre 
conditional Hira mutants, in which Hira was ablated in cardiomyocytes, resulted in embryonic 
lethality in 89% of cases, 56% of embryos at E15.5 presented with a VSD and 33% with a 
constriction of the pulmonary trunk. However, the lack of phenotype in the anterior SHF 
specific Mef2cCre;Hirafl/- mutants suggests that Hira is required in the FHF and ablation in the 
SHF has little effect or acts to exacerbate the phenotype of FHF mutants. In addition, Tie2Cre 
and Wnt1Cre conditional Hira mutants, which tested the requirement of HIRA in the 
endothelial and neural crest cell populations, respectively, did not show any cardiac 
abnormalities. A requirement for HIRA in those tissues is not ruled out since Tie2Cre Hira 
conditional mutants suffer from a growth defect postnatally and Wnt1Cre conditional Hira 
mutants die at birth. As Mesp1Cre is expressed 24h prior to Nkx2.5Cre (E6.5 versus E7.5), it is 
possible that HIRA activity is particularly crucial during the early differentiation steps of 
multipotent cardiovascular progenitors.  
Following ablation of Hira in the cardiogenic mesoderm, less than 2% of the genes 
expressed in the heart at E12.5 were significantly up- or downregulated. HIRA activity is 
required for correct level of expression of troponins which directly affect cardiac contractility 
and Epha3, a tyrosine kinase receptor critical for the formation of atrioventricular cushions. 
The deregulation of these genes during cardiogenesis are likely to be responsible for the VSD 
and the oedema observed at E15.5 in Mesp1cre conditional Hira mutants. The aberrant 
expression of certain genes in the heart is consistent with the previously described association 
with genes poised for transcriptional activation (Huang and Zhu, 2014, Chen et al., 2013). This 
data suggests that HIRA modulates chromatin structure which would then affect the 
accessibility of the transcriptional machinery to regulatory elements.   
In order to investigate a potential direct impact of HIRA on transcription, the HIRA 
genome wide occupancy in the heart was analysed by ChIPseq at E12.5. The heart is 
constituted of a mixed population of cells, however the majority (65 to 70%) at E18.5 are 
cardiomyocytes (Banerjee et al., 2007) with the remaining 30% being fibroblasts, endothelial 
cells, and vascular smooth muscle. The ratio is probably of a similar order at E12.5. HIRA 
binding sites poorly correlated with altered gene expression. However, the majority of HIRA 
bound regions were found to be “distal intergenic” and as previously discussed (see p96), 
there still is an incomplete picture of enhancers across the genome of the animal kingdom 
(Shlyueva et al., 2014).  In an effort to investigate HIRA’s potential involvement with known 
chromatin regulators involved in heart development, a series of co-immunoprecipitation were 
carried out. BRG1 and WHSC1 were found to interact with HIRA at E12.5 and E14.5. WHSC1 is 
known to bind NKX2.5, a major cardiac transcription factor (Nimura et al., 2009). NKX2.5 was 
recently found to bind to the common enhancer of Tnni2 and Tnnt3 (TLT site) (Dupays et al., 
2015). Remarkably, HIRA was also found to bind that exact region by ChIPseq and qChIP. This 
region was identified as an enhancer by Dupays et al, which was further confirmed by the 
overlapping of H3K4me1/H3K27Ac histone enhancer signatures (Shen et al., 2012) as well as 
P300, a enhancer binding protein known to regulate genes during cardiac development (Blow 
et al., 2010) (Figure 5-16). RNAseq analysis revealed that Tnni2 was the most upregulated 
gene in Mesp1Cre;Hirafl/- embryonic hearts, which suggests a mechanism in which HIRA 
negatively regulate this gene during cardiogenesis. Work carried out by Rasha Saleh 
demonstrated that the HIRA enrichment at the TLT site is necessary for H3.3 deposition and is 
specific to differentiated ESCs. A model can be proposed in which HIRA binds to GAGA rich 
regions, and acts in concert with NKX2.5 and WHSC1 at the TLT site to deposit H3.3, thus 
regulating certain target genes (Figure 6-1).  
 
Figure 6-1 Model of regulation of Tnni2 by HIRA 
Model formulated after previously published work (NKX2.5-WHSC1 interaction (Nimura et al., 
2009)  and repression of Tnni2 by NKX2.5 (Dupays et al., 2015)), protein interaction analysis 
and HIRA ChIPseq/qChIP at the TLT site in the heart at E12.5 and during ESC differentiation 
(Rasha Saleh). 45% of HIRA binding sites in vivo contained the binding motif represented. The 
right panels show an H&E staining revealing a VSD at E14.5 (top) and a troponin C staining of 
the heart wall highlighting the disorganisation of the contracting meshwork of myofibrils 
(bottom) in the absence of HIRA.  
 
The two HIRA binding sites detected at the Epha3 locus could indicate a direct 
regulation of that gene by HIRA. Epha3 expression was not significantly altered in Nkx2.5 
hypomorphs, nor was there evidence of NKX2.5 binding close to Epha3 in either the DamID 
(Bouveret et al., 2015) or NKX2.5 ChIPseq (Dupays et al., 2015). The NKX2.5-WHSC1 complex is 
thought to repress targets (Nimura et al., 2009), so the absence of NXK2.5 binding sites at 
Epha3 is not unexpected. BRG1 has been shown to directly repress Epha3 in human adrenal 
carcinoma cell line SW13 (Zhang et al., 2014a), which suggests a possible pathway by which 
HIRA regulate Epha3. The authors revealed that BRG1 associated with the promoter region of 
certain BRG1 regulated genes, but no data at the Epha3 locus was published. Interestingly, 
ADAMTS1, which is regulated by BRG1 (see p20), is required for versican cleavage during the 
remodelling of the developing endocardial cushions (Kern et al., 2006).   However, a study 
which identified 51,000 BRG1-associated regions across several embryonic tissues at E11.5, 
showed that this chromatin remodelling protein does not bind at, or around, Epha3 in the 
heart (Attanasio et al., 2014).  
Conditional ablation of Hira has shed some light on the role of HIRA in mesodermal 
derivatives. There are additional experiments that could prove interesting to better 
understand the exact requirement and roles of HIRA during cardiovascular development. 
 
6.2) Future work 
The data presented in this thesis has described the cardiac defect and transcriptional 
changes following cardiogenic mesodermal ablation of Hira. Identification of HIRA interaction 
partners in WT hearts suggests that HIRA is part of a large complex, which might affect HIRA’s 
effect on the chromatin. HIRA’s genome wide occupancy has shed light on the regulation of 
Tnni2/Tnnt3, and possibly Epha3, however, not all genes differentially expressed in 
Mesp1Cre;Hirafl/- hearts could be explained by a proximal (+/- 5Kb) loci with an enrichment of 
HIRA. There are unanswered questions which could help complete our understanding of the 
role of HIRA during heart formation. For example, a ChIP analysis of total histone H3 levels 
could be carried out in WT and Hira-null ESCs differentiated towards cardiomyocyte. This 
would test whether the selective H3.3 deficiency is independent of total H3 incorporation and 
maintenance. 6.2.1) How are histone modifications affected in the absence of HIRA?  
It would be interesting to explore to what extent chromatin binding of WHSC1 and 
HIRA overlap during different stages of cardiac development, and what signalling mechanisms 
control their interaction. WHSC1 ChIP by Nimura and colleagues (Nimura et al., 2009) was 
performed using a FLAG tagged WHSC1 in the mouse, which might explain why my WHSC1 
qChIP attempts at the TLT site were unsuccessful as there is no antibody available nowadays to 
ChIP WHSC1. NSD2 ChIP (NSD2 is an alternate name  of WHSC1) has been successfully 
performed in human cells (Ram et al., 2011) using an antibody which may have cross-reactivity 
in mice. WHSC1 trimethylates H3K36, which, in the yeast, was found to supress the interaction 
between canonical H3 and histone chaperones (Venkatesh et al., 2012). It is therefore possible 
that an equilibrium between H3.3 and H3K36me3 takes place in certain actively transcribed 
genes, which would be disrupted in the absence of HIRA. A H3K36me3 qChIP at the TLT site 
has already been attempted with approximately 10 WT hearts at E12.5 as a pilot experiment, 
since pooling larger numbers of Mesp1Cre;Hirafl/- hearts becomes challenging. Unfortunately, 
the resulting signal-to-noise ratio was too low to draw any useful conclusions. Most ChIP 
protocols require a starting material of 5 million cells and since a heart at E12.5 represents 
approximately 300,000 cells (Mahalia Page, personal communication), around 16 hearts would 
be needed to collect sufficient amount of total chromatin. However, new techniques using 
ultra low input for micrococcal nuclease-based native ChIP (nChIP) have been described 
(Brind'Amour et al., 2015), which could be applied in the future. An alternative experiment 
would be H3K36me3 ChIPseq in the ESC model, comparing Hira null with WT cells after 
differentiation towards cardiomyocytes, which would palliate the lack of embryonic material. 
This model, used by Wamstad and colleagues (Wamstad et al., 2012), presents the drawback 
of constituting a heterogeneous population of cells, but offers sufficient material to perform 
ChIPseq at early differentiation stages. 
H2A.Z was found to be preferentially associate with H3.3 in ESCs (Yukawa et al., 
2014)(see p17). H3.3 knockdown, in the enhancer region, affected H2A.Z deposition at the 
promoter regions of active genes (Chen et al., 2014), which has often been linked with 
transcriptional activation (Kumar and Wigge, 2010, Dalvai et al., 2013). This cooperation 
between the two variants could be disrupted in Mesp1Cre;Hirafl/-  hearts and a H2A.Z ChIPseq 
might shed some light on the dynamics of histone variants upon the ablation of Hira during 
heart development.  
An important experiment that would strengthen the model presented above would be 
the identification of a direct interaction between NKX2.5 and HIRA. Co-immunprecipitations 
have been attempted, which have been unsuccessful due to a poor batches of anti-NKX2.5 
antibody (data not shown). An alternative would be a NKX2.5 ChIP at the TLT site. Our model 
predicts a decrease of NKX2.5 binding to the TLT in Mesp1Cre;Hirafl/  hearts compared to WT, 
which would be consistent with the marked upregulation of Tnni2/Tnnt3. Furthermore, it is 
also possible for the interaction between NKX2.5 and WHSC1 in the heart to be affected in the 
absence of HIRA. The ESC model mentioned above could be used since co-
immunoprecipitation assays require a substantial amount of material. Alternatively, a tandem 
affinity purification could be used to detect all the proteins binding to NKX2.5, or HIRA. This 
method involves a double tagging of the protein of interest followed by a two-step purification 
process and mass spectroscopic analysis (Rohila et al., 2004). A yeast two-hybrid assay could 
also be done using Nkx2.5 or Hira to construct a bait plasmid. This method has already been 
used with SMAD1 (Liu et al., 2014a) using a library generated with E9.5 to E11.5 hearts 
(DeBenedittis et al., 2011). To palliate a possibly weak or transient interaction between HIRA 
and NKX2.5 and the lack of appropriate antibody, their physical proximity could be assessed. 
Forster resonance energy transfer (FRET) uses fluorescent tagged proteins and the distance-
dependent transfer of energy to investigate molecular interactions in vivo (Karpova and 
McNally, 2006). A newer method taking advantage of the recently developed superresolution 
optical imaging techniques, involving bimolecular fluorescence and photoactivated localization 
(Liu et al., 2014b), could be used in a cardiomyocyte cell line (e.g P19 or HL-1).  Finally, crossing  
Mesp1Cre;Hira-/+;Nkx2.5+/-  mice to Hirafl/fl  mice and observing whether the phenotype worsens 
with hemizygosity of Nkx2.5 could be a sign of synergistic relationship between the two 
proteins. 
An additional validation of the direct regulation by HIRA at the TLT site could be 
achieved by an in vivo transgenic embryo analysis containing a LacZ (or equivalent) reporter in 
conjunction with different point mutations using CRISPR-CAS9 (Inui et al., 2014) at the GAGA 
motif of the TLT site. A similar strategy could be used at the Epha3 putative HIRA binding sites 
alongside qChIP and qRT-PCR to assess whether HIRA binding is affected and correlates with 
the expression of that gene.  6.2.2) Which transcriptional changes are the most causative of the phenotype observed in Mesp1Cre conditional Hira mutants ? 
The lack of oedema at E15.5 in Nkx2.5Cre conditional mutants contrasts the complete 
penetrance of this trait observed in the Mesp1Cre. This suggests that genes responsible for 
cardiac contractility (i.e. troponins) are differentially affected. Identifying dysregulated 
transcripts in Nkx2.5Cre conditional mutants (by RNAseq) and comparing them with the 
Mesp1Cre RNAseq dataset could improve our understanding of the roles of Tnni2/Tnnt3 and 
Epha3 in embryonic lethality, since Nkx2.5Cre conditional mutants are only partially embryonic 
lethal. 6.2.3) How is the spatial conformation of the chromatin affected by the ablation of 
Hira? 
The regulation of Tnni2/Tnnt3 via the TLT site implies that the chromatin undergoes a 
particular reorganisation. Co-immunoprecipitation experiments in HeLa cells showed that HIRA 
interacted with the insulator factor CTCF (Pchelintsev et al., 2013a), which could be interesting 
to investigate in the developing heart. Moreover, CTCF binding sites overlap with H3.3 
deposition in the human genome (Jin et al., 2009, Millau and Gaudreau, 2011). CTCF has also 
been found to “erase” the H3K27me3 repressive histone mark by triggering H3.3 deposition 
(Weth et al., 2014). As mentioned in “5.3.1) Enhancers and H3.3 deposition”, a 3C analysis at 
the TLT site could test for 3D proximity between Tnni2, the TLT site and Tnnt3 which represent 
a combined distance of 17Kb + 38Kb= 55Kb. Additional structural property changes of the 
chromatin in the absence of HIRA at the TLT site could be addressed by circular chromosome 
conformation capture (4C) (Zhao et al., 2006) which can be used to a examine the intra- and/or 
interchromosomal interactions of a given site, genome wide. Finally, a general effect on 
chromatin when Hira is ablated could be assessed using chromosome conformation capture 
carbon copy (5C) which detects all contacts between genomic elements (Figure 6-2). 
 
Figure 6-2 Overview of 3C-derived methods 
The cross-linking, digestion, and ligation steps are shown on the top. In summary, 3C is “one 
versus one”, 4C is “one versus all” and 5C is “all versus all”. Adapted from Laat (2012) (de Wit 
and de Laat, 2012)  
 
 6.2.4) Is the requirement of HIRA specific to the FHF? 
 
In order to validate the specific requirement of HIRA in the FHF, a FHF specific Cre driver 
could be used such as Hcn4Cre (hyperpolarization-activated cyclic nucleotide-gated channel 4) 
(Wu et al., 2014) in conjunction with the Hira conditional allele. A phenotype similar to the one 
observed in Mesp1Cre conditional Hira mutants in FHF conditional mutants would further 
support the hypothesis of an autonomous requirement of HIRA in the FHF.   6.2.5) Final remarks and conclusion 
 
Previous work with constitutively Hira null embryos suggested a possible role of HIRA 
past gastrulation (Roberts et al., 2002). HIRA is regarded to have a general role on stress-
responsive genes (Chujo et al., 2012b), on chromatin integrity at DNA damage sites (Adam et 
al., 2013), or on global maintenance of transcriptional silencing in yeast (Anderson et al., 
2009), which taken together, suggests that HIRA plays a role in maintaining the integrity of 
chromatin. The conditional Hira mutants presented here, which established the tissue-specific 
requirements for HIRA, as well as RNAseq and ChIPseq data demonstrated that HIRA has a 
specific role during heart development. The binding partners of HIRA could have an impact the 
on its genome wide occupancy and the deposition of H3.3 or HIRA could impact their 
recruitment to specific targets. To answer this point, we would need to assess whether their 
recruitment is affected in the absence of HIRA. Since HIRA binding sites do not correlate 
strongly with transcriptional changes, it is possible that HIRA serves as a co-regulator of its 
binding partners. Interestingly, in Drosophila, 5 TFs were found to collectively define cardiac 
cells. PMad, dTCF, Doc, Pnr, and Tin bound to the same enhancers but without any consistent 
“motif grammar” (Junion et al.)(2012). This study opened the concept of developmental 
footprint by TF’s occupancy. Similarly in the mouse, the TFs TBX5, NKX2.5 and GATA4 , a T-box-
homeo- and zinc finger-domain protein, respectively, were found to regulate certain cardiac 
enhancers by cooperating across the genome (Luna-Zurita et al.)(2016). The interdependent 
binding of these heterotypic TFs was shown to regulate gene expression of cardiac 
progenitors. Individual or double knockouts demonstrated that the cooperation of these TFs 
was essential to prevent TFs distribution to lineage-inappropriate sites (Luna-Zurita et al.). The 
ablation of HIRA could have a similar disruptive impact on the genome occupancy of WHSC1 
and BRG1 across the genome. Since, Whsc1 heterozygotes are viable and only partially 
affected, a synergistic interaction could be tested by crossing Whsc1-/+ mice to Hira+/- mice. The 
genome wide occupancy of HIRA in the heart has revealed a consensus sequence which likely 
directs the binding of HIRA to the DNA, in 45% of predicted binding sites. The remaining 55% 
could be the result of combinatorial interactions between HIRA and other TFs or chromatin 
remodellers such as WHSC1/BRG1 or possibly CTCF/NKX2.5.  
HIRA might therefore have a pleiotropic role, acting both directly on the chromatin by 
depositing H3.3 and indirectly by interacting with chromatin remodellers or TFs at specific 
times during development. The latter might explain why certain HIRA binding sites have little 
or no repercussion on transcriptional activity.  
However, the binding of HIRA at the common enhancer of Tnni2 and Tnnt3 directly 
negatively regulate these troponins, which is critical for the formation of contractile myofibers. 
In addition, HIRA has been implicated in the morphogenesis of atrioventricular endocardial 




The following QR codes can be scanned with a smartphone or tablet using a QR reader app. 
Otherwise, the links can be pasted onto any browser. 
Movie 1:      -Transverse OPT reconstructions of Mesp1Cre;Hira-/fl E15.5 embryos, travelling 
from the anterior to the posterior portion of the trunks, with the VSD highlighted. 
        - 3D reconstruction post OPT scanning of a constricted pulmonary trunk in 
Nkx2.5Cre;Hira-/fl E15.5 embryos. 




Movie 2: Nkx2.5Cre;Hirafl/- : OPT through the heart revealing a VSD 
 
http://tiny.cc/6q3g9x 
Movie 3: Myh6MerCreMer;Hirafl/+ adult heart beating 2 weeks post tamixfen injection, 







Genes identified by RNAseq with a marked decreased expression in Mesp1Cre;Hira-/fl 
embryonic hearts at E12.5 compared to their control littermates. The fold change is presented 
here in absolute value.  Test applied: Mann-Whitney unpaired, Benjamini Hochberg FDR, p ≤ 
0.05, FC ≥ 1.5 
EnsemblID external_gene_id 
 








ENSMUSG00000000308 Ckmt1  0 0 8.014016 24 203 8.458333 
ENSMUSG00000031097 Tnni2  0 0 8.014016 923 5261 5.699892 
ENSMUSG00000039099 Wdr93  0 0 8.014016 119.3333333 324 2.715084 
ENSMUSG00000040907 Atp1a3  1.11E-16 3.73E-13 8.014016 200.3333333 930.3333333 4.643927 
ENSMUSG00000096210 H1f0  5.27E-14 1.11E-10 7.524687 3064 4774 1.558094 
ENSMUSG00000022044 Stmn4  1.07E-13 1.79E-10 7.432479 245.6666667 489.6666667 1.993216 
ENSMUSG00000020911 Krt19  1.23E-13 1.88E-10 7.413496 989.3333333 1963 1.984164 
ENSMUSG00000027500 Stmn2  5.34E-13 6.40E-10 7.216349 113.6666667 395.6666667 3.480938 
ENSMUSG00000017723 Wfdc2  7.27E-13 8.09E-10 7.174222 11 78 7.090909 
ENSMUSG00000038412 Higd1a  1.18E-12 1.15E-09 7.107568 1601 2483.333333 1.551114 
ENSMUSG00000023484 Prph  1.24E-12 1.15E-09 7.101398 8.333333333 61 7.32 
ENSMUSG00000049382 Krt8  2.30E-12 2.03E-09 7.015094 285.6666667 762.3333333 2.668611 
ENSMUSG00000029121 Crmp1  2.44E-12 2.04E-09 7.006993 346.3333333 690.3333333 1.993263 
ENSMUSG00000041361 Myzap  9.96E-12 7.60E-09 6.807153 1297.666667 2000.333333 1.541485 
ENSMUSG00000064023 Klk8  1.48E-11 1.06E-08 6.749947 242.6666667 452 1.862637 
ENSMUSG00000021613 Hapln1  1.52E-11 1.06E-08 6.746073 2219.666667 3648.666667 1.64379 
ENSMUSG00000031451 Gas6  3.68E-11 2.47E-08 6.616502 1977.666667 3358.333333 1.698129 
ENSMUSG00000041477 Dcp1b  8.99E-11 5.59E-08 6.483095 152 305 2.006579 
ENSMUSG00000032348 Gsta4  1.54E-10 9.21E-08 6.401756 1351.666667 2031 1.502589 
ENSMUSG00000070473 Cldn3  2.01E-10 1.13E-07 6.360651 10.33333333 59 5.709677 
ENSMUSG00000030871 Ears2  5.40E-10 2.84E-07 6.206929 561 888.6666667 1.584076 
ENSMUSG00000019945 0L02Rik  5.68E-10 2.89E-07 6.199008 234.3333333 420.6666667 1.795164 
ENSMUSG00000026437 Cdk18  2.54E-09 1.11E-06 5.95912 171.6666667 319 1.858252 
ENSMUSG00000021213 Akr1c13  2.85E-09 1.20E-06 5.939898 17 69 4.058824 
ENSMUSG00000027611 Procr  3.98E-09 1.63E-06 5.885189 210.6666667 373.6666667 1.773734 
ENSMUSG00000006311 Etv2  5.10E-09 1.99E-06 5.843745 9.666666667 85 8.793103 
ENSMUSG00000018381 Abi3  5.90E-09 2.23E-06 5.819681 330 568.6666667 1.723232 
ENSMUSG00000062785 Kcnc3  8.88E-09 3.24E-06 5.750785 6.333333333 42 6.631579 
ENSMUSG00000054793 Cadm4  1.03E-08 3.59E-06 5.726539 60.66666667 143.6666667 2.368132 
ENSMUSG00000043664 Tmem221  1.51E-08 5.08E-06 5.660196 0.666666667 21.33333333 32 
ENSMUSG00000029762 Akr1b8  1.67E-08 5.49E-06 5.643322 299 488 1.632107 
ENSMUSG00000030592 Ryr1  1.73E-08 5.60E-06 5.636739 14.33333333 60 4.186047 
ENSMUSG00000034799 Unc13a  4.66E-08 1.37E-05 5.464009 35.33333333 96.33333333 2.726415 
ENSMUSG00000042064 Myo3b  5.08E-08 1.43E-05 5.448522 128.6666667 241.6666667 1.878238 
ENSMUSG00000000365 Rnf17  5.10E-08 1.43E-05 5.447963 69 152.6666667 2.21256 
ENSMUSG00000003355 Fkbp11  7.67E-08 2.08E-05 5.374748 83.66666667 172 2.055777 
ENSMUSG00000000811 Txnrd3  9.80E-08 2.60E-05 5.330375 310 490.6666667 1.582796 
ENSMUSG00000028943 Espn  1.01E-07 2.60E-05 5.325276 20.66666667 69 3.33871 
ENSMUSG00000037161 Mgarp  1.14E-07 2.91E-05 5.302384 171 297.3333333 1.738791 
ENSMUSG00000017652 Cd40  1.29E-07 3.20E-05 5.280403 120.3333333 225.3333333 1.872576 
ENSMUSG00000021622 Ckmt2  1.30E-07 3.20E-05 5.279269 64.33333333 141.3333333 2.196891 
ENSMUSG00000038173 Enpp6  1.61E-07 3.85E-05 5.239973 54 123.3333333 2.283951 
ENSMUSG00000020331 Hcn2  5.42E-07 0.000108 5.010993 8 40 5 
ENSMUSG00000034891 Sncb  5.86E-07 0.000114 4.995874 4.666666667 31 6.642857 
ENSMUSG00000062309 Rpp25  6.19E-07 0.000119 4.985349 126.3333333 226 1.788918 
ENSMUSG00000000617 Grm6  6.44E-07 0.000123 4.977683 4.333333333 30 6.923077 
ENSMUSG00000020303 Stc2  6.50E-07 0.000123 4.975796 105.3333333 197.6666667 1.876582 
ENSMUSG00000043439 A19Rik  6.64E-07 0.000124 4.971724 38 94.33333333 2.482456 
ENSMUSG00000036745 Ttll7  7.58E-07 0.000137 4.945907 184.6666667 305.3333333 1.65343 
ENSMUSG00000024883 Rin1  7.87E-07 0.00014 4.938613 134 234 1.746269 
ENSMUSG00000032202 Rab27a  8.93E-07 0.000155 4.913861 108.6666667 204.6666667 1.883436 
ENSMUSG00000045176 M10Rik  1.28E-06 0.00021 4.8433 139 238.6666667 1.717026 
ENSMUSG00000024827 Gldc  1.37E-06 0.00022 4.829611 199.6666667 346.6666667 1.736227 
ENSMUSG00000039824 Myl6b  1.78E-06 0.000274 4.777147 63.66666667 130.6666667 2.052356 
ENSMUSG00000001588 Acap1  1.82E-06 0.000278 4.772559 284.3333333 433 1.52286 
ENSMUSG00000072949 Acot1  1.94E-06 0.000293 4.759993 164.6666667 274.3333333 1.665992 
ENSMUSG00000031881 Cdh16  2.25E-06 0.000323 4.729476 131.6666667 386 2.931646 
ENSMUSG00000050822 Slc29a4  2.29E-06 0.000323 4.726076 48.66666667 107.6666667 2.212329 
ENSMUSG00000062380 Tubb3  2.83E-06 0.000393 4.68286 87.66666667 188.6666667 2.152091 
ENSMUSG00000038550 Gm129  2.86E-06 0.000393 4.680841 77.66666667 149 1.918455 
ENSMUSG00000059213 Ddn  5.02E-06 0.00062 4.563825 7.333333333 34.33333333 4.681818 
ENSMUSG00000029032 Arhgef16  5.11E-06 0.000626 4.560385 38.33333333 89 2.321739 
ENSMUSG00000026546 Ccdc19  5.20E-06 0.000633 4.556391 37.66666667 88.33333333 2.345133 
ENSMUSG00000037386 Rims2  5.87E-06 0.000703 4.531126 19 63 3.315789 
ENSMUSG00000019312 Grb7  5.90E-06 0.000703 4.529798 20.66666667 65.33333333 3.16129 
ENSMUSG00000023043 Krt18  7.29E-06 0.000844 4.484953 445.3333333 749 1.681886 
ENSMUSG00000031461 Myom2  7.41E-06 0.000852 4.481645 45.66666667 99.33333333 2.175182 
ENSMUSG00000041605 9C18Rik  7.50E-06 0.000857 4.478896 27 69.33333333 2.567901 
ENSMUSG00000004933 Matk  8.32E-06 0.000937 4.456857 23.33333333 64 2.742857 
ENSMUSG00000050335 Lgals3  8.80E-06 0.000978 4.444833 27 70 2.592593 
ENSMUSG00000046714 Foxc2  9.58E-06 0.001058 4.426532 259 437.6666667 1.689833 
ENSMUSG00000021638 Ocln  1.05E-05 0.00115 4.407025 22.66666667 62.33333333 2.75 
ENSMUSG00000038811 Gngt2  1.18E-05 0.001234 4.38199 251.6666667 403.3333333 1.602649 
ENSMUSG00000045725 Prr15  1.18E-05 0.001234 4.38199 213 325.6666667 1.528951 
ENSMUSG00000062044 Lmtk3  1.33E-05 0.00138 4.354781 113.3333333 208.3333333 1.838235 
ENSMUSG00000004864 Mapk13  1.50E-05 0.001502 4.328248 47 100 2.12766 
ENSMUSG00000030674 Qprt  1.64E-05 0.001622 4.309533 66 126.3333333 1.914141 
ENSMUSG00000051367 Six1  1.64E-05 0.001622 4.308723 0.333333333 12.33333333 37 
ENSMUSG00000046727 Cystm1  2.04E-05 0.001979 4.260577 150 465.3333333 3.102222 
ENSMUSG00000037860 Aim2  2.42E-05 0.002262 4.222134 246.6666667 413.6666667 1.677027 
ENSMUSG00000031762 Mt2  2.53E-05 0.002319 4.212285 177 339 1.915254 
ENSMUSG00000023033 Scn8a  2.73E-05 0.002489 4.194727 13.66666667 43.66666667 3.195122 
ENSMUSG00000029001 Fbxo44  2.81E-05 0.002525 4.18818 147.3333333 328.3333333 2.228507 
ENSMUSG00000071553 Cpa2  3.03E-05 0.002676 4.17135 106 240 2.264151 
ENSMUSG00000030263 Lrmp  3.60E-05 0.003019 4.132013 53 126.3333333 2.383648 
ENSMUSG00000042216 Sgsm1  3.71E-05 0.003101 4.124649 77 143 1.857143 
ENSMUSG00000010362 Rdm1  4.28E-05 0.003389 4.091875 376.6666667 601.6666667 1.597345 
ENSMUSG00000042724 Map3k9  4.40E-05 0.00345 4.085563 53 104.3333333 1.968553 
ENSMUSG00000054612 Mgmt  5.41E-05 0.004145 4.0373 104.3333333 174 1.667732 
ENSMUSG00000029522 Pla2g1b  5.75E-05 0.004368 4.022842 1.333333333 15 11.25 
ENSMUSG00000028927 Padi2  6.06E-05 0.004562 4.010462 66 131 1.984848 
ENSMUSG00000023000 Dhh  6.79E-05 0.004892 3.983562 55 105.3333333 1.915152 
ENSMUSG00000021453 Gadd45g  7.06E-05 0.005063 3.974356 340 608.6666667 1.790196 
ENSMUSG00000002500 Rpl3l  7.25E-05 0.005135 3.967962 14.33333333 42.66666667 2.976744 
ENSMUSG00000041261 Car8  7.56E-05 0.00522 3.958063 268 536 2 
ENSMUSG00000000305 Cdh4  8.20E-05 0.005572 3.938566 47.33333333 101 2.133803 
ENSMUSG00000039110 Mycbpap  8.53E-05 0.005751 3.929 249 395.3333333 1.587684 
ENSMUSG00000022057 Adamdec1  8.69E-05 0.005834 3.924611 23.66666667 58.33333333 2.464789 
ENSMUSG00000006731 B4galnt1  9.07E-05 0.006067 3.914212 62.33333333 130 2.085561 
ENSMUSG00000096847 Tmem151b  9.80E-05 0.006504 3.895466 93.66666667 156.6666667 1.672598 
ENSMUSG00000031738 Irx6  0.0001059 0.006965 3.87666 97.66666667 225 2.303754 
ENSMUSG00000074170 Plekhf1  0.0001071 0.006997 3.873917 52.33333333 99.66666667 1.904459 
ENSMUSG00000020733 Slc9a3r1  0.0001167 0.00752 3.852957 243.3333333 373.6666667 1.535616 
ENSMUSG00000028841 Cnksr1  0.0001357 0.008438 3.815877 44 87.33333333 1.984848 
ENSMUSG00000044086 Lmod3  0.00014 0.008578 3.808168 376 637.6666667 1.695922 
ENSMUSG00000070000 Fcho1  0.0001422 0.008619 3.80431 52 98 1.884615 
ENSMUSG00000050423 Ppp1r3g  0.0001593 0.009319 3.776105 93.66666667 153 1.633452 
ENSMUSG00000032011 Thy1  0.0001708 0.009838 3.758698 106 170.3333333 1.606918 
ENSMUSG00000070691 Runx3  0.0001711 0.009838 3.758259 3.333333333 22.66666667 6.8 
ENSMUSG00000023781 Hes7  0.0001853 0.01037 3.738258 11.33333333 35 3.088235 
ENSMUSG00000045348 Nyap1  0.0001935 0.01062 3.727355 146.3333333 221 1.510251 
ENSMUSG00000033182 Kbtbd12  0.0002139 0.01144 3.702008 153.3333333 230.6666667 1.504348 
ENSMUSG00000025650 Col7a1  0.0002215 0.01178 3.693142 159 292 1.836478 
ENSMUSG00000030498 Gas2  0.0002218 0.01178 3.692798 78.33333333 132 1.685106 
ENSMUSG00000028599 Tnfrsf1b  0.0002563 0.0132 3.655881 60 125.6666667 2.094444 
ENSMUSG00000041120 Nbl1  0.0002571 0.0132 3.655082 129.3333333 197.6666667 1.528351 
ENSMUSG00000028125 Abca4  0.0002637 0.0135 3.648574 170.3333333 293.6666667 1.72407 
ENSMUSG00000057606 Colq  0.0002725 0.01391 3.64013 137.3333333 224.3333333 1.633495 
ENSMUSG00000020785 Camkk1  0.0002905 0.01465 3.623627 57.33333333 102.3333333 1.784884 
ENSMUSG00000090394 C07Rik  0.0002985 0.01493 3.616598 115.3333333 179 1.552023 
ENSMUSG00000040280 Ndufa4l2  0.0003091 0.01531 3.607552 114.3333333 177.3333333 1.55102 
ENSMUSG00000048763 Hoxb3  0.0003367 0.01633 3.585293 51.66666667 94.33333333 1.825806 
ENSMUSG00000029403 Cdkl2  0.0003375 0.01633 3.584674 53.66666667 97 1.807453 
ENSMUSG00000001494 Sost  0.0003404 0.01633 3.58244 78 228.3333333 2.92735 
ENSMUSG00000030428 Ttyh1  0.0003441 0.01643 3.579616 19.66666667 57 2.898305 
ENSMUSG00000022487 Gtsf1  0.0003445 0.01643 3.579312 555.3333333 958.3333333 1.72569 
ENSMUSG00000025328 Padi3  0.0003519 0.01664 3.573754 37.66666667 94.66666667 2.513274 
ENSMUSG00000015090 Ptgds  0.0003605 0.01686 3.56743 11.33333333 38 3.352941 
ENSMUSG00000061232 H2-K1  0.0003688 0.01715 3.561459 192.3333333 303 1.57539 
ENSMUSG00000048807 Slc35e4  0.0003733 0.01727 3.558274 106.6666667 182 1.70625 
ENSMUSG00000054641 Mmrn1  0.0003749 0.01729 3.55715 87.33333333 141.6666667 1.622137 
ENSMUSG00000057777 Mab21l2  0.0003833 0.01749 3.551323 59.66666667 105 1.759777 
ENSMUSG00000056895 Hist3h2ba  0.000415 0.01838 3.530357 32.66666667 73.33333333 2.244898 
ENSMUSG00000059077 Pth  0.0004162 0.01839 3.529593 0 37.66666667 #DIV/0! 
ENSMUSG00000036913 Trim67  0.0004308 0.01898 3.520459 32.33333333 66 2.041237 
ENSMUSG00000023873 010I14Rik  0.0004619 0.01988 3.501931 27.66666667 61.33333333 2.216867 
ENSMUSG00000030350 Prmt8  0.0004659 0.01994 3.499632 15.33333333 45.66666667 2.978261 
ENSMUSG00000041556 Fbxo2  0.0004668 0.01994 3.499118 6.666666667 24.66666667 3.7 
ENSMUSG00000032680 15Rik  0.0004856 0.02069 3.488576 69.66666667 117.3333333 1.684211 
ENSMUSG00000068876 Cgn  0.0005096 0.02139 3.475659 84.66666667 137 1.61811 
ENSMUSG00000073530 Pappa2  0.0005326 0.02213 3.463801 18.33333333 48 2.618182 
ENSMUSG00000040562 Gstm2  0.000561 0.02292 3.449801 433 654.6666667 1.511932 
ENSMUSG00000031972 Acta1  0.0005671 0.01114 2.766222 3379.333333 5831.666667 1.725686 
ENSMUSG00000015452 Ager  0.0006068 0.02431 3.428557 93 146.6666667 1.577061 
ENSMUSG00000001930 Vwf  0.0006204 0.02468 3.422535 977.6666667 2094 2.141834 
ENSMUSG00000022667 Cd200r1  0.0006333 0.02497 3.416937 31.33333333 63.66666667 2.031915 
ENSMUSG00000042429 Adora1  0.0006431 0.02519 3.412754 162.6666667 267 1.641393 
ENSMUSG00000001025 S100a6  0.0006535 0.02552 3.408379 209.3333333 333.3333333 1.592357 
ENSMUSG00000023336 Wfdc1  0.0006818 0.02624 3.396795 35.33333333 69.66666667 1.971698 
ENSMUSG00000017713 Tha1  0.0006993 0.02646 3.389853 65.33333333 110 1.683673 
ENSMUSG00000028524 Sgip1  0.000702 0.02649 3.388797 16.66666667 42 2.52 
ENSMUSG00000040441 Slc26a10  0.0007075 0.02663 3.386656 530.3333333 806 1.519799 
ENSMUSG00000087166 L1td1  0.0007163 0.0269 3.383263 7.333333333 28.66666667 3.909091 
ENSMUSG00000047197 Gjd3  0.0007501 0.02771 3.37058 11 32 2.909091 
ENSMUSG00000023032 Slc4a8  0.0007526 0.02771 3.369664 99.66666667 199 1.996656 
ENSMUSG00000061723 Tnnt3  7.53E-04 0.04699 2.194493 275.6666667 420 1.523579 
ENSMUSG00000044737 Klk14  0.0007859 0.02838 3.357714 7.333333333 25.66666667 3.5 
ENSMUSG00000006216 Clcnkb  0.0007946 0.02853 3.354669 10.33333333 30 2.903226 
ENSMUSG00000038453 Srcin1  0.0008108 0.02896 3.349081 8 26.33333333 3.291667 
ENSMUSG00000042129 Rassf4  0.0008131 0.02898 3.348296 199 338.6666667 1.701843 
ENSMUSG00000033544 Angptl1  0.0008318 0.0294 3.34199 14.66666667 38.66666667 2.636364 
ENSMUSG00000037185 Krt80  0.0008409 0.02966 3.338969 209.3333333 381 1.820064 
ENSMUSG00000027246 Ell3  0.0008458 0.02977 3.337354 13 35 2.692308 
ENSMUSG00000030921 Trim30a  0.0009354 0.03166 3.309269 22.66666667 50 2.205882 
ENSMUSG00000000739 Sult5a1  0.0009783 0.0326 3.296694 49 91.33333333 1.863946 
ENSMUSG00000074604 Mgst2  0.001021 0.03381 3.284675 6 22 3.666667 
ENSMUSG00000075588 Hoxb2  0.001069 0.03512 3.271708 32 73 2.28125 
ENSMUSG00000074277 Phldb3  0.001092 0.0356 3.265684 3 16 5.333333 
ENSMUSG00000036834 Plch1  0.001114 0.03597 3.260031 26 67.66666667 2.602564 
ENSMUSG00000030693 Klk10  0.00119 0.03763 3.241266 0 5.333333333 #DIV/0! 
ENSMUSG00000028755 Cda  0.001522 0.04547 3.170456 66.33333333 107.6666667 1.623116 
ENSMUSG00000026471 Mr1  0.001559 0.04616 3.163471 96.33333333 157.3333333 1.633218 
ENSMUSG00000023064 Sncg  0.001603 0.0473 3.15536 28.33333333 57 2.011765 
ENSMUSG00000007122 Casq1  0.004189 0.09098 2.863567 4616.333333 8713.666667 1.887573 
 DOWNREGULATED 
ENSMUSG00000030787 Lyve1  0 0 -8.01402 207.3333333 40 5.183333 
ENSMUSG00000026712 Mrc1  6.00E-15 1.68E-11 -7.80405 516 200 2.58 
ENSMUSG00000026500 Cox20  2.75E-14 6.60E-11 -7.60942 1257 671 1.873323 
ENSMUSG00000036564 Ndrg4  6.58E-14 1.23E-10 -7.4957 3696.333333 2142.333333 1.725377 
ENSMUSG00000036006 Fam65b  1.70E-13 2.37E-10 -7.37095 356.3333333 148.3333333 2.402247 
ENSMUSG00000032816 Igdcc4  2.18E-13 2.81E-10 -7.33751 790.6666667 404 1.957096 
ENSMUSG00000052504 Epha3  7.71E-13 8.09E-10 -7.16615 486.6666667 200.3333333 2.429285 
ENSMUSG00000026365 Cfh  4.06E-12 3.25E-09 -6.93507 928.6666667 414 2.243156 
ENSMUSG00000040537 Adam22  2.02E-10 1.13E-07 -6.35989 338.6666667 133 2.546366 
ENSMUSG00000035551 Igfbpl1  2.80E-10 1.52E-07 -6.3093 542.6666667 206.3333333 2.630048 
ENSMUSG00000069515 Lyz1  6.99E-10 3.45E-07 -6.16641 195 79 2.468354 
ENSMUSG00000041559 Fmod  1.18E-09 5.65E-07 -6.08321 444 218 2.036697 
ENSMUSG00000027971 Ndst4  1.78E-09 8.29E-07 -6.01689 39.33333333 3.666666667 10.72727 
ENSMUSG00000038112 AW551984  2.40E-09 1.09E-06 -5.96812 607 322.6666667 1.881198 
ENSMUSG00000060913 Trim55  2.58E-09 1.11E-06 -5.95605 5520.666667 3618.666667 1.525608 
ENSMUSG00000060882 Kcnd2  9.87E-09 3.53E-06 -5.73293 120 40.66666667 2.95082 
ENSMUSG00000042453 Reln  3.87E-08 1.20E-05 -5.49691 288.3333333 144.3333333 1.997691 
ENSMUSG00000034810 Scn7a  3.92E-08 1.20E-05 -5.49424 129.6666667 49 2.646259 
ENSMUSG00000066113 Adamtsl1  4.41E-08 1.32E-05 -5.47379 286 135.6666667 2.108108 
ENSMUSG00000026840 Lamc3  9.97E-08 2.60E-05 -5.32725 107.3333333 37.33333333 2.875 
ENSMUSG00000046442 Ppm1e  1.32E-07 3.21E-05 -5.27591 367.6666667 201.3333333 1.826159 
ENSMUSG00000033214 Slitrk5  1.70E-07 4.01E-05 -5.23001 576.6666667 274.3333333 2.102066 
ENSMUSG00000027931 Npr1  2.49E-07 5.74E-05 -5.15815 440.3333333 238 1.85014 
ENSMUSG00000051154 Commd3  2.75E-07 6.24E-05 -5.13996 1480 974.3333333 1.518987 
ENSMUSG00000051048 P4ha3  3.51E-07 7.66E-05 -5.09361 429 238.6666667 1.797486 
ENSMUSG00000043090 Zfp866  3.97E-07 8.54E-05 -5.07053 533 319 1.670846 
ENSMUSG00000034353 Ramp1  4.46E-07 9.47E-05 -5.04837 240.6666667 122.6666667 1.961957 
ENSMUSG00000016995 Matn4  4.74E-07 9.95E-05 -5.03659 97.33333333 24.66666667 3.945946 
ENSMUSG00000029675 Eln  5.20E-07 0.000106 -5.01882 5324.666667 2640.666667 2.01641 
ENSMUSG00000039431 Mtmr7  5.42E-07 0.000108 -5.01074 160.3333333 72.33333333 2.21659 
ENSMUSG00000071424 Grid2  5.76E-07 0.000114 -4.99903 28 3 9.333333 
ENSMUSG00000041797 Abca9  7.29E-07 0.000134 -4.95355 168.6666667 78 2.162393 
ENSMUSG00000026768 Itga8  7.44E-07 0.000136 -4.94943 819.3333333 433.6666667 1.889316 
ENSMUSG00000042289 Hsd3b7  8.43E-07 0.000147 -4.92516 332.6666667 186.3333333 1.785331 
ENSMUSG00000029338 Antxr2  1.02E-06 0.000173 -4.88832 2604.333333 1594.666667 1.633152 
ENSMUSG00000039057 Myo16  1.06E-06 0.000178 -4.88035 177 64.33333333 2.751295 
ENSMUSG00000007659 Bcl2l1  1.20E-06 0.000199 -4.8563 717 400.3333333 1.791007 
ENSMUSG00000030323 Ift122  1.37E-06 0.00022 -4.82917 943.6666667 614 1.536916 
ENSMUSG00000024331 Dsc2  1.39E-06 0.00022 -4.82686 1193.666667 659.3333333 1.810415 
ENSMUSG00000000706 Btn1a1  1.39E-06 0.00022 -4.82643 45.33333333 7.666666667 5.913043 
ENSMUSG00000039031 Arhgap18  1.44E-06 0.000225 -4.81994 1438.666667 938.3333333 1.533215 
ENSMUSG00000027820 Mme  1.67E-06 0.00026 -4.78962 607.3333333 377.6666667 1.60812 
ENSMUSG00000028020 Glrb  2.06E-06 0.000308 -4.74794 134.6666667 59.66666667 2.256983 
ENSMUSG00000027570 Col9a3  2.13E-06 0.000314 -4.74097 530 237.3333333 2.233146 
ENSMUSG00000020524 Gria1  2.13E-06 0.000314 -4.74078 141.3333333 60.66666667 2.32967 
ENSMUSG00000028015 Ctso  2.23E-06 0.000322 -4.73174 395.3333333 232 1.704023 
ENSMUSG00000020776 Fbf1  2.92E-06 0.000398 -4.67665 1194.333333 799.3333333 1.494162 
ENSMUSG00000078670 Fam174b  3.09E-06 0.000417 -4.66494 565.6666667 320 1.767708 
ENSMUSG00000022831 Hcls1  3.10E-06 0.000417 -4.66401 164.3333333 78.66666667 2.088983 
ENSMUSG00000035829 Ppp1r26  3.15E-06 0.000418 -4.66053 215.3333333 112.3333333 1.916914 
ENSMUSG00000038871 Bpgm  3.19E-06 0.000418 -4.65832 1033 504 2.049603 
ENSMUSG00000040896 Kcnd3  3.20E-06 0.000418 -4.65787 138.6666667 63.33333333 2.189474 
ENSMUSG00000031734 Irx3  3.21E-06 0.000418 -4.6569 303.3333333 171 1.773879 
ENSMUSG00000036446 Lum  3.50E-06 0.000445 -4.63912 1436 934.3333333 1.536925 
ENSMUSG00000060429 Sntb1  4.71E-06 0.000587 -4.57753 213 113 1.884956 
ENSMUSG00000025993 Slc40a1  5.81E-06 0.000702 -4.53304 255.6666667 141.3333333 1.808962 
ENSMUSG00000049796 Crh  6.86E-06 0.000811 -4.49808 78 28.66666667 2.72093 
ENSMUSG00000025757 Hspa4l  7.16E-06 0.000836 -4.48899 1034 696 1.485632 
ENSMUSG00000073940 Hbb-b2  7.81E-06 0.000886 -4.4703 2036 977 2.08393 
ENSMUSG00000042604 Kcna4  8.79E-06 0.000978 -4.44505 107.3333333 46.33333333 2.316547 
ENSMUSG00000022514 Il1rap  1.08E-05 0.001173 -4.40131 355 198.3333333 1.789916 
ENSMUSG00000048814 Lonrf2  1.13E-05 0.001212 -4.39144 126.3333333 58.33333333 2.165714 
ENSMUSG00000041836 Ptpre  1.17E-05 0.001234 -4.38329 144.6666667 70.66666667 2.04717 
ENSMUSG00000030653 Pde2a  1.23E-05 0.001286 -4.37167 387.3333333 183.3333333 2.112727 
ENSMUSG00000001942 Siae  1.34E-05 0.001384 -4.35282 319 170.6666667 1.869141 
ENSMUSG00000024899 Papss2  1.45E-05 0.001472 -4.33661 505.6666667 196.6666667 2.571186 
ENSMUSG00000059361 Nrsn2  1.47E-05 0.001483 -4.33374 69.33333333 24.66666667 2.810811 
ENSMUSG00000025969 Nrp2  1.80E-05 0.001759 -4.28811 641 418.3333333 1.532271 
ENSMUSG00000006522 Itih3  2.48E-05 0.0023 -4.21661 191 85.66666667 2.229572 
ENSMUSG00000044468 Fam46c  2.50E-05 0.002302 -4.21516 431 144 2.993056 
ENSMUSG00000069919 Hba-a1  2.78E-05 0.002511 -4.19061 5061.333333 2899.333333 1.745689 
ENSMUSG00000033152 Podxl2  3.02E-05 0.002676 -4.17195 584.6666667 382.3333333 1.529207 
ENSMUSG00000026676 Ccdc3  3.31E-05 0.002852 -4.15081 301 158.3333333 1.901053 
ENSMUSG00000052187 Hbb-y  3.36E-05 0.002877 -4.14765 44972.33333 22564.66667 1.993042 
ENSMUSG00000043943 Naalad2  3.41E-05 0.002889 -4.1444 125.6666667 60.66666667 2.071429 
ENSMUSG00000054435 Gimap4  3.89E-05 0.0032 -4.11404 397.3333333 197 2.01692 
ENSMUSG00000024620 Pdgfrb  3.96E-05 0.00322 -4.10998 1191.666667 699 1.704816 
ENSMUSG00000022488 Nckap1l  4.08E-05 0.003276 -4.10302 230.6666667 124.3333333 1.855228 
ENSMUSG00000030098 Grip2  4.15E-05 0.003315 -4.09913 399.6666667 252.6666667 1.581794 
ENSMUSG00000044350 Lacc1  5.73E-05 0.004368 -4.02387 363.6666667 229 1.588064 
ENSMUSG00000027692 Tnik  6.14E-05 0.004601 -4.0074 466.6666667 305.3333333 1.528384 
ENSMUSG00000015944 Gatsl2  6.36E-05 0.004699 -3.99904 278 151.3333333 1.837004 
ENSMUSG00000042066 Tmcc2  6.38E-05 0.004699 -3.99822 1021.666667 531.6666667 1.92163 
ENSMUSG00000024411 Aqp4  6.66E-05 0.004859 -3.98826 361 212.6666667 1.697492 
ENSMUSG00000044338 Aplnr  6.74E-05 0.004892 -3.98539 212 68.33333333 3.102439 
ENSMUSG00000031596 Slc7a2  6.77E-05 0.004892 -3.98416 147.3333333 77.66666667 1.896996 
ENSMUSG00000039904 Gpr37  7.12E-05 0.00509 -3.97211 42.66666667 12.33333333 3.459459 
ENSMUSG00000037709 Fam13a  7.29E-05 0.00514 -3.96675 282.6666667 172 1.643411 
ENSMUSG00000006342 Susd2  7.40E-05 0.005175 -3.96314 144.3333333 75.33333333 1.915929 
ENSMUSG00000025855 Prkar1b  7.48E-05 0.005188 -3.96054 167 91 1.835165 
ENSMUSG00000030681 Mvp  7.61E-05 0.005236 -3.95639 304 186.3333333 1.631485 
ENSMUSG00000049107 Ntf3  7.75E-05 0.005286 -3.95216 75.66666667 31.33333333 2.414894 
ENSMUSG00000031129 Slc9a9  0.0001109 0.007189 -3.86542 142.3333333 75 1.897778 
ENSMUSG00000030513 Pcsk6  0.0001169 0.00752 -3.85254 1056 386.3333333 2.733391 
ENSMUSG00000038552 Fndc4  0.0001241 0.007911 -3.83788 533.6666667 359.3333333 1.485158 
ENSMUSG00000052336 Cx3cr1  0.0001244 0.007911 -3.83729 143.3333333 76 1.885965 
ENSMUSG00000006574 Slc4a1  0.0001309 0.008262 -3.82476 3232 991.3333333 3.260256 
ENSMUSG00000015243 Abca1  0.0001375 0.008493 -3.81262 586.3333333 345.6666667 1.696239 
ENSMUSG00000033590 Myo5c  0.0001446 0.008701 -3.80016 92.66666667 41.66666667 2.224 
ENSMUSG00000069516 Lyz2  0.0001478 0.008786 -3.79474 619.6666667 289.3333333 2.141705 
ENSMUSG00000052305 Hbb-b1  0.0001481 0.008786 -3.79423 4395.666667 2255.333333 1.94901 
ENSMUSG00000037605 Lphn3  0.0001641 0.009533 -3.7687 316.3333333 177.6666667 1.780488 
ENSMUSG00000052430 Bmpr1b  0.0001736 0.009914 -3.75463 73.66666667 31.66666667 2.326316 
ENSMUSG00000025889 Snca  0.0001761 0.009988 -3.75104 395 221.3333333 1.784639 
ENSMUSG00000036186 Fam69b  0.0001782 0.01007 -3.74807 212.6666667 125 1.701333 
ENSMUSG00000021822 Plau  0.0001797 0.01012 -3.74597 225.3333333 121.3333333 1.857143 
ENSMUSG00000022887 Masp1  0.0001857 0.01037 -3.73772 337 217.6666667 1.548239 
ENSMUSG00000086040 Wipf3  0.0001859 0.01037 -3.73744 562.6666667 359.6666667 1.564411 
ENSMUSG00000031618 Nr3c2  0.0001872 0.01041 -3.73569 28.33333333 6.666666667 4.25 
ENSMUSG00000025089 Gfra1  0.0001908 0.01054 -3.7309 73.33333333 31.33333333 2.340426 
ENSMUSG00000022483 Col2a1  0.0001917 0.01055 -3.72971 3134.666667 1663.333333 1.884569 
ENSMUSG00000031543 Ank1  0.0001946 0.01064 -3.72593 692 348.3333333 1.986603 
ENSMUSG00000036040 Adamtsl2  0.0002006 0.01089 -3.71826 255 131.6666667 1.936709 
ENSMUSG00000030116 Mfap5  0.0002034 0.01098 -3.71476 164.6666667 82 2.00813 
ENSMUSG00000041378 Cldn5  0.0002061 0.01109 -3.71142 85.33333333 38.66666667 2.206897 
ENSMUSG00000048865 Arhgap30  0.0002135 0.01144 -3.70248 52 19 2.736842 
ENSMUSG00000033458 Fan1  0.0002249 0.01186 -3.68927 186.6666667 108.3333333 1.723077 
ENSMUSG00000021301 Hecw1  0.0002254 0.01186 -3.6887 44.66666667 15 2.977778 
ENSMUSG00000034881 Tbxa2r  0.000229 0.01201 -3.68467 111.6666667 54 2.067901 
ENSMUSG00000034059 Ypel4  0.0002499 0.01302 -3.66236 73.33333333 32.33333333 2.268041 
ENSMUSG00000028780 Sema3c  0.0002505 0.01302 -3.66175 1115 722 1.544321 
ENSMUSG00000020034 Tcp11l2  0.0002526 0.01309 -3.65961 572 366.6666667 1.56 
ENSMUSG00000015852 Fcrls  0.0002757 0.01403 -3.63712 127.6666667 64.66666667 1.974227 
ENSMUSG00000029671 Wnt16  0.000308 0.0153 -3.60848 57.66666667 23 2.507246 
ENSMUSG00000030996 Art1  0.0003361 0.01633 -3.58576 56 22 2.545455 
ENSMUSG00000024935 Slc1a1  0.0003495 0.01658 -3.57554 59 16 3.6875 
ENSMUSG00000022883 Robo1  0.0003556 0.01672 -3.57102 1456.666667 883 1.649679 
ENSMUSG00000063297 Luzp2  0.0003705 0.01718 -3.56025 82.66666667 37.66666667 2.19469 
ENSMUSG00000043257 Pigv  0.0003771 0.01731 -3.55561 221 134.6666667 1.641089 
ENSMUSG00000055639 Dach1  0.0003864 0.01758 -3.5492 220 134.6666667 1.633663 
ENSMUSG00000040253 Gbp7  0.0004008 0.01809 -3.53956 41.33333333 14 2.952381 
ENSMUSG00000048582 Gja3  0.0004024 0.01811 -3.5385 39.33333333 12.66666667 3.105263 
ENSMUSG00000023216 Epb4.2  0.0004105 0.01829 -3.53324 316.3333333 95.33333333 3.318182 
ENSMUSG00000003476 Crhr2  0.000411 0.01829 -3.53292 146.3333333 66 2.217172 
ENSMUSG00000040118 Cacna2d1  0.0004579 0.01983 -3.50425 1530.666667 1000.666667 1.529647 
ENSMUSG00000057378 Ryr3  0.0004994 0.02117 -3.48108 677 327.6666667 2.066124 
ENSMUSG00000074671 Tspyl3  0.0005075 0.02135 -3.47677 102.3333333 52.33333333 1.955414 
ENSMUSG00000038264 Sema7a  0.00055 0.02274 -3.45514 47 17.33333333 2.711538 
ENSMUSG00000038775 Vill  0.0005603 0.02292 -3.45014 155 89.66666667 1.728625 
ENSMUSG00000014361 Mertk  0.0005945 0.02406 -3.43411 306 200.6666667 1.524917 
ENSMUSG00000029866 Kel  0.0006574 0.02558 -3.40676 653 193 3.38342 
ENSMUSG00000037124 Trim58  0.0006581 0.02558 -3.40646 27.33333333 6 4.555556 
ENSMUSG00000009633 G0s2  0.0006642 0.02575 -3.40395 228.6666667 141.3333333 1.617925 
ENSMUSG00000053835 H2-T24  0.0006822 0.02624 -3.39663 160.3333333 59 2.717514 
ENSMUSG00000020334 Slc22a4  0.0006842 0.02624 -3.39583 47.66666667 13 3.666667 
ENSMUSG00000035296 Sgcg  0.000692 0.0264 -3.39273 87.33333333 35.66666667 2.448598 
ENSMUSG00000024621 Csf1r  0.0007335 0.02726 -3.37674 562 323 1.739938 
ENSMUSG00000027878 Notch2  0.0007518 0.02771 -3.36996 1090.666667 734.6666667 1.484574 
ENSMUSG00000026532 Spta1  0.000755 0.02774 -3.36879 864.6666667 287.3333333 3.009281 
ENSMUSG00000050211 Pla2g4e  0.0007658 0.02807 -3.36487 62 27.33333333 2.268293 
ENSMUSG00000042353 Frem3  0.0007714 0.02809 -3.36286 31 9.333333333 3.321429 
ENSMUSG00000044067 Gpr22  0.0007759 0.0282 -3.36125 602.6666667 385.3333333 1.564014 
ENSMUSG00000052062 Pard3b  0.0008148 0.02898 -3.34772 317.6666667 211.6666667 1.500787 
ENSMUSG00000033114 Slc35d2  0.0008296 0.0294 -3.34273 221.6666667 140.6666667 1.575829 
ENSMUSG00000064179 Tnnt1  0.0008493 0.02983 -3.33621 8775.666667 4871.666667 1.801368 
ENSMUSG00000047473 Zfp30  0.0008661 0.03016 -3.33076 171.3333333 103 1.66343 
ENSMUSG00000051236 Msrb3  0.0008669 0.03016 -3.3305 1596.333333 1065.333333 1.498436 
ENSMUSG00000004552 Ctse  0.0008677 0.03016 -3.33024 250.6666667 80.66666667 3.107438 
ENSMUSG00000020656 Grhl1  0.0008801 0.03047 -3.32629 429 267.3333333 1.604738 
ENSMUSG00000028542 Slc6a9  0.0008989 0.03098 -3.3204 267 158.3333333 1.686316 
ENSMUSG00000021068 Nin  0.0009198 0.03145 -3.31397 966.3333333 646.3333333 1.495101 
ENSMUSG00000020599 Rgs9  0.0009287 0.0316 -3.31128 93.33333333 45.66666667 2.043796 
ENSMUSG00000027338 Prnd  0.0009318 0.0316 -3.31035 78.66666667 30 2.622222 
ENSMUSG00000036941 Elac1  0.0009648 0.0324 -3.3006 136.3333333 79 1.725738 
ENSMUSG00000033111 406C13Rik  0.0009786 0.0326 -3.29661 317 194 1.634021 
ENSMUSG00000043410 Hfm1  0.001023 0.03381 -3.28412 49.33333333 20.33333333 2.42623 
ENSMUSG00000026380 Tfcp2l1  0.001054 0.03477 -3.2757 176 107.6666667 1.634675 
ENSMUSG00000036353 P2ry12  0.00113 0.03627 -3.25598 35.66666667 12.33333333 2.891892 
ENSMUSG00000068196 Col8a1  0.001175 0.03732 -3.24488 149 88.33333333 1.686792 
ENSMUSG00000042671 Rgs8  0.001176 0.03732 -3.24464 93.66666667 22 4.257576 
ENSMUSG00000069814 D14Rik  0.001199 0.03784 -3.23912 104 41.66666667 2.496 
ENSMUSG00000029826 Zc3hav1  0.001211 0.03815 -3.23628 305 178.3333333 1.71028 
ENSMUSG00000039109 F13a1  0.001258 0.0394 -3.22539 255.6666667 110.6666667 2.310241 
ENSMUSG00000007279 Scube2  0.001262 0.03946 -3.22448 325.3333333 137.3333333 2.368932 
ENSMUSG00000032125 Robo4  0.001287 0.04009 -3.21886 208 105 1.980952 
ENSMUSG00000038068 Rnf144b  0.001306 0.04053 -3.21466 164.6666667 100.3333333 1.641196 
ENSMUSG00000027750 Postn  0.001334 0.04104 -3.20856 9034.666667 5652 1.59849 
ENSMUSG00000055912 Tmem150a  0.001407 0.04272 -3.19321 251.3333333 165.3333333 1.520161 
ENSMUSG00000029193 Cckar  0.001435 0.04341 -3.18752 21.33333333 5 4.266667 
ENSMUSG00000030353 Tead4  0.001481 0.04451 -3.17838 157 96 1.635417 
ENSMUSG00000036655 Colec11  0.001482 0.04451 -3.17819 101.6666667 53.66666667 1.89441 
ENSMUSG00000020641 Rsad2  0.001551 0.04601 -3.16497 98 36.66666667 2.672727 
ENSMUSG00000039899 Fgl2  0.00164 0.04805 -3.1487 612.3333333 390 1.570085 
ENSMUSG00000031972 Acta1  0.005671 0.1114 2.766222 3379.333333 5831.666667 0.57948 
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